Approximately O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
55 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
table O-ADR O-ADR
below O-ADR O-ADR
lists O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Ferriprox O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Progressive O-ADR O-ADR
Multifocal O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
JC B-ADR B-ADR
virus I-ADR I-ADR
infection I-ADR I-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
PML B-ADR B-ADR
and O-ADR O-ADR
death B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
skin O-ADR O-ADR
discoloration O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
changing O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
alternate O-ADR O-ADR
medication O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
Serious O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Tissue O-ADR B-ADR
inflammation O-ADR I-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
prostatic O-ADR B-ADR
hyperplasia O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
false O-ADR O-ADR
positive O-ADR O-ADR
11 O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
choline O-ADR O-ADR
PET O-ADR O-ADR
images O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
923 O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
TANZEUM O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
TANZEUM O-ADR O-ADR
of O-ADR O-ADR
93 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
to O-ADR O-ADR
Fatal B-ADR B-ADR
Immune B-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Adverse I-ADR O-ADR
Reactions I-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
a O-ADR O-ADR
Including O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
item O-ADR O-ADR
{ O-ADR O-ADR
Cataracts O-ADR O-ADR
- O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
posterior B-ADR B-ADR
subcapsular I-ADR I-ADR
cataract I-ADR I-ADR
formation O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Tumor O-ADR O-ADR
Lysis O-ADR O-ADR
Syndrome O-ADR O-ADR
Tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
TLS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
toxicity I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
GILOTRIF O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
documented O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
or O-ADR O-ADR
intolerance O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Contact O-ADR O-ADR
Lens O-ADR O-ADR
Wear O-ADR O-ADR
DUREZOL O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
instilled O-ADR O-ADR
while O-ADR O-ADR
wearing O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hemorrhage B-ADR B-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
hemorrhage B-ADR B-ADR
including O-ADR O-ADR
hemoptysis B-ADR B-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
hemorrhage I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
of O-ADR O-ADR
Volume B-ADR O-ADR
DepletionVolume O-ADR O-ADR
depletion B-ADR B-ADR
includes O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
hypovolemia B-ADR B-ADR
, O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
hypotension B-ADR B-ADR
. O-ADR O-ADR
To O-ADR O-ADR
adjust O-ADR O-ADR
for O-ADR O-ADR
normal O-ADR O-ADR
growth O-ADR O-ADR
, O-ADR O-ADR
z O-ADR O-ADR
- O-ADR O-ADR
scores O-ADR O-ADR
were O-ADR O-ADR
derived O-ADR O-ADR
( O-ADR O-ADR
measured O-ADR O-ADR
in O-ADR O-ADR
standard O-ADR O-ADR
deviations O-ADR O-ADR
[ O-ADR O-ADR
SD O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
normalize O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
natural O-ADR O-ADR
growth O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
by O-ADR O-ADR
comparisons O-ADR O-ADR
to O-ADR O-ADR
age O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
sex O-ADR O-ADR
- O-ADR O-ADR
matched O-ADR O-ADR
population O-ADR O-ADR
standards O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
MCL O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
lymphocytosis O-ADR B-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
400 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
/ O-ADR O-ADR
mcL O-ADR O-ADR
have O-ADR O-ADR
developed O-ADR O-ADR
intracranial O-ADR B-ADR
hemorrhage O-ADR I-ADR
, O-ADR O-ADR
lethargy O-ADR B-ADR
, O-ADR O-ADR
gait O-ADR B-ADR
instability O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache O-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
was O-ADR O-ADR
47 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
between O-ADR O-ADR
16 O-ADR O-ADR
and O-ADR O-ADR
93 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
. O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
About O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
binding O-ADR O-ADR
or O-ADR O-ADR
neutralizing O-ADR O-ADR
) O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
with O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Janssen O-ADR O-ADR
Products O-ADR O-ADR
, O-ADR O-ADR
LP O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
JANSSEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
526 O-ADR O-ADR
- O-ADR O-ADR
7736 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormality O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
neutropenia B-ADR B-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
herpes B-ADR B-ADR
simplex I-ADR I-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
encephalitis B-ADR B-ADR
and O-ADR O-ADR
multiorgan B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
general O-ADR O-ADR
, O-ADR O-ADR
limiting O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
injected O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
sternocleidomastoid O-ADR O-ADR
muscle O-ADR O-ADR
may O-ADR O-ADR
decrease O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
dysphagia O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
under O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Interstitial O-ADR O-ADR
Lung O-ADR O-ADR
Disease O-ADR O-ADR
( O-ADR O-ADR
ILD O-ADR O-ADR
) O-ADR O-ADR
ILD B-ADR B-ADR
or O-ADR O-ADR
ILD B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
adverse I-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
lung B-ADR B-ADR
infiltration I-ADR I-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
respiratory I-ADR I-ADR
distress I-ADR I-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
alveolitis B-ADR B-ADR
allergic I-ADR I-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3865 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
GILOTRIF O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
; O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
is O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
metabolic B-ADR B-ADR
changes I-ADR I-ADR
include O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
dyslipidemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
. O-ADR O-ADR
Pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
was O-ADR O-ADR
fatal B-ADR B-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
cardiomyopathy B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
was O-ADR O-ADR
86 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
27 O-ADR O-ADR
to O-ADR O-ADR
253 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
ULORIC O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
559 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
neutrophil O-ADR O-ADR
counts O-ADR O-ADR
of O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
500 O-ADR O-ADR
cells O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
transfusion O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
anemia O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Perform O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
TB O-ADR O-ADR
; O-ADR O-ADR
if O-ADR O-ADR
positive O-ADR O-ADR
, O-ADR O-ADR
start O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
TB O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
starting O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
included O-ADR O-ADR
: O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR O-ADR
, O-ADR O-ADR
flushing O-ADR O-ADR
/ O-ADR O-ADR
feeling O-ADR O-ADR
hot B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
oxygen I-ADR I-ADR
saturation I-ADR I-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
tachypnea B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
twitching I-ADR I-ADR
, O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
/ O-ADR O-ADR
increased O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
pallor B-ADR B-ADR
, O-ADR O-ADR
rigors B-ADR B-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myalgia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
Inhibitors O-ADR O-ADR
STENDRA O-ADR O-ADR
metabolism O-ADR O-ADR
is O-ADR O-ADR
principally O-ADR O-ADR
mediated O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
CYP450 O-ADR O-ADR
isoform O-ADR O-ADR
3A4 O-ADR O-ADR
( O-ADR O-ADR
CYP3A4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Endophthalmitis B-ADR B-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
detachments I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
following O-ADR O-ADR
intravitreal O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
angio B-ADR B-ADR
- O-ADR O-ADR
edema O-ADR O-ADR
, O-ADR O-ADR
dermatitis B-ADR B-ADR
, O-ADR O-ADR
dermographism B-ADR B-ADR
, O-ADR O-ADR
ecchymosis B-ADR B-ADR
, O-ADR O-ADR
eczema B-ADR B-ADR
, O-ADR O-ADR
hair B-ADR B-ADR
color I-ADR I-ADR
changes I-ADR I-ADR
, O-ADR O-ADR
hair B-ADR B-ADR
growth I-ADR I-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
peeling B-ADR B-ADR
skin I-ADR I-ADR
, O-ADR O-ADR
petechiae B-ADR B-ADR
, O-ADR O-ADR
photosensitivity B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
purpura B-ADR B-ADR
, O-ADR O-ADR
skin B-ADR B-ADR
discoloration I-ADR I-ADR
, O-ADR O-ADR
skin B-ADR B-ADR
lesion I-ADR I-ADR
, O-ADR O-ADR
skin B-ADR B-ADR
odor I-ADR I-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
Call O-ADR O-ADR
your O-ADR O-ADR
doctor O-ADR O-ADR
for O-ADR O-ADR
medical O-ADR O-ADR
advice O-ADR O-ADR
about O-ADR O-ADR
side O-ADR O-ADR
effects O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
DALVANCE O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subject O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
trial O-ADR O-ADR
had O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
baseline O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
20 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
arthritis B-ADR B-ADR
, O-ADR O-ADR
joint B-ADR B-ADR
stiffness I-ADR I-ADR
, O-ADR O-ADR
joint B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
spasms I-ADR I-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
a O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
stopped O-ADR O-ADR
at O-ADR O-ADR
once O-ADR O-ADR
and O-ADR O-ADR
alternative O-ADR O-ADR
treatments O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
efficacy O-ADR O-ADR
or O-ADR O-ADR
safety O-ADR O-ADR
between O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
immunoreactivity O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Thyroid O-ADR O-ADR
C O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
Tumors O-ADR O-ADR
Carcinogenicity O-ADR O-ADR
of O-ADR O-ADR
albiglutide O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
rapid O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
clearing O-ADR O-ADR
, O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibodies O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
dosing O-ADR O-ADR
or O-ADR O-ADR
repeated O-ADR O-ADR
dosing O-ADR O-ADR
appears O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
with O-ADR O-ADR
cutaneous B-ADR B-ADR
manifestations I-ADR I-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
flushing B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Have O-ADR O-ADR
anaphylactic O-ADR O-ADR
and O-ADR O-ADR
hypersensitivity O-ADR O-ADR
treatment O-ADR O-ADR
measures O-ADR O-ADR
available O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
ages O-ADR O-ADR
of O-ADR O-ADR
18 O-ADR O-ADR
and O-ADR O-ADR
69 O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
date O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
CERDELGA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
87 O-ADR O-ADR
females O-ADR O-ADR
and O-ADR O-ADR
72 O-ADR O-ADR
males O-ADR O-ADR
. O-ADR O-ADR
Psoriasis O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
OTEZLA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
1426 O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
plaque O-ADR O-ADR
psoriasis O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
candidates O-ADR O-ADR
for O-ADR O-ADR
phototherapy O-ADR O-ADR
or O-ADR O-ADR
systemic O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
ILD B-ADR B-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
Asian O-ADR O-ADR
ethnicity O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
Asians O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
gastrointestinal O-ADR O-ADR
perforation O-ADR O-ADR
or O-ADR O-ADR
fistula O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
During O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
141 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
aged O-ADR O-ADR
< O-ADR O-ADR
24 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
33 O-ADR O-ADR
aged O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
58 O-ADR O-ADR
aged O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
11 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
43 O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
17 O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
DOTAREM O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Cardiac O-ADR O-ADR
Toxicities O-ADR O-ADR
worsening B-ADR B-ADR
of I-ADR I-ADR
pre I-ADR I-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
cardiac I-ADR I-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
congestive B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
ejection I-ADR I-ADR
fraction I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
restrictive B-ADR B-ADR
cardiomyopathy I-ADR I-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
ischemia I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
including O-ADR O-ADR
fatalities B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
hyperglycemia O-ADR O-ADR
has O-ADR O-ADR
resolved O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
required O-ADR O-ADR
continuation O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diabetic O-ADR O-ADR
treatment O-ADR O-ADR
despite O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
unstable O-ADR O-ADR
or O-ADR O-ADR
poorly O-ADR O-ADR
controlled O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
recent O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cardiovascular O-ADR O-ADR
or O-ADR O-ADR
cerebrovascular O-ADR O-ADR
events O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
adverse B-ADR O-ADR
cardiovascular I-ADR O-ADR
effects I-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
AP O-ADR O-ADR
CML O-ADR O-ADR
and O-ADR O-ADR
BP O-ADR O-ADR
CML O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
cabazitaxel O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
and O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
undertaken O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
safety O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
male O-ADR O-ADR
( O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
78 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
respiratory O-ADR O-ADR
illness O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
acute O-ADR O-ADR
exacerbation O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
respiratory O-ADR O-ADR
compromise O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
additional O-ADR O-ADR
monitoring O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
almost O-ADR O-ADR
entirely O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
99 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
51 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
18 O-ADR O-ADR
- O-ADR O-ADR
82 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
few O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
Caucasian O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
Caucasian O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Macrovascular O-ADR O-ADR
Outcomes O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
XIAFLEX O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
a O-ADR O-ADR
restricted O-ADR O-ADR
program O-ADR O-ADR
called O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postapproval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
prophylactic O-ADR O-ADR
measures O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
pretreatment O-ADR O-ADR
nontoxic O-ADR O-ADR
cytoreduction O-ADR O-ADR
and O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
hydration O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
prevention O-ADR O-ADR
of O-ADR O-ADR
TLS O-ADR O-ADR
during O-ADR O-ADR
BLINCYTO O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Antibodies O-ADR O-ADR
directed O-ADR O-ADR
against O-ADR O-ADR
the O-ADR O-ADR
belatacept O-ADR O-ADR
molecule O-ADR O-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
398 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
212 O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
product O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
10 O-ADR O-ADR
days O-ADR O-ADR
or O-ADR O-ADR
longer O-ADR O-ADR
, O-ADR O-ADR
IOP O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
: O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
certain O-ADR O-ADR
heart O-ADR O-ADR
conditions O-ADR O-ADR
. O-ADR O-ADR
Beta O-ADR O-ADR
- O-ADR O-ADR
agonist O-ADR O-ADR
medications O-ADR O-ADR
may O-ADR O-ADR
produce O-ADR O-ADR
transient O-ADR B-ADR
hyperglycemia B-ADR I-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Amyvid O-ADR O-ADR
caused O-ADR O-ADR
no O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
earlier O-ADR O-ADR
onset O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
ruled O-ADR O-ADR
out O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
possible O-ADR O-ADR
that O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
were O-ADR O-ADR
present O-ADR O-ADR
earlier O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
from O-ADR O-ADR
NORTHERA O-ADR O-ADR
were O-ADR O-ADR
hypertension B-ADR B-ADR
or O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
Ability O-ADR O-ADR
to O-ADR O-ADR
Drive O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
Machines O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
neurologic B-ADR O-ADR
events I-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
seizures B-ADR B-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
loss B-ADR B-ADR
of I-ADR I-ADR
consciousness I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
During O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
and O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
tested O-ADR O-ADR
at O-ADR O-ADR
multiple O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
protein O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
( O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
then O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reasons O-ADR O-ADR
for O-ADR O-ADR
interruption O-ADR O-ADR
or O-ADR O-ADR
discontinuations O-ADR O-ADR
were O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
First O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
various O-ADR O-ADR
times O-ADR O-ADR
from O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
occurring O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
initial O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
the O-ADR O-ADR
status O-ADR O-ADR
of O-ADR O-ADR
both O-ADR O-ADR
mucous B-ADR B-ADR
membrane I-ADR I-ADR
discoloration I-ADR I-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
pigmentary I-ADR I-ADR
abnormalities I-ADR I-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
a O-ADR O-ADR
quarter O-ADR O-ADR
of O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
mucous B-ADR B-ADR
membrane I-ADR I-ADR
discoloration I-ADR I-ADR
had O-ADR O-ADR
concurrent O-ADR O-ADR
retinal B-ADR B-ADR
pigmentary I-ADR I-ADR
abnormalities I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
previously O-ADR O-ADR
maintained O-ADR O-ADR
on O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
( O-ADR O-ADR
or O-ADR O-ADR
its O-ADR O-ADR
equivalent O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
most O-ADR O-ADR
susceptible O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
when O-ADR O-ADR
their O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
almost O-ADR O-ADR
completely O-ADR O-ADR
withdrawn O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
connective O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
myositis B-ADR B-ADR
, O-ADR O-ADR
chondropathy B-ADR B-ADR
, O-ADR O-ADR
trismus B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
lipase O-ADR O-ADR
and O-ADR O-ADR
amylase O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
patient O-ADR O-ADR
presenting O-ADR O-ADR
with O-ADR O-ADR
new O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
Liver O-ADR O-ADR
Function O-ADR O-ADR
Test O-ADR O-ADR
Abnormalities O-ADR O-ADR
: O-ADR O-ADR
Among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
0 O-ADR O-ADR
or O-ADR O-ADR
1 O-ADR O-ADR
ALT O-ADR O-ADR
levels O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
ALT B-ADR B-ADR
elevation I-ADR I-ADR
. O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
and O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
II O-ADR O-ADR
studies O-ADR O-ADR
compared O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
warfarin O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
deep O-ADR O-ADR
vein O-ADR O-ADR
thrombosis O-ADR O-ADR
and O-ADR O-ADR
pulmonary O-ADR O-ADR
embolism O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactionsare O-ADR O-ADR
discussed O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Nephrogenic B-ADR B-ADR
systemic I-ADR I-ADR
fibrosis I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
hot I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Bayer O-ADR O-ADR
HealthCare O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
84 O-ADR O-ADR
- O-ADR O-ADR
BAYER O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
842 O-ADR O-ADR
- O-ADR O-ADR
2937 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
appropriately O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
laboratory O-ADR O-ADR
parameters O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
, O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
count O-ADR O-ADR
and O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
BLINCYTO O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
6 O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
participants O-ADR O-ADR
was O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
participants O-ADR O-ADR
were O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
and O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
participants O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
neurological O-ADR B-ADR
toxicity O-ADR I-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hyponatremia B-ADR B-ADR
include O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
difficulty B-ADR B-ADR
concentrating I-ADR I-ADR
, O-ADR O-ADR
memory B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
confusion B-ADR B-ADR
, O-ADR O-ADR
weakness B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
unsteadiness B-ADR B-ADR
, O-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
falls B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Extravasation B-ADR B-ADR
: O-ADR O-ADR
Assure O-ADR O-ADR
good O-ADR O-ADR
venous O-ADR O-ADR
access O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
infusion O-ADR O-ADR
site O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
: O-ADR O-ADR
Weight O-ADR O-ADR
Change O-ADR O-ADR
Results O-ADR O-ADR
Categorized O-ADR O-ADR
by O-ADR O-ADR
BMI O-ADR O-ADR
at O-ADR O-ADR
Baseline O-ADR O-ADR
: O-ADR O-ADR
Comparator O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
52 O-ADR O-ADR
- O-ADR O-ADR
Week O-ADR O-ADR
Study O-ADR O-ADR
in O-ADR O-ADR
Adults O-ADR O-ADR
with O-ADR O-ADR
Schizophrenia O-ADR O-ADR
BMI O-ADR O-ADR
< O-ADR O-ADR
23 O-ADR O-ADR
SAPHRIS O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
295 O-ADR O-ADR
BMI O-ADR O-ADR
23 O-ADR O-ADR
- O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
27 O-ADR O-ADR
SAPHRIS O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
290 O-ADR O-ADR
BMI O-ADR O-ADR
> O-ADR O-ADR
27 O-ADR O-ADR
SAPHRIS O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
302 O-ADR O-ADR
Mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
body I-ADR I-ADR
weight I-ADR I-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Data O-ADR O-ADR
on O-ADR O-ADR
mean O-ADR O-ADR
changes B-ADR O-ADR
in I-ADR O-ADR
body I-ADR O-ADR
weight I-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
meeting O-ADR O-ADR
a O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
criterion O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
body O-ADR O-ADR
weight O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trial O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Genital O-ADR O-ADR
Mycotic O-ADR O-ADR
Infections O-ADR O-ADR
INVOKANA O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
Investigator O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
Maximal O-ADR O-ADR
Local B-ADR B-ADR
Skin I-ADR I-ADR
Reactions I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
Area O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
57 O-ADR O-ADR
Days O-ADR O-ADR
Post O-ADR O-ADR
Treatment O-ADR O-ADR
Period O-ADR O-ADR
( O-ADR O-ADR
face O-ADR O-ADR
/ O-ADR O-ADR
scalp O-ADR O-ADR
trials O-ADR O-ADR
) O-ADR O-ADR
Face O-ADR O-ADR
and O-ADR O-ADR
Scalp O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
545 O-ADR O-ADR
) O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
015 O-ADR O-ADR
% O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
Skin B-ADR B-ADR
reactions I-ADR I-ADR
Any I-ADR I-ADR
Gradea I-ADR I-ADR
> I-ADR I-ADR
Baseline I-ADR I-ADR
Grade I-ADR I-ADR
4 I-ADR I-ADR
87 O-ADR O-ADR
( O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
Mild O-ADR O-ADR
( O-ADR O-ADR
grade O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Moderate O-ADR O-ADR
( O-ADR O-ADR
grade O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Severe O-ADR O-ADR
( O-ADR O-ADR
grade O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
was O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
118 O-ADR O-ADR
to O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Metabolic O-ADR O-ADR
Changes O-ADR O-ADR
Atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
metabolic B-ADR O-ADR
changes I-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase B-ADR B-ADR
cardiovascular I-ADR I-ADR
/ O-ADR O-ADR
cerebrovascular O-ADR O-ADR
risk I-ADR I-ADR
. O-ADR O-ADR
Pain B-ADR B-ADR
increases I-ADR I-ADR
occurring O-ADR O-ADR
during O-ADR O-ADR
patch O-ADR O-ADR
application O-ADR O-ADR
usually O-ADR O-ADR
began O-ADR O-ADR
to O-ADR O-ADR
resolve O-ADR O-ADR
after O-ADR O-ADR
patch O-ADR O-ADR
removal O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Tardive O-ADR O-ADR
Dyskinesia O-ADR O-ADR
A O-ADR O-ADR
syndrome O-ADR O-ADR
of O-ADR O-ADR
potentially O-ADR O-ADR
irreversible O-ADR O-ADR
, O-ADR O-ADR
involuntary B-ADR B-ADR
, I-ADR I-ADR
dyskinetic I-ADR I-ADR
movements I-ADR I-ADR
can O-ADR O-ADR
develop O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Increases O-ADR B-ADR
in O-ADR I-ADR
Low O-ADR I-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein O-ADR I-ADR
Cholesterol O-ADR I-ADR
( O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
High O-ADR O-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein O-ADR I-ADR
Cholesterol O-ADR I-ADR
( O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
HDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Upper O-ADR O-ADR
Limb O-ADR O-ADR
Spasticity O-ADR O-ADR
From O-ADR O-ADR
230 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
positive O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
17 O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
compromised O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
or O-ADR O-ADR
dysphagia O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
other O-ADR O-ADR
chemotherapy O-ADR O-ADR
was O-ADR O-ADR
continued O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
prescribed O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
enrolled O-ADR O-ADR
30 O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
29 O-ADR O-ADR
were O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
ALL O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
for O-ADR O-ADR
lymphoblastic O-ADR O-ADR
lymphoma O-ADR O-ADR
( O-ADR O-ADR
LBL O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
following O-ADR O-ADR
allergy O-ADR O-ADR
to O-ADR O-ADR
native O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
coli O-ADR O-ADR
asparaginase O-ADR O-ADR
or O-ADR O-ADR
pegaspargase O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
tardive O-ADR O-ADR
dyskinesia O-ADR B-ADR
and O-ADR O-ADR
the O-ADR O-ADR
likelihood O-ADR O-ADR
that O-ADR O-ADR
it O-ADR O-ADR
will O-ADR O-ADR
become O-ADR O-ADR
irreversible O-ADR O-ADR
are O-ADR O-ADR
believed O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
total O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
administered O-ADR O-ADR
increases O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
unapproved O-ADR O-ADR
uses O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
spasticity O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adults O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
approved O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
spread B-ADR B-ADR
of I-ADR I-ADR
toxin I-ADR I-ADR
effect I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
doses O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Neuroleptic O-ADR O-ADR
Malignant O-ADR O-ADR
Syndrome O-ADR O-ADR
( O-ADR O-ADR
NMS O-ADR O-ADR
) O-ADR O-ADR
A O-ADR O-ADR
potentially O-ADR O-ADR
fatal O-ADR B-ADR
symptom O-ADR O-ADR
complex O-ADR O-ADR
sometimes O-ADR O-ADR
referred O-ADR O-ADR
to O-ADR O-ADR
as O-ADR O-ADR
Neuroleptic B-ADR B-ADR
Malignant I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
NMS B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
FANAPT O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
during O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
suspected O-ADR O-ADR
ILD O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
GILOTRIF O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
confirmed O-ADR O-ADR
ILD O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
belimumab O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Across O-ADR O-ADR
repeated O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
icatibant O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
palmar B-ADR B-ADR
- O-ADR O-ADR
plantar O-ADR O-ADR
erythrodysesthesia I-ADR I-ADR
syndrome I-ADR I-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
of O-ADR O-ADR
183 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
hematology O-ADR B-ADR
laboratory O-ADR I-ADR
abnormality O-ADR I-ADR
, O-ADR O-ADR
with O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
[ O-ADR O-ADR
3 O-ADR O-ADR
of O-ADR O-ADR
183 O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
being O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Infusion O-ADR O-ADR
Reactions O-ADR O-ADR
Infusion B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
reactions O-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
Serum O-ADR O-ADR
Liver O-ADR O-ADR
Biochemistries O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
Co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
worsening O-ADR O-ADR
or O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
with O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TIVICAY O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
SJIA O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
SJIA O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
are O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
and O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
Neuraceq O-ADR O-ADR
were O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
quantity O-ADR O-ADR
of O-ADR O-ADR
concurrently O-ADR O-ADR
administered O-ADR O-ADR
lipids O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
compensate O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
amount O-ADR O-ADR
of O-ADR O-ADR
lipid O-ADR O-ADR
infused O-ADR O-ADR
as O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Cleviprex O-ADR O-ADR
formulation O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reports O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressants O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
allergy O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
macrolides O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis O-ADR O-ADR
interrupt O-ADR O-ADR
AFINITOR O-ADR O-ADR
until O-ADR O-ADR
resolution O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
post B-ADR B-ADR
- O-ADR O-ADR
transplant O-ADR O-ADR
lymphoproliferative I-ADR I-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
PTLD B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
predominantly O-ADR O-ADR
involving O-ADR O-ADR
the O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
( O-ADR O-ADR
CNS O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR B-ADR
DISCONTINUATION O-ADR O-ADR
OF O-ADR O-ADR
ELIQUIS O-ADR O-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC B-ADR B-ADR
EVENTS I-ADR I-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
EPIDURAL B-ADR O-ADR
HEMATOMA I-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
ULORIC O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
1377 O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
674 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
and O-ADR O-ADR
515 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Genzyme O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
745 O-ADR O-ADR
- O-ADR O-ADR
4447 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Refer O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
for O-ADR O-ADR
additional O-ADR O-ADR
information O-ADR O-ADR
regarding O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
include O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
663 O-ADR O-ADR
- O-ADR O-ADR
0412 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Talk O-ADR O-ADR
with O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
regularly O-ADR O-ADR
about O-ADR O-ADR
whether O-ADR O-ADR
you O-ADR O-ADR
should O-ADR O-ADR
continue O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
anemia O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
about O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
pharmacologic O-ADR O-ADR
interventions O-ADR O-ADR
that O-ADR O-ADR
help O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
orthostatic O-ADR O-ADR
hypotension O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
sitting O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
edge O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
bed O-ADR O-ADR
for O-ADR O-ADR
several O-ADR O-ADR
minutes O-ADR O-ADR
before O-ADR O-ADR
attempting O-ADR O-ADR
to O-ADR O-ADR
stand O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
morning O-ADR O-ADR
and O-ADR O-ADR
slowly O-ADR O-ADR
rising O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
seated O-ADR O-ADR
position O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
bilirubin O-ADR O-ADR
is O-ADR O-ADR
elevated O-ADR O-ADR
, O-ADR O-ADR
perform O-ADR O-ADR
fractionation O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Parameters O-ADR O-ADR
: O-ADR O-ADR
activated B-ADR B-ADR
partial I-ADR I-ADR
thromboplastin I-ADR I-ADR
time I-ADR I-ADR
prolonged I-ADR I-ADR
, O-ADR O-ADR
creatine B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
bicarbonate B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
sodium B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
EEG B-ADR B-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
glucose B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
cholesterol B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
triglycerides B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
amylase B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
potassium B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
TSH B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
platelet B-ADR B-ADR
count I-ADR I-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
hematocrit B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
hemoglobin B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
MCV B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
RBC B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
creatinine B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
urea I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
BUN B-ADR B-ADR
/ O-ADR O-ADR
creatinine O-ADR O-ADR
ratio I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
CPK B-ADR B-ADR
) I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
alkaline B-ADR B-ADR
phosphatase I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
LDH B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
PSA B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
urine B-ADR B-ADR
output I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
lymphocyte B-ADR B-ADR
count I-ADR I-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
neutrophil B-ADR B-ADR
count I-ADR I-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
WBC B-ADR B-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
coagulation B-ADR B-ADR
test I-ADR I-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
LDL B-ADR B-ADR
) I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
prothrombin B-ADR B-ADR
time I-ADR I-ADR
prolonged I-ADR I-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
casts I-ADR I-ADR
, O-ADR O-ADR
urine B-ADR B-ADR
positive I-ADR I-ADR
for I-ADR I-ADR
white I-ADR I-ADR
blood I-ADR I-ADR
cells I-ADR I-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
require O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
JEVTANA O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
DUAVEE O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
condition O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
prescribed O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
pediatric O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
abnormal B-ADR B-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
versus O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Potassium O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
MULTAQ O-ADR O-ADR
and O-ADR O-ADR
maintained O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
range O-ADR O-ADR
during O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Bleeding O-ADR O-ADR
ELIQUIS O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
and O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
serious O-ADR O-ADR
, O-ADR O-ADR
potentially O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
bleeding B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
andAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
Insulin O-ADR O-ADR
Secretagogues O-ADR O-ADR
or O-ADR O-ADR
Insulin O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
when O-ADR O-ADR
TANZEUM O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
sulfonylureas O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
increased O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
postoperative O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
indwelling O-ADR O-ADR
epidural O-ADR O-ADR
catheters O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
medicinal O-ADR O-ADR
products O-ADR O-ADR
affecting O-ADR O-ADR
hemostasis O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
appears O-ADR O-ADR
highest O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
: O-ADR O-ADR
oChronic O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73m2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
oroAcute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
Rapid O-ADR O-ADR
intravenous O-ADR O-ADR
infusions O-ADR O-ADR
of O-ADR O-ADR
DALVANCE O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
resemble O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
Red B-ADR B-ADR
- O-ADR O-ADR
Man O-ADR O-ADR
Syndrome I-ADR I-ADR
, O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
including O-ADR O-ADR
flushing B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
upper I-ADR I-ADR
body I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
This O-ADR O-ADR
trial O-ADR O-ADR
involved O-ADR O-ADR
SAPHRIS O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
15 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
151 O-ADR O-ADR
clinically O-ADR O-ADR
stable O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
electrocardiographic O-ADR O-ADR
assessments O-ADR O-ADR
throughout O-ADR O-ADR
the O-ADR O-ADR
dosing O-ADR O-ADR
interval O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
steady O-ADR O-ADR
state O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
: O-ADR O-ADR
Closely O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
rapidly O-ADR O-ADR
proliferating O-ADR O-ADR
tumor O-ADR O-ADR
or O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Neonatal B-ADR B-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
gasping B-ADR B-ADR
syndrome I-ADR I-ADR
if O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
neonates O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
, O-ADR O-ADR
ECG O-ADR O-ADR
and O-ADR O-ADR
vital O-ADR O-ADR
sign O-ADR O-ADR
changes O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
MDD O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
changes O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
MDD O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
pyrexia B-ADR B-ADR
are O-ADR O-ADR
increased O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Venous O-ADR O-ADR
Thromboembolism O-ADR O-ADR
Venous B-ADR B-ADR
thromboembolism I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
the O-ADR O-ADR
similarity O-ADR O-ADR
in O-ADR O-ADR
hypersensitivity O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
acute O-ADR O-ADR
HAE O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
closely O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
- O-ADR O-ADR
Syncope B-ADR B-ADR
, O-ADR O-ADR
convulsion B-ADR B-ADR
, O-ADR O-ADR
dystonia B-ADR B-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
( O-ADR O-ADR
elvitegravir O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
cobicistat O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
emtricitabine O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
ATRIPLA O-ADR O-ADR
( O-ADR O-ADR
efavirenz O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
emtricitabine O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
atazanavir O-ADR O-ADR
( O-ADR O-ADR
ATV O-ADR O-ADR
) O-ADR O-ADR
+ O-ADR O-ADR
ritonavir O-ADR O-ADR
( O-ADR O-ADR
RTV O-ADR O-ADR
) O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
( O-ADR O-ADR
emtricitabine O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
TIVICAY O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
previous O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
dolutegravir O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Dementia O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Psychosis O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
weight O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
ADRs O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
subject O-ADR O-ADR
were O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cutaneous B-ADR B-ADR
reactions I-ADR I-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
acneiform B-ADR B-ADR
rash I-ADR I-ADR
was O-ADR O-ADR
90 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
cutaneous B-ADR B-ADR
reactions I-ADR I-ADR
was O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
600 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
FIRAZYR O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
FIRAZYR O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
by O-ADR O-ADR
healthcare O-ADR O-ADR
professionals O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
higher O-ADR O-ADR
infusion O-ADR O-ADR
rates O-ADR O-ADR
. O-ADR O-ADR
Macular O-ADR O-ADR
Edema O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
History O-ADR O-ADR
of O-ADR O-ADR
Uveitis O-ADR O-ADR
or O-ADR O-ADR
Diabetes O-ADR O-ADR
Mellitus O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
during O-ADR O-ADR
GILENYA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
VZV O-ADR O-ADR
vaccination O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
patients O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
commencing O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
, O-ADR O-ADR
following O-ADR O-ADR
which O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
postponed O-ADR O-ADR
for O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
to O-ADR O-ADR
allow O-ADR O-ADR
the O-ADR O-ADR
full O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
vaccination O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
more O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
TNF O-ADR O-ADR
treatment O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Fourteen O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
stopped O-ADR O-ADR
therapy O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
completion O-ADR O-ADR
; O-ADR O-ADR
seven O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
five O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
physician O-ADR O-ADR
or O-ADR O-ADR
patient O-ADR O-ADR
choice O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
during O-ADR O-ADR
frontline O-ADR O-ADR
protocol O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
with O-ADR O-ADR
regular O-ADR O-ADR
measurement O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypertension B-ADR B-ADR
including O-ADR O-ADR
hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
the O-ADR O-ADR
prevalence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
appears O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
highest O-ADR O-ADR
among O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
elderly O-ADR O-ADR
women O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
impossible O-ADR O-ADR
to O-ADR O-ADR
rely O-ADR O-ADR
upon O-ADR O-ADR
prevalence O-ADR O-ADR
estimates O-ADR O-ADR
to O-ADR O-ADR
predict O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
inception O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
metabolic B-ADR B-ADR
changes I-ADR I-ADR
include O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
dyslipidemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
body B-ADR B-ADR
weight I-ADR I-ADR
gain I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
intensity O-ADR O-ADR
was O-ADR O-ADR
483 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
500 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AP O-ADR O-ADR
CML O-ADR O-ADR
and O-ADR O-ADR
BP O-ADR O-ADR
CML O-ADR O-ADR
cohorts O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
. O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
creatinine I-ADR I-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
subdural B-ADR B-ADR
hematoma I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
More O-ADR O-ADR
Frequently O-ADR O-ADR
Than O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Given O-ADR O-ADR
Placebo O-ADR O-ADR
in O-ADR O-ADR
Pooled O-ADR O-ADR
Studies O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
NESINA25 O-ADR O-ADR
mg O-ADR O-ADR
Placebo O-ADR O-ADR
Active O-ADR O-ADR
Comparator O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
5902 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2926 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
2257 O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
257 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
89 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
113 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
247 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
72 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
121 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
Upper B-ADR B-ADR
Respiratory I-ADR I-ADR
Tract I-ADR I-ADR
Infection I-ADR I-ADR
247 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
61 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
113 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
Pancreatitis O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
program O-ADR O-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
of O-ADR O-ADR
5902 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
five O-ADR O-ADR
of O-ADR O-ADR
5183 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hyponatremia B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
sodium O-ADR O-ADR
levels O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
hyponatremia O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
symptomatic O-ADR O-ADR
hyponatremia O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
reporting O-ADR O-ADR
severe O-ADR O-ADR
adverse O-ADR O-ADR
gastrointestinal O-ADR O-ADR
reactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
POTIGA O-ADR O-ADR
causes O-ADR O-ADR
mucous B-ADR B-ADR
membrane I-ADR I-ADR
discoloration I-ADR I-ADR
and O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
clear O-ADR O-ADR
whether O-ADR O-ADR
this O-ADR O-ADR
discoloration B-ADR B-ADR
is O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
healthy O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
large O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
/ O-ADR O-ADR
vilanterol O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
vilanterol O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
higher O-ADR O-ADR
systemic O-ADR O-ADR
exposure O-ADR O-ADR
than O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
prolongation B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
QTc I-ADR I-ADR
interval I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
has O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
producing O-ADR O-ADR
ventricular B-ADR B-ADR
arrhythmias I-ADR I-ADR
. O-ADR O-ADR
Eight O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Thyroid O-ADR O-ADR
Accumulation O-ADR O-ADR
Failure O-ADR O-ADR
to O-ADR O-ADR
block O-ADR O-ADR
thyroid O-ADR O-ADR
uptake O-ADR O-ADR
of O-ADR O-ADR
iodine O-ADR O-ADR
123 O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
thyroid O-ADR B-ADR
neoplasia O-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Particular O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
in O-ADR O-ADR
observing O-ADR O-ADR
patients O-ADR O-ADR
postoperatively O-ADR O-ADR
or O-ADR O-ADR
during O-ADR O-ADR
periods O-ADR O-ADR
of O-ADR O-ADR
stress O-ADR O-ADR
for O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
inadequate O-ADR O-ADR
adrenal O-ADR O-ADR
response O-ADR O-ADR
. O-ADR O-ADR
Delay O-ADR O-ADR
in O-ADR O-ADR
stopping O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
rash O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
AGRANULOCYTOSIS O-ADR B-ADR
/ O-ADR O-ADR
NEUTROPENIA O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
AGRANULOCYTOSIS O-ADR B-ADR
/ O-ADR O-ADR
NEUTROPENIA O-ADR O-ADR
* O-ADR O-ADR
Ferriprox O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
agranulocytosis B-ADR B-ADR
that O-ADR O-ADR
can O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
and O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
unstable O-ADR O-ADR
cardiac O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
narrow O-ADR O-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
symptomatic O-ADR O-ADR
prostatic O-ADR O-ADR
hypertrophy O-ADR O-ADR
or O-ADR O-ADR
bladder O-ADR O-ADR
outlet O-ADR O-ADR
obstruction O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
fatal B-ADR B-ADR
pneumonia B-ADR B-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
subject O-ADR O-ADR
receiving O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
each O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
this O-ADR O-ADR
safety O-ADR O-ADR
study O-ADR O-ADR
indicate O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
greatest O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
VTE B-ADR B-ADR
is O-ADR O-ADR
present O-ADR O-ADR
after O-ADR O-ADR
initially O-ADR O-ADR
starting O-ADR O-ADR
a O-ADR O-ADR
COC O-ADR O-ADR
or O-ADR O-ADR
restarting O-ADR O-ADR
( O-ADR O-ADR
following O-ADR O-ADR
a O-ADR O-ADR
4 O-ADR O-ADR
week O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
pill O-ADR O-ADR
- O-ADR O-ADR
free O-ADR O-ADR
interval O-ADR O-ADR
) O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
different O-ADR O-ADR
COC O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
published O-ADR O-ADR
report O-ADR O-ADR
of O-ADR O-ADR
18 O-ADR O-ADR
F O-ADR O-ADR
- O-ADR O-ADR
methylcholine O-ADR O-ADR
PET O-ADR O-ADR
imaging O-ADR O-ADR
indicated O-ADR O-ADR
that O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
colchicine O-ADR O-ADR
for O-ADR O-ADR
two O-ADR O-ADR
weeks O-ADR O-ADR
resolved O-ADR O-ADR
the O-ADR O-ADR
colchicine O-ADR O-ADR
effect O-ADR O-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
or O-ADR O-ADR
using O-ADR O-ADR
thyroid O-ADR O-ADR
ultrasound O-ADR O-ADR
is O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
value O-ADR O-ADR
for O-ADR O-ADR
early O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
. O-ADR O-ADR
Reports O-ADR O-ADR
of O-ADR O-ADR
penile O-ADR B-ADR
` O-ADR O-ADR
` O-ADR O-ADR
popping O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
sounds O-ADR O-ADR
or O-ADR O-ADR
sensations O-ADR O-ADR
A O-ADR O-ADR
popping B-ADR B-ADR
sensation I-ADR I-ADR
in I-ADR I-ADR
the I-ADR I-ADR
penis I-ADR I-ADR
' O-ADR O-ADR
' O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
detumescence B-ADR B-ADR
, O-ADR O-ADR
hematoma B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
pain B-ADR B-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
73 O-ADR O-ADR
/ O-ADR O-ADR
551 O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
281 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
741 O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AMPYRA O-ADR O-ADR
for O-ADR O-ADR
over O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
501 O-ADR O-ADR
for O-ADR O-ADR
over O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
and O-ADR O-ADR
352 O-ADR O-ADR
for O-ADR O-ADR
over O-ADR O-ADR
two O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
effects O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Severe O-ADR O-ADR
or O-ADR O-ADR
Persistent O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Toxicity O-ADR O-ADR
Diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
96 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
cases O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Interrupt O-ADR O-ADR
Ferriprox O-ADR O-ADR
if O-ADR O-ADR
infection O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Zydelig O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
GILOTRIF O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
3800 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
2135 O-ADR O-ADR
NSCLC O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILOTRIF O-ADR O-ADR
monotherapy O-ADR O-ADR
at O-ADR O-ADR
or O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
receptor O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
worsening O-ADR B-ADR
of O-ADR I-ADR
chronic B-ADR I-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
sometimes O-ADR O-ADR
require O-ADR O-ADR
hemodialysis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
many O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
this O-ADR O-ADR
hyponatremia B-ADR B-ADR
appears O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
the O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome B-ADR O-ADR
of I-ADR O-ADR
inappropriate I-ADR O-ADR
antidiuretic I-ADR O-ADR
hormone I-ADR O-ADR
secretion I-ADR O-ADR
( O-ADR O-ADR
SIADH B-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Corporal B-ADR B-ADR
rupture I-ADR I-ADR
( O-ADR O-ADR
penile B-ADR B-ADR
fracture I-ADR I-ADR
) O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
injury B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
penis I-ADR I-ADR
: O-ADR O-ADR
Avoid O-ADR O-ADR
injecting O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
urethra O-ADR O-ADR
, O-ADR O-ADR
nerves O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
vessels O-ADR O-ADR
, O-ADR O-ADR
corpora O-ADR O-ADR
cavernosa O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
collagen O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
structures O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
penis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
general O-ADR O-ADR
, O-ADR O-ADR
discontinuation O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
with O-ADR O-ADR
longer O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
fail O-ADR O-ADR
to O-ADR O-ADR
improve O-ADR O-ADR
after O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
( O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
) O-ADR O-ADR
neurological B-ADR B-ADR
toxicities I-ADR I-ADR
following O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
BLINCYTO O-ADR O-ADR
administration O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
encephalopathy B-ADR B-ADR
, O-ADR O-ADR
convulsions B-ADR B-ADR
, O-ADR O-ADR
speech B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
disturbances B-ADR B-ADR
in I-ADR I-ADR
consciousness I-ADR I-ADR
, O-ADR O-ADR
confusion B-ADR B-ADR
and O-ADR O-ADR
disorientation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
balance B-ADR B-ADR
disorders I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
555 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Amyvid O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
toxicity I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
week O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
capable O-ADR O-ADR
of O-ADR O-ADR
inhibiting O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
from O-ADR O-ADR
binding O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
mannose O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
phosphate O-ADR O-ADR
receptor O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
once O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
one O-ADR O-ADR
week O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
and O-ADR O-ADR
persisted O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
triglycerides I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Skin B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
SJS B-ADR B-ADR
and O-ADR O-ADR
TEN B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
when O-ADR O-ADR
TREANDA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
allopurinol O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
these O-ADR O-ADR
syndromes O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Drug B-ADR B-ADR
Induced I-ADR B-ADR
Liver I-ADR I-ADR
Injury I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
APTIOM O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
jaundice O-ADR O-ADR
or O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
significant O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
( O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
) O-ADR O-ADR
included O-ADR O-ADR
546 O-ADR O-ADR
CML O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
287 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CP O-ADR O-ADR
CML O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
imatinib O-ADR O-ADR
only O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
24 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
intensity O-ADR O-ADR
of O-ADR O-ADR
484 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
in O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
HAE O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
intravenous O-ADR O-ADR
or O-ADR O-ADR
subcutaneous O-ADR O-ADR
KALBITOR O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
6 O-ADR O-ADR
ADA O-ADR O-ADR
positive O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
during O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
56 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Using O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
your O-ADR O-ADR
chance O-ADR O-ADR
of O-ADR O-ADR
getting O-ADR O-ADR
cancer O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
uterus O-ADR O-ADR
( O-ADR O-ADR
womb O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
well O-ADR O-ADR
hydrated O-ADR O-ADR
before O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
in O-ADR O-ADR
Cycle O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
subsequent O-ADR O-ADR
cycles O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
and O-ADR O-ADR
cerebrovascular B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
stroke B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Hypertension O-ADR O-ADR
Hypertension B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
hypertensive B-ADR B-ADR
crisis I-ADR I-ADR
and O-ADR O-ADR
hypertensive B-ADR B-ADR
emergency I-ADR I-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
supine O-ADR O-ADR
hypertension O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
managed O-ADR O-ADR
by O-ADR O-ADR
elevation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
head O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
bed O-ADR O-ADR
, O-ADR O-ADR
reduce O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
NORTHERA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Obtain O-ADR O-ADR
periodic O-ADR O-ADR
liver O-ADR O-ADR
testing O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Subjects O-ADR O-ADR
IMPAACT O-ADR O-ADR
P1093 O-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
ongoing O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
comparative O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
160 O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
pediatric O-ADR O-ADR
subjects O-ADR O-ADR
aged O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
23 O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
, O-ADR O-ADR
INSTI O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
subjects O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxins O-ADR O-ADR
may O-ADR O-ADR
weaken B-ADR B-ADR
neck I-ADR I-ADR
muscles I-ADR I-ADR
that O-ADR O-ADR
serve O-ADR O-ADR
as O-ADR O-ADR
accessory O-ADR O-ADR
muscles O-ADR O-ADR
of O-ADR O-ADR
ventilation O-ADR O-ADR
. O-ADR O-ADR
Macular B-ADR B-ADR
edema I-ADR I-ADR
occurred O-ADR O-ADR
predominantly O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Counsel O-ADR O-ADR
patients O-ADR O-ADR
regarding O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
and O-ADR O-ADR
inform O-ADR O-ADR
them O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
tumors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
mass O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
neck O-ADR O-ADR
, O-ADR O-ADR
dysphagia O-ADR O-ADR
, O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
hoarseness O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Heart O-ADR O-ADR
Rate O-ADR O-ADR
Increase O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
mean B-ADR O-ADR
heart I-ADR B-ADR
rate I-ADR I-ADR
in I-ADR O-ADR
patients I-ADR O-ADR
treated I-ADR O-ADR
with I-ADR O-ADR
TANZEUM I-ADR O-ADR
was I-ADR O-ADR
higher I-ADR I-ADR
by I-ADR O-ADR
an I-ADR O-ADR
average I-ADR O-ADR
of I-ADR O-ADR
1 I-ADR O-ADR
to I-ADR O-ADR
2 I-ADR O-ADR
bpm I-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
mean O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
across O-ADR O-ADR
study O-ADR O-ADR
visits O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
aid O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
with O-ADR O-ADR
expertise O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
before O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
lymphatic O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
place O-ADR O-ADR
DUAVEE O-ADR O-ADR
in O-ADR O-ADR
pill O-ADR O-ADR
boxes O-ADR O-ADR
or O-ADR O-ADR
pill O-ADR O-ADR
organizers O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
APTC O-ADR B-ADR
events O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
ULORIC O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
allopurinol O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Perform O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
TB O-ADR O-ADR
; O-ADR O-ADR
if O-ADR O-ADR
positive O-ADR O-ADR
, O-ADR O-ADR
start O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
TB O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
starting O-ADR O-ADR
CIMZIA O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Worsening O-ADR O-ADR
of O-ADR O-ADR
Narrow O-ADR O-ADR
- O-ADR O-ADR
Angle O-ADR O-ADR
Glaucoma O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
narrow O-ADR O-ADR
- O-ADR O-ADR
angle O-ADR O-ADR
glaucoma O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
abnormal O-ADR O-ADR
LVEF O-ADR O-ADR
, O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
coronary O-ADR O-ADR
syndrome O-ADR O-ADR
within O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
current O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
Class O-ADR O-ADR
II O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
( O-ADR O-ADR
New O-ADR O-ADR
York O-ADR O-ADR
Heart O-ADR O-ADR
Association O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
history O-ADR O-ADR
RVO O-ADR O-ADR
or O-ADR O-ADR
RPED O-ADR O-ADR
, O-ADR O-ADR
QTc O-ADR O-ADR
interval O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
480 O-ADR O-ADR
msec O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
refractory O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
uncontrolled O-ADR O-ADR
arrhythmias O-ADR O-ADR
, O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pneumonitis O-ADR O-ADR
or O-ADR O-ADR
interstitial O-ADR O-ADR
lung O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
G6PD O-ADR O-ADR
deficiency O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
ELIQUIS O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
pathological O-ADR O-ADR
hemorrhage O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
BMD O-ADR O-ADR
and O-ADR O-ADR
biochemical O-ADR O-ADR
markers O-ADR O-ADR
on O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
bone O-ADR O-ADR
health O-ADR O-ADR
and O-ADR O-ADR
future O-ADR O-ADR
fracture O-ADR O-ADR
risk O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
reactivation O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
reported O-ADR O-ADR
thromboembolic B-ADR B-ADR
events I-ADR I-ADR
in O-ADR O-ADR
wet O-ADR O-ADR
AMD O-ADR O-ADR
studies O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
year O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
32 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
1824 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
group O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
. O-ADR O-ADR
Optic B-ADR B-ADR
atrophy I-ADR I-ADR
and O-ADR O-ADR
optic B-ADR B-ADR
nerve I-ADR I-ADR
disorder I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
potential O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
vision B-ADR B-ADR
loss I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Macrovascular O-ADR O-ADR
Outcomes O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
clinically O-ADR O-ADR
important O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
586 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Pancreatitis B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
CIMZIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
or O-ADR O-ADR
sepsis O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
extension O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
adjudicated O-ADR O-ADR
APTC O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
ULORIC O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
97 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
57 O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
56 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
allopurinol O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
02 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Report O-ADR O-ADR
any O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
NSF O-ADR O-ADR
following O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
to O-ADR O-ADR
Bayer O-ADR O-ADR
HealthCare O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
842 O-ADR O-ADR
- O-ADR O-ADR
2937 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Study O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
with O-ADR O-ADR
expertise O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
to O-ADR O-ADR
aid O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
whether O-ADR O-ADR
initiating O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
tuberculosis O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
appropriate O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
individual O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
Beta O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
withdrawn O-ADR O-ADR
only O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
gradual O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
immunosuppressants O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
exceeded O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
aware O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
clinical O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
heart I-ADR I-ADR
rate I-ADR I-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
function O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
JARDIANCE O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
prolonged O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
diarrhea O-ADR O-ADR
lasting O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
diarrhea O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
until O-ADR O-ADR
diarrhea O-ADR O-ADR
resolves O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
resume O-ADR O-ADR
GILOTRIF O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
compares O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
where O-ADR O-ADR
ethnicity O-ADR O-ADR
was O-ADR O-ADR
recorded O-ADR O-ADR
the O-ADR O-ADR
ethnic O-ADR O-ADR
distribution O-ADR O-ADR
was O-ADR O-ADR
74 O-ADR O-ADR
% O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
others O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
viral B-ADR B-ADR
diseases I-ADR I-ADR
or O-ADR O-ADR
CJD B-ADR B-ADR
have O-ADR O-ADR
ever O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
albumin O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
Kyprolis O-ADR O-ADR
if O-ADR O-ADR
PRES O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
: O-ADR O-ADR
Key O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
Higher O-ADR O-ADR
Rate O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
Arm O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
Arm O-ADR O-ADR
Grading O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
CTCAE O-ADR O-ADR
Version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Reflects O-ADR O-ADR
corresponding O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
( O-ADR O-ADR
collectively O-ADR O-ADR
pancytopenia B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
frequency O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Ischemic O-ADR O-ADR
Heart O-ADR O-ADR
Disease O-ADR O-ADR
, O-ADR O-ADR
Arrhythmias O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Congestive O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
NORTHERA O-ADR O-ADR
may O-ADR O-ADR
exacerbate B-ADR B-ADR
existing I-ADR I-ADR
ischemic I-ADR I-ADR
heart I-ADR I-ADR
disease I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
constitutional O-ADR O-ADR
findings O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
organ B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
liver B-ADR B-ADR
injury I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
1368 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
were O-ADR O-ADR
received O-ADR O-ADR
for O-ADR O-ADR
940 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
76 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
91 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
leukemia O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
lymphoma O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
unknown O-ADR O-ADR
disease O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
adequate O-ADR O-ADR
hydration O-ADR O-ADR
is O-ADR O-ADR
required O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
in O-ADR O-ADR
Cycle O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
volume O-ADR O-ADR
overload O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
cardiac O-ADR B-ADR
failure O-ADR I-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
developed O-ADR O-ADR
PML B-ADR B-ADR
after O-ADR O-ADR
taking O-ADR O-ADR
GILENYA O-ADR O-ADR
for O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
as O-ADR O-ADR
a O-ADR O-ADR
complication O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
dysphagia B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
. O-ADR O-ADR
They O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
interchangeable O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
preparations O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
biological O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
or O-ADR O-ADR
converted O-ADR O-ADR
into O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
assessed O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
specific O-ADR O-ADR
assay O-ADR O-ADR
method O-ADR O-ADR
[ O-ADR O-ADR
seeDescription O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Skin O-ADR O-ADR
Reactions O-ADR O-ADR
Skin B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
postmarketing O-ADR O-ADR
safety O-ADR O-ADR
reports O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
toxic B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
bullous B-ADR B-ADR
exanthema I-ADR I-ADR
. O-ADR O-ADR
A O-ADR O-ADR
RCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
Receptor O-ADR O-ADR
activator O-ADR O-ADR
of O-ADR O-ADR
nuclear O-ADR O-ADR
factor O-ADR O-ADR
kappa O-ADR O-ADR
- O-ADR O-ADR
B O-ADR O-ADR
ligand O-ADR O-ADR
( O-ADR O-ADR
RANKL O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
expressed O-ADR O-ADR
on O-ADR O-ADR
activated O-ADR O-ADR
T O-ADR O-ADR
and O-ADR O-ADR
B O-ADR O-ADR
lymphocytes O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
lymph O-ADR O-ADR
nodes O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
four O-ADR O-ADR
suicides B-ADR B-ADR
in O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
events O-ADR O-ADR
is O-ADR O-ADR
too O-ADR O-ADR
small O-ADR O-ADR
to O-ADR O-ADR
allow O-ADR O-ADR
any O-ADR O-ADR
conclusion O-ADR O-ADR
about O-ADR O-ADR
drug O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
suicide B-ADR B-ADR
. O-ADR O-ADR
Hepatic O-ADR O-ADR
Transaminases O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
hepatic I-ADR I-ADR
transaminases I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
primarily O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
most O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
elevations O-ADR O-ADR
had O-ADR O-ADR
levels O-ADR O-ADR
< O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
epidemiological O-ADR O-ADR
studies O-ADR O-ADR
suggest O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
hyperglycemia B-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR O-ADR
events I-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
into O-ADR O-ADR
these O-ADR O-ADR
structures O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
possible O-ADR O-ADR
permanent O-ADR B-ADR
injury O-ADR I-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
tendon O-ADR B-ADR
rupture O-ADR I-ADR
or O-ADR O-ADR
ligament O-ADR B-ADR
damage O-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
skin O-ADR B-ADR
laceration O-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
demographic O-ADR O-ADR
characteristics O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
among O-ADR O-ADR
the O-ADR O-ADR
4 O-ADR O-ADR
pivotal O-ADR O-ADR
studies O-ADR O-ADR
and O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
within O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
chickenpox O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
antiviral O-ADR O-ADR
agents O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
of O-ADR O-ADR
Interest O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
Abiraterone O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
791 O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
394 O-ADR O-ADR
) O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormality O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hypertriglyceridemia B-ADR B-ADR
62 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
53 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
High B-ADR B-ADR
AST I-ADR I-ADR
30 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
36 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Hypokalemia B-ADR B-ADR
28 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
19 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
Hypophosphatemia B-ADR B-ADR
23 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
High B-ADR B-ADR
ALT I-ADR I-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
High B-ADR B-ADR
Total I-ADR I-ADR
Bilirubin I-ADR I-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
0 O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
Chemotherapy O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
enrolled O-ADR O-ADR
1088 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
received O-ADR O-ADR
prior O-ADR O-ADR
cytotoxic O-ADR O-ADR
chemotherapy O-ADR O-ADR
. O-ADR O-ADR
Such O-ADR O-ADR
monitoring O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
unnecessary O-ADR O-ADR
procedures O-ADR O-ADR
, O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
low O-ADR O-ADR
test O-ADR O-ADR
specificity O-ADR O-ADR
for O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
background O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
EOVIST O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
feeling B-ADR B-ADR
hot I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
Thoracic O-ADR O-ADR
and O-ADR O-ADR
Mediastinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis I-ADR I-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
Ferriprox O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
immediately O-ADR O-ADR
any O-ADR O-ADR
symptoms O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
CORPORAL B-ADR B-ADR
RUPTURE I-ADR I-ADR
( O-ADR O-ADR
PENILE B-ADR B-ADR
FRACTURE I-ADR I-ADR
) O-ADR O-ADR
OR O-ADR O-ADR
OTHER O-ADR O-ADR
SERIOUS O-ADR O-ADR
PENILE B-ADR B-ADR
INJURY I-ADR I-ADR
IN O-ADR O-ADR
THE O-ADR O-ADR
TREATMENT O-ADR O-ADR
OF O-ADR O-ADR
PEYRONIE O-ADR O-ADR
' O-ADR O-ADR
S O-ADR O-ADR
DISEASE O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
* O-ADR O-ADR
Corporal B-ADR B-ADR
rupture I-ADR I-ADR
( O-ADR O-ADR
penile B-ADR B-ADR
fracture I-ADR I-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Preexisting O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
elevated O-ADR O-ADR
baseline O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
during O-ADR O-ADR
exposure O-ADR O-ADR
were O-ADR O-ADR
obtained O-ADR O-ADR
by O-ADR O-ADR
general O-ADR O-ADR
inquiry O-ADR O-ADR
and O-ADR O-ADR
recorded O-ADR O-ADR
by O-ADR O-ADR
clinical O-ADR O-ADR
investigators O-ADR O-ADR
using O-ADR O-ADR
their O-ADR O-ADR
own O-ADR O-ADR
terminology O-ADR O-ADR
. O-ADR O-ADR
Investigations O-ADR O-ADR
: O-ADR O-ADR
blood B-ADR B-ADR
bilirubin I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
creatinine I-ADR I-ADR
phosphokinase I-ADR I-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
Also O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
diuretics O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
otherwise O-ADR O-ADR
volume O-ADR O-ADR
depleted O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
organisms O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
apparent O-ADR O-ADR
pattern O-ADR O-ADR
with O-ADR O-ADR
respect O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
anatomic O-ADR O-ADR
site O-ADR O-ADR
of O-ADR O-ADR
fracture B-ADR B-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
urinary O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
and O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypertension B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
impact O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
belatacept O-ADR O-ADR
antibodies O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
belatacept O-ADR O-ADR
antibodies O-ADR O-ADR
) O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
determined O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Rule O-ADR O-ADR
out O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
of O-ADR O-ADR
diarrhea O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
crofelemer O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
small O-ADR O-ADR
changes O-ADR B-ADR
in O-ADR I-ADR
BMD O-ADR I-ADR
with O-ADR O-ADR
regard O-ADR O-ADR
to O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
consequences O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
fracture O-ADR B-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
Coexisting O-ADR O-ADR
Conditions O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
all O-ADR O-ADR
medicines O-ADR O-ADR
containing O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
convulsive O-ADR O-ADR
disorders O-ADR O-ADR
or O-ADR O-ADR
thyrotoxicosis O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
unusually O-ADR O-ADR
responsive O-ADR O-ADR
to O-ADR O-ADR
sympathomimetic O-ADR O-ADR
amines O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Arthralgia B-ADR B-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
and O-ADR O-ADR
disabling O-ADR O-ADR
arthralgia B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
DPP O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
characteristics O-ADR O-ADR
, O-ADR O-ADR
volume O-ADR O-ADR
status O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
and O-ADR O-ADR
corrected O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hyperkalemia O-ADR O-ADR
INVOKANA O-ADR O-ADR
can O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
hyperkalemia B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Myelosuppression O-ADR O-ADR
Thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Avoidance O-ADR O-ADR
of O-ADR O-ADR
Contact O-ADR O-ADR
Lenses O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
chronic O-ADR O-ADR
inflammatory O-ADR O-ADR
diseases O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
highly O-ADR O-ADR
active O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapies O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
fold O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
general O-ADR O-ADR
population O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR O-ADR
, O-ADR O-ADR
even O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Isolated O-ADR O-ADR
delayed O-ADR O-ADR
onset O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
transient O-ADR B-ADR
asystole B-ADR I-ADR
and O-ADR O-ADR
unexplained O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
exclusion O-ADR O-ADR
criteria O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizure O-ADR O-ADR
, O-ADR O-ADR
underlying O-ADR O-ADR
brain O-ADR O-ADR
injury O-ADR O-ADR
with O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
consciousness O-ADR O-ADR
, O-ADR O-ADR
transient O-ADR B-ADR
ischemic O-ADR I-ADR
attack O-ADR I-ADR
within O-ADR O-ADR
the O-ADR O-ADR
past O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
cerebral O-ADR O-ADR
vascular O-ADR O-ADR
accident O-ADR O-ADR
, O-ADR O-ADR
brain O-ADR B-ADR
metastases O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
brain O-ADR B-ADR
arteriovenous O-ADR I-ADR
malformation O-ADR I-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
: O-ADR O-ADR
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
, O-ADR O-ADR
cholecystitis B-ADR B-ADR
, O-ADR O-ADR
cholelithiasis B-ADR B-ADR
, O-ADR O-ADR
arterial B-ADR B-ADR
thrombotic I-ADR I-ADR
events I-ADR I-ADR
and O-ADR O-ADR
reflex B-ADR B-ADR
sympathetic I-ADR I-ADR
dystrophy I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
multiple O-ADR O-ADR
myeloma O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
TLS O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
was O-ADR O-ADR
equivalent O-ADR O-ADR
to O-ADR O-ADR
1716 O-ADR O-ADR
person O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
finding O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
DISTANT B-ADR B-ADR
SPREAD I-ADR I-ADR
OF I-ADR I-ADR
TOXIN I-ADR I-ADR
EFFECT I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
DISTANT B-ADR B-ADR
SPREAD I-ADR I-ADR
OF I-ADR I-ADR
TOXIN I-ADR I-ADR
EFFECT I-ADR I-ADR
Postmarketing O-ADR O-ADR
reports O-ADR O-ADR
indicate O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR B-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
spread B-ADR B-ADR
from I-ADR I-ADR
the I-ADR I-ADR
area I-ADR I-ADR
of I-ADR I-ADR
injection I-ADR I-ADR
to I-ADR O-ADR
produce I-ADR O-ADR
symptoms I-ADR O-ADR
consistent I-ADR O-ADR
with I-ADR O-ADR
botulinum I-ADR O-ADR
toxin I-ADR B-ADR
effects I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
You O-ADR O-ADR
and O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
should O-ADR O-ADR
talk O-ADR O-ADR
regularly O-ADR O-ADR
about O-ADR O-ADR
whether O-ADR O-ADR
you O-ADR O-ADR
still O-ADR O-ADR
need O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Death B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
The O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
anaphylactic B-ADR B-ADR
) I-ADR I-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
experiences O-ADR O-ADR
anticholinergic O-ADR O-ADR
CNS O-ADR O-ADR
effects O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
glucose O-ADR O-ADR
, O-ADR O-ADR
lipids O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hematologic O-ADR O-ADR
parameters O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
generalized B-ADR B-ADR
rash O-ADR O-ADR
/ O-ADR O-ADR
erythema O-ADR O-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
and O-ADR O-ADR
bronchospasm B-ADR B-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
if O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
; O-ADR O-ADR
An O-ADR O-ADR
induration O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
mm O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
positive O-ADR O-ADR
tuberculin O-ADR O-ADR
skin O-ADR O-ADR
test O-ADR O-ADR
, O-ADR O-ADR
even O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
previously O-ADR O-ADR
vaccinated O-ADR O-ADR
with O-ADR O-ADR
Bacille O-ADR O-ADR
Calmette O-ADR O-ADR
- O-ADR O-ADR
Guerin O-ADR O-ADR
( O-ADR O-ADR
BCG O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
NULOJIX O-ADR O-ADR
in O-ADR O-ADR
transplant O-ADR O-ADR
recipients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
unknown O-ADR O-ADR
serostatus O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Pheochromocytoma O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
information O-ADR O-ADR
to O-ADR O-ADR
guide O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Cleviprex O-ADR O-ADR
in O-ADR O-ADR
treating O-ADR O-ADR
hypertension O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
pheochromocytoma O-ADR O-ADR
. O-ADR O-ADR
Invasive O-ADR O-ADR
Fungal O-ADR O-ADR
Infections O-ADR O-ADR
If O-ADR O-ADR
patients O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
systemic O-ADR O-ADR
illness O-ADR O-ADR
and O-ADR O-ADR
they O-ADR O-ADR
reside O-ADR O-ADR
or O-ADR O-ADR
travel O-ADR O-ADR
in O-ADR O-ADR
regions O-ADR O-ADR
where O-ADR O-ADR
mycoses O-ADR O-ADR
are O-ADR O-ADR
endemic O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infection O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
recrudescent O-ADR O-ADR
P O-ADR O-ADR
. O-ADR O-ADR
falciparum O-ADR O-ADR
infection O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
different O-ADR O-ADR
antimalarial O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
cases O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
obstructive B-ADR B-ADR
uropathy I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
deaths B-ADR B-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
arms O-ADR O-ADR
( O-ADR O-ADR
KRd O-ADR O-ADR
versus O-ADR O-ADR
Rd O-ADR O-ADR
) O-ADR O-ADR
included O-ADR O-ADR
renal B-ADR O-ADR
0 I-ADR O-ADR
( I-ADR O-ADR
0 I-ADR O-ADR
% I-ADR O-ADR
) I-ADR O-ADR
versus I-ADR O-ADR
1 I-ADR O-ADR
( I-ADR O-ADR
< I-ADR O-ADR
1 I-ADR O-ADR
% I-ADR O-ADR
) I-ADR O-ADR
, I-ADR O-ADR
and I-ADR O-ADR
other I-ADR O-ADR
adverse I-ADR O-ADR
events I-ADR O-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
versus O-ADR O-ADR
10 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Galactorrhea B-ADR B-ADR
, O-ADR O-ADR
amenorrhea B-ADR B-ADR
, O-ADR O-ADR
gynecomastia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
impotence B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
prolactin O-ADR O-ADR
- O-ADR O-ADR
elevating O-ADR O-ADR
compounds O-ADR O-ADR
. O-ADR O-ADR
Such O-ADR O-ADR
monitoring O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
unnecessary O-ADR O-ADR
procedures O-ADR O-ADR
, O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
low O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
testing O-ADR O-ADR
for O-ADR O-ADR
MTC O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
background O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
following O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
flushing O-ADR O-ADR
/ O-ADR O-ADR
feeling O-ADR O-ADR
hot B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
oxygen I-ADR I-ADR
saturation I-ADR I-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
tachypnea B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
twitching I-ADR I-ADR
, O-ADR O-ADR
agitation B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
/ O-ADR O-ADR
increased O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
pallor B-ADR B-ADR
, O-ADR O-ADR
rigors B-ADR B-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myalgia B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
antifibrinolytic O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
tranexamic O-ADR O-ADR
acid O-ADR O-ADR
, O-ADR O-ADR
aminocaproic O-ADR O-ADR
acid O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
individuals O-ADR O-ADR
receiving O-ADR O-ADR
apixaban O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
persistently O-ADR O-ADR
positive O-ADR O-ADR
antibodies O-ADR O-ADR
experienced O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
Childbearing O-ADR O-ADR
Potential O-ADR O-ADR
Premenopausal O-ADR O-ADR
women O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
undergone O-ADR O-ADR
a O-ADR O-ADR
hysterectomy O-ADR O-ADR
or O-ADR O-ADR
oophorectomy O-ADR O-ADR
must O-ADR O-ADR
use O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
while O-ADR O-ADR
using O-ADR O-ADR
MULTAQ O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
infusion B-ADR B-ADR
related I-ADR I-ADR
reactions I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
persistently O-ADR O-ADR
positive O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
54 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
99 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
Evaluation O-ADR O-ADR
of O-ADR O-ADR
erectile O-ADR O-ADR
dysfunction O-ADR O-ADR
( O-ADR O-ADR
ED O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
include O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
assessment O-ADR O-ADR
to O-ADR O-ADR
identify O-ADR O-ADR
potential O-ADR O-ADR
underlying O-ADR O-ADR
causes O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
treatment O-ADR O-ADR
options O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
found O-ADR O-ADR
, O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
investigate O-ADR O-ADR
the O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
. O-ADR O-ADR
Premedicate O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
of O-ADR O-ADR
JEVTANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Pancytopenia O-ADR O-ADR
( O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Ribavirin O-ADR O-ADR
and O-ADR O-ADR
Peginterferon O-ADR O-ADR
Alfa O-ADR O-ADR
) O-ADR O-ADR
Serious O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
pancytopenia B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
postmarketing O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
See O-ADR O-ADR
you O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
right O-ADR O-ADR
away O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
get O-ADR O-ADR
vaginal O-ADR O-ADR
bleeding O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
two O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
, O-ADR O-ADR
ascites B-ADR B-ADR
and O-ADR O-ADR
encephalopathy B-ADR B-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
arm O-ADR O-ADR
receiving O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
plus O-ADR O-ADR
antivirals O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
plus O-ADR O-ADR
antivirals O-ADR O-ADR
arm O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Renal O-ADR O-ADR
Failure O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JEVTANA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
four O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
. O-ADR O-ADR
Thromboembolic B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
among O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
among O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
ESA O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
the O-ADR O-ADR
similarity O-ADR O-ADR
in O-ADR O-ADR
hypersensitivity O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
acute O-ADR O-ADR
HAE O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
AMPLIFY O-ADR O-ADR
Study O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
ELIQUIS O-ADR O-ADR
was O-ADR O-ADR
154 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
enoxaparin O-ADR O-ADR
/ O-ADR O-ADR
warfarin O-ADR O-ADR
was O-ADR O-ADR
152 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
Neutropenic B-ADR B-ADR
deaths B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
JEVTANA O-ADR O-ADR
immediately O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
and O-ADR O-ADR
administer O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
uncommon O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
ischemic B-ADR B-ADR
cardiac I-ADR I-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
myocardial B-ADR B-ADR
ischemia I-ADR I-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
coronary B-ADR B-ADR
occlusion I-ADR I-ADR
requiring O-ADR O-ADR
revascularization O-ADR O-ADR
; O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
multiple O-ADR O-ADR
underlying O-ADR O-ADR
cardiac O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postapproval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
interrupting O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
if O-ADR O-ADR
patients O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Diarrhea O-ADR O-ADR
Diarrhea B-ADR B-ADR
has O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
dehydration B-ADR B-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
renal B-ADR B-ADR
impairment I-ADR I-ADR
; O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
b O-ADR O-ADR
The O-ADR O-ADR
600 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
psoriatic O-ADR O-ADR
arthritis O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
typically O-ADR O-ADR
occurred O-ADR O-ADR
early O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
5 O-ADR O-ADR
cycles O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
binding O-ADR O-ADR
and O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
continue O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
portion O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
RA O-ADR O-ADR
for O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
other O-ADR O-ADR
than O-ADR O-ADR
lymphoma O-ADR B-ADR
and O-ADR O-ADR
NMSC O-ADR B-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
- O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
56 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
01 O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
00 O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
79 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
presents O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
INLYTA O-ADR O-ADR
or O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
9 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
of O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
Any O-ADR O-ADR
SAPHRIS O-ADR O-ADR
Dose O-ADR O-ADR
Group O-ADR O-ADR
and O-ADR O-ADR
Which O-ADR O-ADR
Occurred O-ADR O-ADR
at O-ADR O-ADR
Greater O-ADR O-ADR
Incidence O-ADR O-ADR
Than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
Group O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
Week O-ADR O-ADR
Bipolar O-ADR O-ADR
Mania O-ADR O-ADR
Trials O-ADR O-ADR
* O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
flexible O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
confounded O-ADR O-ADR
by O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
preexisting O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
GILENYA O-ADR O-ADR
is O-ADR O-ADR
uncertain O-ADR O-ADR
. O-ADR O-ADR
Vaginal O-ADR O-ADR
bleeding O-ADR O-ADR
after O-ADR O-ADR
menopause O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
warning O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
cancer O-ADR B-ADR
of O-ADR I-ADR
the O-ADR I-ADR
uterus O-ADR I-ADR
( O-ADR I-ADR
womb O-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
INLYTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
swallowing O-ADR O-ADR
or O-ADR O-ADR
breathing O-ADR O-ADR
difficulties O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
complications O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
carriers O-ADR O-ADR
of O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
active O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
throughout O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
following O-ADR O-ADR
termination O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypoglycemia O-ADR B-ADR
was O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
event O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
hypoglycemia O-ADR B-ADR
where O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
required O-ADR O-ADR
the O-ADR O-ADR
assistance O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
person O-ADR O-ADR
to O-ADR O-ADR
recover O-ADR O-ADR
, O-ADR O-ADR
lost O-ADR B-ADR
consciousness O-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR B-ADR
( O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
whether O-ADR O-ADR
biochemical O-ADR O-ADR
documentation O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
low O-ADR O-ADR
glucose O-ADR O-ADR
value O-ADR O-ADR
was O-ADR O-ADR
obtained O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
male B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
candidal B-ADR B-ADR
balanitis I-ADR I-ADR
, O-ADR O-ADR
balanoposthitis B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
males O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
Includes O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
flexible O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
90 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
16 O-ADR O-ADR
weeks O-ADR O-ADR
up O-ADR O-ADR
through O-ADR O-ADR
two O-ADR O-ADR
years O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
were O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
metformin O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
pioglitazone O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
pioglitazone O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
background O-ADR O-ADR
of O-ADR O-ADR
metformin O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
+ O-ADR O-ADR
proteinuria B-ADR B-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
between O-ADR O-ADR
one O-ADR O-ADR
and O-ADR O-ADR
three O-ADR O-ADR
years O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
studies O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
test O-ADR O-ADR
results O-ADR O-ADR
were O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
belatacept O-ADR O-ADR
in O-ADR O-ADR
specific O-ADR O-ADR
assays O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Reduction O-ADR O-ADR
in O-ADR O-ADR
Bone O-ADR O-ADR
Mineral O-ADR O-ADR
Density O-ADR O-ADR
Decreases B-ADR B-ADR
in I-ADR I-ADR
bone I-ADR I-ADR
mineral I-ADR I-ADR
density I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
products O-ADR O-ADR
containing O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
need O-ADR O-ADR
for O-ADR O-ADR
continued O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reassessed O-ADR O-ADR
periodically O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
NORTHERA O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
301 O-ADR O-ADR
and O-ADR O-ADR
302 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
306 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
303 O-ADR O-ADR
and O-ADR O-ADR
304 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Anxiety B-ADR B-ADR
, O-ADR O-ADR
bipolar B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
suicide B-ADR B-ADR
attempt I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Wound B-ADR B-ADR
Complications I-ADR I-ADR
: O-ADR O-ADR
Withhold O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
dehiscence O-ADR O-ADR
or O-ADR O-ADR
complications O-ADR O-ADR
requiring O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
infectious B-ADR O-ADR
adverse I-ADR O-ADR
reactions I-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
causative O-ADR O-ADR
organism O-ADR O-ADR
is O-ADR O-ADR
reported O-ADR O-ADR
if O-ADR O-ADR
specified O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
physician O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Perioperative O-ADR O-ADR
Hypertension O-ADR O-ADR
The O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
Cleviprex O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
perioperative O-ADR O-ADR
setting O-ADR O-ADR
was O-ADR O-ADR
both O-ADR O-ADR
small O-ADR O-ADR
and O-ADR O-ADR
brief O-ADR O-ADR
( O-ADR O-ADR
about O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
nutrition O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
metabolic B-ADR B-ADR
acidosis I-ADR I-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
chickenpox O-ADR O-ADR
, O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
varicella O-ADR O-ADR
zoster O-ADR O-ADR
immune O-ADR O-ADR
globulin O-ADR O-ADR
( O-ADR O-ADR
VZIG O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
reported O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
following O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Allergic O-ADR O-ADR
Reactions O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
injectable O-ADR O-ADR
drug O-ADR O-ADR
product O-ADR O-ADR
, O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
anaphylaxis B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
discontinue O-ADR O-ADR
TRULICITY O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
provides O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
Zydelig O-ADR O-ADR
monotherapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
provides O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hematologic O-ADR O-ADR
Toxicity O-ADR O-ADR
Beleodaq O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
( O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
lymphopenia B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
anemia B-ADR B-ADR
; O-ADR O-ADR
monitor O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
weekly O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
modify O-ADR O-ADR
dosage O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Liver O-ADR O-ADR
Disease O-ADR O-ADR
Discontinue O-ADR O-ADR
Natazia O-ADR O-ADR
if O-ADR O-ADR
jaundice O-ADR O-ADR
develops O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patient O-ADR O-ADR
died B-ADR B-ADR
as O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
and O-ADR O-ADR
one O-ADR O-ADR
additional O-ADR O-ADR
patient O-ADR O-ADR
required O-ADR O-ADR
hospitalization O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
dermatitis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
one O-ADR O-ADR
week O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
drug O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
and O-ADR O-ADR
persisted O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Gallbladder O-ADR O-ADR
Disease O-ADR O-ADR
Studies O-ADR O-ADR
suggest O-ADR O-ADR
a O-ADR O-ADR
small O-ADR O-ADR
increased O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
gallbladder B-ADR B-ADR
disease I-ADR I-ADR
among O-ADR O-ADR
COC O-ADR O-ADR
users O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Protamine O-ADR O-ADR
sulfate O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
K O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
affect O-ADR O-ADR
the O-ADR O-ADR
anticoagulant O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
dabigatran O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
retinal O-ADR B-ADR
abnormalities O-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
abnormal O-ADR B-ADR
visual O-ADR I-ADR
acuity O-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Impairment B-ADR B-ADR
in I-ADR I-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Merz O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
LLC O-ADR O-ADR
at O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
493 O-ADR O-ADR
- O-ADR O-ADR
6646 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
periodic O-ADR O-ADR
( O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
systematic O-ADR O-ADR
visual O-ADR O-ADR
monitoring O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
ophthalmic O-ADR O-ADR
professional O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
76 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
44 O-ADR O-ADR
of O-ADR O-ADR
58 O-ADR O-ADR
) O-ADR O-ADR
completed O-ADR O-ADR
all O-ADR O-ADR
planned O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Neurological B-ADR B-ADR
toxicities I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
Alternatively O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
enteric O-ADR O-ADR
coated O-ADR O-ADR
aspirin O-ADR O-ADR
( O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
325 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
TECFIDERA O-ADR O-ADR
dosing O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
or O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
flushing B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosing O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
second B-ADR B-ADR
primary I-ADR I-ADR
malignancy I-ADR I-ADR
was O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin I-ADR I-ADR
cancer I-ADR I-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
to O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Clinically O-ADR O-ADR
significant O-ADR O-ADR
hypersensitivity B-ADR B-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Vertex O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Incorporated O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
634 O-ADR O-ADR
- O-ADR O-ADR
8789 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
visual B-ADR B-ADR
changes I-ADR I-ADR
were O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
impact O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
and O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
malignancies O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
active O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
infections O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
fully O-ADR O-ADR
understood O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
most O-ADR O-ADR
cases O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
of O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
intensity O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
sudden O-ADR O-ADR
drop O-ADR B-ADR
in O-ADR I-ADR
estrogen O-ADR I-ADR
levels O-ADR I-ADR
causes O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
surgical O-ADR B-ADR
menopause O-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
periodically O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
URI B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
bruising I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
( O-ADR O-ADR
versus O-ADR O-ADR
interferon O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
1a O-ADR O-ADR
) O-ADR O-ADR
study O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
Screen O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
by O-ADR O-ADR
obtaining O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
higher O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
among O-ADR O-ADR
47 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XTANDI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
study O-ADR O-ADR
were O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
eye I-ADR I-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
visual B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Toviaz O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
antimuscarinic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
decreased O-ADR O-ADR
gastrointestinal O-ADR O-ADR
motility O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
constipation O-ADR O-ADR
. O-ADR O-ADR
AEDs O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
infections B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
immunosuppressive O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Analysis O-ADR O-ADR
of O-ADR O-ADR
seventeen O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
modal O-ADR O-ADR
duration O-ADR O-ADR
10 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
largely O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
revealed O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
between O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death O-ADR B-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Other O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
, O-ADR O-ADR
Including O-ADR O-ADR
Ocular O-ADR O-ADR
Manifestations O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
nephritis B-ADR B-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
meningitis B-ADR B-ADR
, O-ADR O-ADR
pericarditis B-ADR B-ADR
, O-ADR O-ADR
uveitis B-ADR B-ADR
, O-ADR O-ADR
iritis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hemolytic B-ADR B-ADR
anemia I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
presented O-ADR O-ADR
inTable O-ADR O-ADR
2occurred O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
tended O-ADR O-ADR
to O-ADR O-ADR
resolve O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
with O-ADR O-ADR
continued O-ADR O-ADR
dosing O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypotension O-ADR O-ADR
and O-ADR O-ADR
Reflex O-ADR O-ADR
Tachycardia O-ADR O-ADR
Cleviprex O-ADR O-ADR
may O-ADR O-ADR
produce O-ADR O-ADR
systemic B-ADR B-ADR
hypotension I-ADR I-ADR
and O-ADR O-ADR
reflex B-ADR B-ADR
tachycardia I-ADR I-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
their O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
become O-ADR O-ADR
pregnant O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
pregnancy O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
TAFINLAR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
study O-ADR O-ADR
beginning O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Cleviprex O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
active O-ADR O-ADR
comparators O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
within O-ADR O-ADR
one O-ADR O-ADR
hour O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
infusion O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Fluid O-ADR O-ADR
Retention O-ADR O-ADR
Estrogens O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
some O-ADR O-ADR
degree O-ADR O-ADR
of O-ADR O-ADR
fluid B-ADR B-ADR
retention I-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
SEGA O-ADR O-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
starting O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
Tablets O-ADR O-ADR
or O-ADR O-ADR
AFINITOR O-ADR O-ADR
DISPERZ O-ADR O-ADR
by O-ADR O-ADR
approximately O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
adjust O-ADR O-ADR
subsequent O-ADR O-ADR
doses O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
therapeutic O-ADR O-ADR
drug O-ADR O-ADR
monitoring O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
JEVTANA O-ADR O-ADR
group O-ADR O-ADR
was O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
many O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trial O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
taking O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
cause O-ADR O-ADR
liver O-ADR O-ADR
enzyme O-ADR O-ADR
elevations O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
nonsteroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
[ O-ADR O-ADR
NSAIDs O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
methotrexate O-ADR O-ADR
[ O-ADR O-ADR
MTX O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
isoniazid O-ADR O-ADR
prophylaxis O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
relationship O-ADR O-ADR
between O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
and O-ADR O-ADR
liver O-ADR B-ADR
enzyme O-ADR I-ADR
elevation O-ADR I-ADR
is O-ADR O-ADR
not O-ADR O-ADR
clear O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
from O-ADR O-ADR
unintentional O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
flushing B-ADR B-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
within O-ADR O-ADR
minutes O-ADR O-ADR
following O-ADR O-ADR
Vizamyl O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
following O-ADR O-ADR
EOVIST O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
demonstrate O-ADR O-ADR
hemodynamic O-ADR O-ADR
instability O-ADR O-ADR
on O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
alone O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
symptomatic B-ADR O-ADR
hypotension I-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
biopsy O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
demonstrated O-ADR O-ADR
deposition B-ADR B-ADR
of I-ADR I-ADR
anti I-ADR O-ADR
- O-ADR O-ADR
rhGAA O-ADR O-ADR
antibodies I-ADR I-ADR
in O-ADR I-ADR
the O-ADR I-ADR
lesion O-ADR I-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
chronic B-ADR B-ADR
leukemia I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
RA O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
decreased O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
food O-ADR O-ADR
consumption O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
encouraged O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Halofantrine O-ADR O-ADR
and O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
within O-ADR O-ADR
one O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
other O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
potential O-ADR O-ADR
additive O-ADR O-ADR
effects O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
e O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
brain B-ADR B-ADR
stem I-ADR I-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
cerebral B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
gastric B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
epistaxis B-ADR B-ADR
, O-ADR O-ADR
gingival B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
hematuria B-ADR B-ADR
, O-ADR O-ADR
vaginal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
hemorrhage B-ADR B-ADR
intracranial I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vitreous B-ADR B-ADR
hemorrhage I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
KALBITOR O-ADR O-ADR
HAE O-ADR O-ADR
program O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
dose O-ADR O-ADR
modification O-ADR O-ADR
of O-ADR O-ADR
trametinib O-ADR O-ADR
is O-ADR O-ADR
required O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
cutaneous O-ADR O-ADR
malignancies O-ADR O-ADR
. O-ADR O-ADR
GI B-ADR B-ADR
bleed I-ADR I-ADR
includes O-ADR O-ADR
rectal B-ADR B-ADR
bleeding I-ADR I-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
led O-ADR O-ADR
to O-ADR O-ADR
withdrawal O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
may O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
headache O-ADR O-ADR
, O-ADR O-ADR
mental O-ADR O-ADR
status O-ADR O-ADR
changes O-ADR O-ADR
, O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
unusual O-ADR O-ADR
bowel O-ADR O-ADR
habits O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypotension O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
nonspecific O-ADR O-ADR
symptoms O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
resemble O-ADR O-ADR
other O-ADR O-ADR
causes O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
brain O-ADR O-ADR
metastasis O-ADR O-ADR
or O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
pediatric O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
increases B-ADR B-ADR
( I-ADR O-ADR
at I-ADR O-ADR
Endpoint I-ADR O-ADR
) I-ADR I-ADR
in I-ADR I-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
were O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Fatal B-ADR B-ADR
hepatic B-ADR B-ADR
impairment I-ADR I-ADR
occurs O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Suicidal O-ADR O-ADR
Behavior O-ADR O-ADR
and O-ADR O-ADR
Ideation O-ADR O-ADR
HORIZANT O-ADR O-ADR
( O-ADR O-ADR
gabapentin O-ADR O-ADR
enacarbil O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
prodrug O-ADR O-ADR
of O-ADR O-ADR
gabapentin O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
antiepileptic O-ADR O-ADR
drug O-ADR O-ADR
( O-ADR O-ADR
AED O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
9 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
hypopituitarism B-ADR B-ADR
and O-ADR O-ADR
some O-ADR O-ADR
had O-ADR O-ADR
additional O-ADR O-ADR
concomitant O-ADR O-ADR
endocrinopathies B-ADR B-ADR
such O-ADR O-ADR
as O-ADR O-ADR
adrenal B-ADR B-ADR
insufficiency I-ADR I-ADR
, O-ADR O-ADR
hypogonadism B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypothyroidism B-ADR B-ADR
. O-ADR O-ADR
Recurrent O-ADR O-ADR
reactions O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
flu B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
illness I-ADR I-ADR
or O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
events O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatigue B-ADR B-ADR
occurring O-ADR O-ADR
after O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
infusions O-ADR O-ADR
and O-ADR O-ADR
lasting O-ADR O-ADR
usually O-ADR O-ADR
for O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
Several O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
falls B-ADR B-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
few O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
. O-ADR O-ADR
Careful O-ADR O-ADR
consideration O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
clinical O-ADR O-ADR
status O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
delaying O-ADR O-ADR
the O-ADR O-ADR
Vimizim O-ADR O-ADR
infusion O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Tumor O-ADR O-ADR
Lysis O-ADR O-ADR
Syndrome O-ADR O-ADR
Tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
experienced O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
upon O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
medication O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
study O-ADR O-ADR
AS O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
. O-ADR O-ADR
Heart O-ADR B-ADR
Rate O-ADR I-ADR
Increase O-ADR I-ADR
and O-ADR O-ADR
Tachycardia O-ADR B-ADR
Related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
GI B-ADR B-ADR
fistula I-ADR I-ADR
was O-ADR O-ADR
fatal B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
hematomas B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
permanent B-ADR B-ADR
paralysis I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse B-ADR O-ADR
reactions I-ADR O-ADR
related I-ADR O-ADR
to I-ADR O-ADR
renal I-ADR O-ADR
function I-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
FARXIGA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Rash B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
subjects O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
male O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
rash B-ADR B-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
/ O-ADR O-ADR
64 O-ADR O-ADR
[ O-ADR O-ADR
20 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
females O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
37 O-ADR O-ADR
[ O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
males O-ADR O-ADR
; O-ADR O-ADR
discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
rash B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
64 O-ADR O-ADR
[ O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
females O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
37 O-ADR O-ADR
[ O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
males O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
AdreView O-ADR O-ADR
imaging O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
if O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
medications O-ADR O-ADR
would O-ADR O-ADR
involve O-ADR O-ADR
risks O-ADR O-ADR
which O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
value O-ADR O-ADR
of O-ADR O-ADR
AdreView O-ADR O-ADR
imaging O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
findings O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
observed O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
reversible O-ADR O-ADR
with O-ADR O-ADR
dose O-ADR O-ADR
interruption O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ZYTIGA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
left O-ADR O-ADR
ventricular O-ADR O-ADR
ejection O-ADR O-ADR
fraction O-ADR O-ADR
< O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
New O-ADR O-ADR
York O-ADR O-ADR
Heart O-ADR O-ADR
Association O-ADR O-ADR
( O-ADR O-ADR
NYHA O-ADR O-ADR
) O-ADR O-ADR
Class O-ADR O-ADR
III O-ADR O-ADR
or O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
( O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
NYHA O-ADR O-ADR
Class O-ADR O-ADR
II O-ADR O-ADR
to O-ADR O-ADR
IV O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
( O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
established O-ADR O-ADR
because O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
these O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patient O-ADR O-ADR
demographics O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
Dermatitis O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
dermatitis I-ADR I-ADR
( O-ADR O-ADR
eg O-ADR O-ADR
, O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
rash B-ADR B-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
full O-ADR O-ADR
thickness O-ADR B-ADR
dermal B-ADR I-ADR
ulceration I-ADR I-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Hepatic B-ADR B-ADR
adenomas I-ADR I-ADR
are O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
COC O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
considered O-ADR O-ADR
ADRs O-ADR O-ADR
are O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
incidences O-ADR O-ADR
these O-ADR O-ADR
pneumonia B-ADR B-ADR
events O-ADR O-ADR
were O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Toxicity O-ADR O-ADR
Nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
Beleodaq O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
antiemetic O-ADR O-ADR
and O-ADR O-ADR
antidiarrheal O-ADR O-ADR
medications O-ADR O-ADR
. O-ADR O-ADR
GRANIX O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
upon O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
of O-ADR O-ADR
three O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
myeloablative O-ADR O-ADR
chemotherapy O-ADR O-ADR
for O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
348 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
lung O-ADR O-ADR
cancer O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
240 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
non O-ADR B-ADR
- O-ADR O-ADR
Hodgkin O-ADR O-ADR
' O-ADR I-ADR
s O-ADR O-ADR
lymphoma O-ADR I-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
92 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
medically O-ADR O-ADR
feasible O-ADR O-ADR
, O-ADR O-ADR
stop O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
before O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
withdrawal O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
elevated O-ADR O-ADR
levels O-ADR O-ADR
of O-ADR O-ADR
circulating O-ADR O-ADR
catecholamines O-ADR O-ADR
and O-ADR O-ADR
their O-ADR O-ADR
metabolites O-ADR O-ADR
. O-ADR O-ADR
Neovascular O-ADR O-ADR
( O-ADR O-ADR
Wet O-ADR O-ADR
) O-ADR O-ADR
Age O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Macular O-ADR O-ADR
Degeneration O-ADR O-ADR
( O-ADR O-ADR
AMD O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
in O-ADR O-ADR
1824 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
wet O-ADR O-ADR
AMD O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
1223 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
masked O-ADR O-ADR
, O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
VIEW1 O-ADR O-ADR
and O-ADR O-ADR
VIEW2 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
CIMZIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
or O-ADR O-ADR
sepsis O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Impairment O-ADR O-ADR
in O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
FARXIGA O-ADR O-ADR
increases B-ADR B-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
decreases B-ADR B-ADR
eGFR I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
occurring O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
COMETRIQ O-ADR O-ADR
arm O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
between O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
difference O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
included O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
frequency O-ADR O-ADR
: O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
palmar B-ADR B-ADR
- O-ADR O-ADR
plantar O-ADR O-ADR
erythrodysesthesia I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PPES B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
weight I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
hair B-ADR B-ADR
color I-ADR I-ADR
changes I-ADR I-ADR
, O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
75 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
34 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
abnormalities O-ADR O-ADR
are O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
parameters O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
continued O-ADR O-ADR
to O-ADR O-ADR
ensure O-ADR O-ADR
that O-ADR O-ADR
further O-ADR O-ADR
deterioration O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
is O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Transaminase B-ADR B-ADR
Elevations I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
KALYDECO O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CF O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
G551D O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
required O-ADR O-ADR
hospitalization O-ADR O-ADR
and O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
NESINA O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
potential O-ADR O-ADR
causes O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
alternative O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
diabetes O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
Vimizim O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
occurring O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
withdrew O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Somnolence O-ADR O-ADR
and O-ADR O-ADR
Fatigue O-ADR O-ADR
APTIOM O-ADR O-ADR
causes O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
somnolence B-ADR B-ADR
and O-ADR O-ADR
fatigue O-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
malaise B-ADR B-ADR
, O-ADR O-ADR
hypersomnia B-ADR B-ADR
, O-ADR O-ADR
sedation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
lethargy B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Tardive B-ADR B-ADR
Dyskinesia I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
if O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Seizure B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
XTANDI O-ADR O-ADR
who O-ADR O-ADR
previously O-ADR O-ADR
received O-ADR O-ADR
docetaxel O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
chemotherapy O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
. O-ADR O-ADR
2Includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
paresthesia I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
oral B-ADR B-ADR
dysesthesia I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
repeated O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
included O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
pharyngolaryngeal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
contact B-ADR B-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
discomfort I-ADR I-ADR
. O-ADR O-ADR
This O-ADR O-ADR
study O-ADR O-ADR
showed O-ADR O-ADR
a O-ADR O-ADR
statistically O-ADR O-ADR
significant O-ADR O-ADR
reduction B-ADR B-ADR
in I-ADR I-ADR
heart I-ADR I-ADR
rate I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
averaging O-ADR O-ADR
about O-ADR O-ADR
three O-ADR O-ADR
beats O-ADR O-ADR
per O-ADR O-ADR
minute O-ADR O-ADR
, O-ADR O-ADR
observed O-ADR O-ADR
thirty O-ADR O-ADR
minutes O-ADR O-ADR
after O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immune O-ADR O-ADR
- O-ADR O-ADR
Mediated O-ADR O-ADR
Reactions O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
cutaneous I-ADR I-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
including O-ADR O-ADR
necrotizing B-ADR B-ADR
skin I-ADR I-ADR
lesions I-ADR I-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Inform O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
them O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
take O-ADR O-ADR
too O-ADR O-ADR
much O-ADR O-ADR
DUAVEE O-ADR O-ADR
, O-ADR O-ADR
call O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
: O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
hypoxia B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
wheezing B-ADR B-ADR
, O-ADR O-ADR
convulsions B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
coldness I-ADR I-ADR
, O-ADR O-ADR
restlessness B-ADR B-ADR
, O-ADR O-ADR
nervousness B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
stridor B-ADR B-ADR
, O-ADR O-ADR
pharyngeal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
apnea B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
spasm I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
conjunctivitis B-ADR B-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
PML O-ADR O-ADR
include O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapies O-ADR O-ADR
and O-ADR O-ADR
impairment O-ADR O-ADR
of O-ADR O-ADR
immune O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Angioedema B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
upper B-ADR B-ADR
airway I-ADR I-ADR
swelling I-ADR I-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
. O-ADR O-ADR
Titration O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
over O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
5 O-ADR O-ADR
days O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
for O-ADR O-ADR
YERVOY O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
likely O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
: O-ADR O-ADR
myocarditis B-ADR B-ADR
, O-ADR O-ADR
angiopathy B-ADR B-ADR
, O-ADR O-ADR
temporal B-ADR B-ADR
arteritis I-ADR I-ADR
, O-ADR O-ADR
vasculitis B-ADR B-ADR
, O-ADR O-ADR
polymyalgia B-ADR B-ADR
rheumatica I-ADR I-ADR
, O-ADR O-ADR
conjunctivitis B-ADR B-ADR
, O-ADR O-ADR
blepharitis B-ADR B-ADR
, O-ADR O-ADR
episcleritis B-ADR B-ADR
, O-ADR O-ADR
scleritis B-ADR B-ADR
, O-ADR O-ADR
leukocytoclastic B-ADR B-ADR
vasculitis I-ADR I-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
, O-ADR O-ADR
psoriasis B-ADR B-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
, O-ADR O-ADR
arthritis B-ADR B-ADR
, O-ADR O-ADR
autoimmune B-ADR B-ADR
thyroiditis I-ADR I-ADR
, O-ADR O-ADR
sarcoidosis B-ADR B-ADR
, O-ADR O-ADR
neurosensory B-ADR B-ADR
hypoacusis I-ADR I-ADR
, O-ADR O-ADR
autoimmune B-ADR B-ADR
central I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
encephalitis B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
myositis B-ADR B-ADR
, O-ADR O-ADR
polymyositis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ocular B-ADR B-ADR
myositis I-ADR I-ADR
. O-ADR O-ADR
periodontal O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
dental O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
anemia O-ADR O-ADR
, O-ADR O-ADR
coagulopathy O-ADR O-ADR
, O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
ill O-ADR O-ADR
- O-ADR O-ADR
fitting O-ADR O-ADR
dentures O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
receive O-ADR O-ADR
all O-ADR O-ADR
recommended O-ADR O-ADR
vaccinations O-ADR O-ADR
. O-ADR O-ADR
Drugs O-ADR O-ADR
that O-ADR O-ADR
affect O-ADR O-ADR
the O-ADR O-ADR
immune O-ADR O-ADR
system O-ADR O-ADR
by O-ADR O-ADR
blocking O-ADR O-ADR
TNF O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
new O-ADR B-ADR
tuberculosis O-ADR I-ADR
and O-ADR O-ADR
reactivation O-ADR B-ADR
of O-ADR I-ADR
latent O-ADR I-ADR
tuberculosis O-ADR I-ADR
( O-ADR O-ADR
TB O-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
complaints I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
39 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
Tumor O-ADR O-ADR
Growth O-ADR O-ADR
Stimulatory O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
Malignant O-ADR O-ADR
Cells O-ADR O-ADR
The O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factor O-ADR O-ADR
( O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
) O-ADR O-ADR
receptor O-ADR O-ADR
through O-ADR O-ADR
which O-ADR O-ADR
GRANIX O-ADR O-ADR
acts O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
found O-ADR O-ADR
on O-ADR O-ADR
tumor O-ADR O-ADR
cell O-ADR O-ADR
lines O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
CERDELGA O-ADR O-ADR
is O-ADR O-ADR
predicted O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR O-ADR
ECG I-ADR I-ADR
intervals I-ADR I-ADR
( I-ADR O-ADR
PR I-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
substantially O-ADR O-ADR
elevated O-ADR O-ADR
eliglustat O-ADR O-ADR
plasma O-ADR O-ADR
concentrations O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
CERDELGA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
cardiac O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
recent O-ADR O-ADR
acute O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
bradycardia O-ADR O-ADR
, O-ADR O-ADR
heart O-ADR O-ADR
block O-ADR O-ADR
, O-ADR O-ADR
ventricular O-ADR O-ADR
arrhythmia O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
Class O-ADR O-ADR
IA O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
quinidine O-ADR O-ADR
, O-ADR O-ADR
procainamide O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Class O-ADR O-ADR
III O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
amiodarone O-ADR O-ADR
, O-ADR O-ADR
sotalol O-ADR O-ADR
) O-ADR O-ADR
antiarrhythmic O-ADR O-ADR
medications O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Antibody O-ADR O-ADR
titers O-ADR O-ADR
were O-ADR O-ADR
determined O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
bridging O-ADR O-ADR
enzyme O-ADR O-ADR
- O-ADR O-ADR
linked O-ADR O-ADR
immunosorbent O-ADR O-ADR
assay O-ADR O-ADR
( O-ADR O-ADR
ELISA O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
glucarpidase O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
in O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
16 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Delayed O-ADR O-ADR
reactions O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
several O-ADR O-ADR
days O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
psychotic B-ADR B-ADR
behavior I-ADR I-ADR
including O-ADR O-ADR
aggressive B-ADR B-ADR
thoughts I-ADR I-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic B-ADR B-ADR
events I-ADR I-ADR
after O-ADR O-ADR
premature O-ADR O-ADR
discontinuation O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
* O-ADR O-ADR
Immune B-ADR B-ADR
Reconstitution I-ADR I-ADR
Syndrome I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
first O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
47 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
27 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
52 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
was O-ADR O-ADR
34 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
- O-ADR O-ADR
106 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prophylactic O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
steroidal O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drug O-ADR O-ADR
[ O-ADR O-ADR
NSAID O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
colchicine O-ADR O-ADR
upon O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
beneficial O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Acute B-ADR B-ADR
cardiorespiratory I-ADR I-ADR
failure I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
cardiac O-ADR O-ADR
hypertrophy O-ADR O-ADR
, O-ADR O-ADR
possibly O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
fluid B-ADR B-ADR
overload I-ADR I-ADR
with O-ADR O-ADR
intravenous O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Systemic B-ADR B-ADR
immune I-ADR I-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
possible O-ADR O-ADR
type B-ADR B-ADR
III I-ADR I-ADR
immune I-ADR I-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
two O-ADR O-ADR
drug O-ADR O-ADR
classes O-ADR O-ADR
can O-ADR O-ADR
lower O-ADR B-ADR
blood O-ADR I-ADR
pressure O-ADR I-ADR
significantly O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
symptomatic B-ADR B-ADR
hypotension I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
lightheadedness B-ADR B-ADR
, O-ADR O-ADR
fainting B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
rhabdomyolysis B-ADR B-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
studies O-ADR O-ADR
show O-ADR O-ADR
no O-ADR O-ADR
significant O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
estrogens O-ADR O-ADR
for O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
. O-ADR O-ADR
Extravasation O-ADR O-ADR
into O-ADR O-ADR
tissues O-ADR O-ADR
during O-ADR O-ADR
Gadavist O-ADR O-ADR
administration B-ADR O-ADR
may I-ADR I-ADR
result I-ADR I-ADR
in I-ADR I-ADR
moderate I-ADR I-ADR
irritation I-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
MULTAQ O-ADR O-ADR
offers O-ADR O-ADR
no O-ADR O-ADR
benefit O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
AF O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
specific O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
site O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Prophylaxis O-ADR O-ADR
for O-ADR O-ADR
Pneumocystis O-ADR O-ADR
jiroveci O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hemorrhage O-ADR O-ADR
Hemorrhages B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
major O-ADR O-ADR
hemorrhages B-ADR B-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
symptomatic B-ADR B-ADR
bleeding I-ADR I-ADR
in O-ADR I-ADR
a O-ADR I-ADR
critical O-ADR I-ADR
area O-ADR O-ADR
or O-ADR O-ADR
organ O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Includes O-ADR O-ADR
13 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
before O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
apixaban O-ADR O-ADR
( O-ADR O-ADR
administered O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
post O-ADR O-ADR
surgery O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
at O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
- O-ADR O-ADR
14 O-ADR O-ADR
weeks O-ADR O-ADR
duration O-ADR O-ADR
with O-ADR O-ADR
dalfampridine O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MS O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
examination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
fundus O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
macula O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
MS O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
regular O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
examinations O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
JEVTANA O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
mitoxantrone O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
limited O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
hypophysitis B-ADR B-ADR
was O-ADR O-ADR
diagnosed O-ADR O-ADR
by O-ADR O-ADR
imaging O-ADR O-ADR
studies O-ADR O-ADR
through O-ADR O-ADR
enlargement O-ADR B-ADR
of O-ADR I-ADR
the O-ADR I-ADR
pituitary O-ADR I-ADR
gland O-ADR I-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
GILOTRIF O-ADR O-ADR
excluded O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
abnormal O-ADR O-ADR
left O-ADR O-ADR
ventricular O-ADR O-ADR
ejection O-ADR O-ADR
fraction O-ADR O-ADR
( O-ADR O-ADR
LVEF O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
institutional O-ADR O-ADR
lower O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
. O-ADR O-ADR
Reactions O-ADR O-ADR
already O-ADR O-ADR
listed O-ADR O-ADR
for O-ADR O-ADR
either O-ADR O-ADR
adults O-ADR O-ADR
or O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
parts O-ADR O-ADR
of O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
those O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Overdosage O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
included O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
prolonged O-ADR O-ADR
diarrhea O-ADR O-ADR
not O-ADR O-ADR
responsive O-ADR O-ADR
to O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheal O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
single O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
predominated O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
compromised O-ADR O-ADR
cardiac O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
acute B-ADR B-ADR
exacerbation I-ADR I-ADR
of I-ADR I-ADR
their I-ADR I-ADR
cardiac I-ADR I-ADR
or I-ADR I-ADR
respiratory I-ADR I-ADR
compromise I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
fluid B-ADR B-ADR
overload I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
additional O-ADR O-ADR
monitoring O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
subjects O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
were O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
age O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Acute O-ADR O-ADR
Kidney O-ADR O-ADR
Injury O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
kidney I-ADR I-ADR
injury I-ADR I-ADR
requiring O-ADR O-ADR
dialysis O-ADR O-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Classical O-ADR O-ADR
HL O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
auto O-ADR O-ADR
- O-ADR O-ADR
HSCT O-ADR O-ADR
consolidation O-ADR O-ADR
: O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
motor I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
were O-ADR O-ADR
tuberculosis B-ADR B-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
10 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
More O-ADR O-ADR
of O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
( O-ADR O-ADR
Ages O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
Years O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Any O-ADR O-ADR
SAPHRIS O-ADR O-ADR
Dose O-ADR O-ADR
Group O-ADR O-ADR
and O-ADR O-ADR
Which O-ADR O-ADR
Occurred O-ADR O-ADR
at O-ADR O-ADR
Greater O-ADR O-ADR
Incidence O-ADR O-ADR
Than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
Group O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
Week O-ADR O-ADR
Bipolar O-ADR O-ADR
Mania O-ADR O-ADR
Trial O-ADR O-ADR
1Includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
tachycardia B-ADR B-ADR
and O-ADR O-ADR
heart B-ADR B-ADR
rate I-ADR I-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
have O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
cancer O-ADR O-ADR
, O-ADR O-ADR
talk O-ADR O-ADR
with O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
about O-ADR O-ADR
whether O-ADR O-ADR
you O-ADR O-ADR
should O-ADR O-ADR
use O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
Infections B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
tonsilitis B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
ear B-ADR B-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
types O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
eight O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
those O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ADT O-ADR O-ADR
for O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
or O-ADR O-ADR
adjuvant O-ADR O-ADR
AI O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
arthralgia B-ADR B-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Increasing O-ADR O-ADR
the O-ADR O-ADR
daily O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
beyond O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
appropriate O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
situation O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
32 O-ADR O-ADR
of O-ADR O-ADR
1560 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
QTcF B-ADR B-ADR
( I-ADR I-ADR
corrected I-ADR I-ADR
QT I-ADR I-ADR
by I-ADR O-ADR
the I-ADR I-ADR
Fridericia I-ADR O-ADR
method I-ADR O-ADR
) I-ADR O-ADR
greater I-ADR I-ADR
than I-ADR I-ADR
or I-ADR I-ADR
equal I-ADR I-ADR
to I-ADR I-ADR
500 I-ADR I-ADR
ms I-ADR I-ADR
and O-ADR O-ADR
76 O-ADR O-ADR
of O-ADR O-ADR
1520 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
increase B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
QTcF I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
60 O-ADR O-ADR
ms O-ADR O-ADR
by O-ADR O-ADR
automated O-ADR O-ADR
machine O-ADR O-ADR
- O-ADR O-ADR
read O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
ECG O-ADR O-ADR
. O-ADR O-ADR
Red O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
transfusions O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TREANDA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
chlorambucil O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
complications O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
hyponatremia B-ADR B-ADR
( O-ADR O-ADR
as O-ADR O-ADR
low O-ADR O-ADR
as O-ADR O-ADR
112 O-ADR O-ADR
mEq O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
including O-ADR O-ADR
seizures B-ADR B-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
nausea O-ADR O-ADR
/ O-ADR O-ADR
vomiting O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
gait B-ADR B-ADR
instability I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injury B-ADR O-ADR
. O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
Hodgkin O-ADR O-ADR
Lymphoma O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
TREANDA O-ADR O-ADR
in O-ADR O-ADR
176 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
indolent O-ADR O-ADR
B O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
NHL O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
APTIOM O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
jaundice O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
significant O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
laboratory O-ADR O-ADR
evidence O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
recipient O-ADR O-ADR
was O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
, O-ADR O-ADR
mycophenolate O-ADR O-ADR
mofetil O-ADR O-ADR
( O-ADR O-ADR
MMF O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
corticosteroids O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Investigators O-ADR O-ADR
graded O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
occurring O-ADR O-ADR
on O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
as O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
mild O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in B-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
moderate O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in B-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
42 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
severe O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in B-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
COMETRIQ O-ADR O-ADR
was O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
90 O-ADR O-ADR
% O-ADR O-ADR
white O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
vulvovaginal B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
in O-ADR O-ADR
females O-ADR O-ADR
and O-ADR O-ADR
balanitis B-ADR B-ADR
in O-ADR O-ADR
males O-ADR O-ADR
. O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
: O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
esophageal B-ADR B-ADR
ulcer I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypertension O-ADR O-ADR
, O-ADR O-ADR
Hypokalemia O-ADR O-ADR
and O-ADR O-ADR
Fluid O-ADR O-ADR
Retention O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
Mineralocorticoid O-ADR O-ADR
Excess O-ADR O-ADR
ZYTIGA O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fluid B-ADR B-ADR
retention I-ADR I-ADR
as O-ADR O-ADR
a O-ADR O-ADR
consequence O-ADR O-ADR
of O-ADR O-ADR
increased B-ADR B-ADR
mineralocorticoid I-ADR I-ADR
levels I-ADR I-ADR
resulting O-ADR O-ADR
from O-ADR O-ADR
CYP17 O-ADR O-ADR
inhibition O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
two O-ADR O-ADR
identical O-ADR O-ADR
, O-ADR O-ADR
pooled O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
multi O-ADR O-ADR
- O-ADR O-ADR
center O-ADR O-ADR
trials O-ADR O-ADR
through O-ADR O-ADR
Day O-ADR O-ADR
365 O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
AdreView O-ADR O-ADR
contains O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
) O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
serious O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
premature O-ADR O-ADR
or O-ADR O-ADR
low O-ADR O-ADR
birth O-ADR O-ADR
- O-ADR O-ADR
weight O-ADR O-ADR
infants O-ADR O-ADR
. O-ADR O-ADR
COCs O-ADR O-ADR
also O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
stroke B-ADR B-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
underlying O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Acute O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
disturbances O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
necessitate O-ADR O-ADR
the O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
COC O-ADR O-ADR
use O-ADR O-ADR
until O-ADR O-ADR
markers O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
return O-ADR O-ADR
to O-ADR O-ADR
normal O-ADR O-ADR
and O-ADR O-ADR
COC O-ADR O-ADR
causation O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
association O-ADR O-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
between O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
analysis O-ADR O-ADR
suggested O-ADR O-ADR
that O-ADR O-ADR
ZYKADIA O-ADR O-ADR
causes O-ADR O-ADR
concentration O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
the I-ADR I-ADR
QTc I-ADR I-ADR
interval I-ADR I-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Elevations B-ADR B-ADR
in I-ADR I-ADR
alanine I-ADR I-ADR
aminotransferase I-ADR I-ADR
( O-ADR O-ADR
ALT O-ADR I-ADR
) O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
27 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
year O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
types O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
hypoglycemia B-ADR B-ADR
, O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Monitoring O-ADR O-ADR
A O-ADR O-ADR
woman O-ADR O-ADR
who O-ADR O-ADR
is O-ADR O-ADR
taking O-ADR O-ADR
COCs O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
yearly O-ADR O-ADR
visit O-ADR O-ADR
with O-ADR O-ADR
her O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
check O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
indicated O-ADR O-ADR
healthcare O-ADR O-ADR
. O-ADR O-ADR
Studies O-ADR O-ADR
also O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
suggest O-ADR O-ADR
a O-ADR O-ADR
teratogenic B-ADR B-ADR
effect I-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
so O-ADR O-ADR
far O-ADR O-ADR
as O-ADR O-ADR
cardiac B-ADR O-ADR
anomalies I-ADR O-ADR
and O-ADR O-ADR
limb B-ADR O-ADR
- O-ADR O-ADR
reduction O-ADR O-ADR
defects I-ADR O-ADR
are O-ADR O-ADR
concerned O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
taken O-ADR O-ADR
inadvertently O-ADR O-ADR
during O-ADR O-ADR
early O-ADR O-ADR
pregnancy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
progression O-ADR O-ADR
of O-ADR O-ADR
retinal O-ADR B-ADR
abnormalities O-ADR I-ADR
and O-ADR O-ADR
their O-ADR O-ADR
reversibility O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
migraines B-ADR B-ADR
) O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
breast B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
menstrual B-ADR B-ADR
disorders I-ADR I-ADR
( O-ADR O-ADR
metrorrhagia B-ADR B-ADR
, O-ADR O-ADR
menstruation B-ADR B-ADR
irregular I-ADR I-ADR
, O-ADR O-ADR
menorrhagia B-ADR B-ADR
, O-ADR O-ADR
vaginal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
dysfunctional B-ADR B-ADR
uterine I-ADR I-ADR
bleeding I-ADR I-ADR
, O-ADR O-ADR
genital B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
abnormal B-ADR B-ADR
withdrawal I-ADR I-ADR
bleeding I-ADR I-ADR
, O-ADR O-ADR
uterine B-ADR B-ADR
hemorrhage I-ADR I-ADR
) O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
or O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
acne B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
mood B-ADR B-ADR
changes I-ADR I-ADR
( O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
mood B-ADR B-ADR
swings I-ADR I-ADR
, O-ADR O-ADR
depressed B-ADR B-ADR
mood I-ADR I-ADR
, O-ADR O-ADR
mood B-ADR B-ADR
altered I-ADR I-ADR
, O-ADR O-ADR
affect B-ADR B-ADR
lability I-ADR I-ADR
, O-ADR O-ADR
dysthymic B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
crying B-ADR B-ADR
) O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
weight I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Inform O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
instruct O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Seizures B-ADR B-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
lower O-ADR O-ADR
the O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Bradycardia B-ADR B-ADR
: O-ADR O-ADR
XALKORI O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
bradycardia B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Embryofetal O-ADR O-ADR
Toxicity O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
ALT I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
, O-ADR O-ADR
urine O-ADR O-ADR
glucose O-ADR O-ADR
and O-ADR O-ADR
urine O-ADR O-ADR
protein O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
documented O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
LABA O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
and O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
hospitalizations O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
were O-ADR O-ADR
convulsion B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
premedication O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
mitigated O-ADR O-ADR
or O-ADR O-ADR
masked O-ADR O-ADR
an O-ADR O-ADR
infusion O-ADR O-ADR
reaction O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
insufficient O-ADR O-ADR
evidence O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
premedication O-ADR O-ADR
diminishes O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
any O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
chronic O-ADR O-ADR
infection O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
begin O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Acute B-ADR B-ADR
cardiorespiratory I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
possibly O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
fluid B-ADR B-ADR
overload I-ADR I-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
hypertrophic O-ADR O-ADR
cardiomyopathy O-ADR O-ADR
[ O-ADR O-ADR
seeBoxed O-ADR O-ADR
WarningandWarning O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
a O-ADR O-ADR
program O-ADR O-ADR
under O-ADR O-ADR
a O-ADR O-ADR
REMS O-ADR O-ADR
that O-ADR O-ADR
restricts O-ADR O-ADR
use O-ADR O-ADR
to O-ADR O-ADR
enrolled O-ADR O-ADR
hospitals O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Discontinuation B-ADR O-ADR
Syndrome I-ADR O-ADR
: O-ADR O-ADR
Taper O-ADR O-ADR
dose O-ADR O-ADR
when O-ADR O-ADR
possible O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
discontinuation O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
ILARIS O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
Phimosis B-ADR B-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
unknown O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
precise O-ADR O-ADR
estimates O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
. O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
hypoparathyroidism O-ADR O-ADR
, O-ADR O-ADR
thyroid O-ADR O-ADR
surgery O-ADR O-ADR
, O-ADR O-ADR
parathyroid O-ADR O-ADR
surgery O-ADR O-ADR
, O-ADR O-ADR
malabsorption O-ADR O-ADR
syndromes O-ADR O-ADR
, O-ADR O-ADR
excision O-ADR O-ADR
of O-ADR O-ADR
small O-ADR O-ADR
intestine O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
receiving O-ADR O-ADR
dialysis O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
clinical O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
mineral O-ADR O-ADR
levels O-ADR O-ADR
( O-ADR O-ADR
phosphorus O-ADR O-ADR
and O-ADR O-ADR
magnesium O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
recommended O-ADR O-ADR
within O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
total O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ELIQUIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
experienced O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Adverse B-ADR O-ADR
reactions I-ADR O-ADR
of I-ADR O-ADR
the I-ADR O-ADR
hematologic I-ADR O-ADR
system I-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
medically O-ADR O-ADR
significant O-ADR O-ADR
cytopenia B-ADR B-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
infrequently O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
hemodialysis O-ADR O-ADR
, O-ADR O-ADR
physicians O-ADR O-ADR
may O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
prompt O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
GBCA O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
enhance O-ADR O-ADR
the O-ADR O-ADR
contrast O-ADR O-ADR
agent O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
elimination O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Gallbladder O-ADR O-ADR
Disease O-ADR O-ADR
A O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
gallbladder B-ADR B-ADR
disease I-ADR I-ADR
requiring O-ADR O-ADR
surgery O-ADR O-ADR
in O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
receiving O-ADR O-ADR
estrogens O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pain B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Interference O-ADR O-ADR
with O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
Serum O-ADR O-ADR
iron O-ADR O-ADR
determination O-ADR O-ADR
using O-ADR O-ADR
complexometric O-ADR O-ADR
methods O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
ferrocene O-ADR O-ADR
complexation O-ADR O-ADR
method O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
falsely O-ADR O-ADR
high O-ADR O-ADR
or O-ADR O-ADR
low O-ADR O-ADR
values O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
examination O-ADR O-ADR
with O-ADR O-ADR
EOVIST O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
caloxetate O-ADR O-ADR
trisodium O-ADR O-ADR
excipients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
instances O-ADR O-ADR
, O-ADR O-ADR
HBV B-ADR B-ADR
reactivation I-ADR I-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
Selected O-ADR O-ADR
Hematological O-ADR O-ADR
Parameters O-ADR O-ADR
Previously O-ADR O-ADR
Untreated O-ADR O-ADR
( O-ADR O-ADR
SPRINT O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
SPRINT O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Previous O-ADR O-ADR
Treatment O-ADR O-ADR
Failures O-ADR O-ADR
( O-ADR O-ADR
RESPOND O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Percentage O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
Reporting O-ADR O-ADR
Selected O-ADR O-ADR
Hematological O-ADR O-ADR
Parameters O-ADR O-ADR
Percentage O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
Reporting O-ADR O-ADR
Selected O-ADR O-ADR
Hematological O-ADR O-ADR
Parameters O-ADR O-ADR
Hematological O-ADR O-ADR
Parameters O-ADR O-ADR
VICTRELIS O-ADR O-ADR
+ O-ADR O-ADR
PegIntron O-ADR O-ADR
+ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1225 O-ADR O-ADR
) O-ADR O-ADR
PegIntron O-ADR O-ADR
+ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
467 O-ADR O-ADR
) O-ADR O-ADR
VICTRELIS O-ADR O-ADR
+ O-ADR O-ADR
PegIntron O-ADR O-ADR
+ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
323 O-ADR O-ADR
) O-ADR O-ADR
PegIntron O-ADR O-ADR
+ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
80 O-ADR O-ADR
) O-ADR O-ADR
Hemoglobin B-ADR B-ADR
( I-ADR I-ADR
g I-ADR I-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) I-ADR O-ADR
6 O-ADR O-ADR
3 O-ADR O-ADR
10 O-ADR O-ADR
1 O-ADR O-ADR
Neutrophils B-ADR B-ADR
( I-ADR I-ADR
* I-ADR I-ADR
10 I-ADR I-ADR
9 I-ADR I-ADR
/ I-ADR I-ADR
L O-ADR O-ADR
) I-ADR I-ADR
8 O-ADR O-ADR
4 O-ADR O-ADR
7 O-ADR O-ADR
4 O-ADR O-ADR
Platelets B-ADR B-ADR
( I-ADR I-ADR
* I-ADR I-ADR
10 I-ADR I-ADR
9 I-ADR I-ADR
/ I-ADR I-ADR
L O-ADR O-ADR
) I-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
serious O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
f O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
acute I-ADR I-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
administering O-ADR O-ADR
Vizamyl O-ADR O-ADR
, O-ADR O-ADR
ask O-ADR O-ADR
patients O-ADR O-ADR
about O-ADR O-ADR
prior O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
those O-ADR O-ADR
containing O-ADR O-ADR
polysorbate O-ADR O-ADR
80 O-ADR O-ADR
. O-ADR O-ADR
Have O-ADR O-ADR
resuscitation O-ADR O-ADR
equipment O-ADR O-ADR
and O-ADR O-ADR
trained O-ADR O-ADR
personnel O-ADR O-ADR
immediately O-ADR O-ADR
available O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
Vizamyl O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
adult O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
without O-ADR O-ADR
comparison O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
358 O-ADR O-ADR
/ O-ADR O-ADR
1953 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Hypertension B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
congenital O-ADR O-ADR
prolongation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
or O-ADR O-ADR
sudden O-ADR O-ADR
death O-ADR O-ADR
. O-ADR O-ADR
Ovarian O-ADR O-ADR
Cancer O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
epidemiological O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
only O-ADR O-ADR
products O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
particular O-ADR O-ADR
for O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
ovarian B-ADR B-ADR
cancer I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
interrupt O-ADR O-ADR
ULORIC O-ADR O-ADR
and O-ADR O-ADR
assess O-ADR O-ADR
patient O-ADR O-ADR
for O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
treat O-ADR O-ADR
cause O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
resolution O-ADR O-ADR
or O-ADR O-ADR
stabilization O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
modifications O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
drug O-ADR O-ADR
( O-ADR O-ADR
primarily O-ADR O-ADR
PegIntron O-ADR O-ADR
and O-ADR O-ADR
REBETOL O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
is O-ADR O-ADR
advised O-ADR O-ADR
when O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
are O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
results O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
III O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
call O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
377 O-ADR O-ADR
- O-ADR O-ADR
3784 O-ADR O-ADR
or O-ADR O-ADR
contact O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SUICIDAL B-ADR B-ADR
THOUGHTS I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
undergoing O-ADR O-ADR
a O-ADR O-ADR
sickle O-ADR O-ADR
cell O-ADR O-ADR
crisis O-ADR O-ADR
. O-ADR O-ADR
Take O-ADR O-ADR
the O-ADR O-ADR
next O-ADR O-ADR
dose O-ADR O-ADR
at O-ADR O-ADR
your O-ADR O-ADR
regular O-ADR O-ADR
time O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
STRIBILD O-ADR O-ADR
developed O-ADR O-ADR
laboratory O-ADR O-ADR
findings O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
proximal B-ADR B-ADR
renal I-ADR I-ADR
tubular I-ADR I-ADR
dysfunction I-ADR I-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
overlap O-ADR O-ADR
in O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
distinguish O-ADR O-ADR
between O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
in O-ADR O-ADR
all O-ADR O-ADR
cases O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Infections B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Malignancies B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Heart B-ADR B-ADR
Failure I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
and O-ADR O-ADR
controlled O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
predict O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
broader O-ADR O-ADR
patient O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
with O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
500 O-ADR O-ADR
Units O-ADR O-ADR
group O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
dizziness B-ADR B-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
muscle B-ADR B-ADR
atrophy I-ADR I-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Therapeutic O-ADR O-ADR
Infectious O-ADR O-ADR
Agents O-ADR O-ADR
Other O-ADR O-ADR
uses O-ADR O-ADR
of O-ADR O-ADR
therapeutic O-ADR O-ADR
infectious O-ADR O-ADR
agents O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
live O-ADR O-ADR
attenuated O-ADR O-ADR
bacteria O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
BCG O-ADR O-ADR
bladder O-ADR O-ADR
instillation O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
cancer O-ADR O-ADR
) O-ADR O-ADR
could O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
infections O-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
disseminated O-ADR B-ADR
infections O-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
higher O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XTANDI O-ADR O-ADR
arm O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
incidences O-ADR O-ADR
were O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
arrest I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
distress I-ADR I-ADR
, O-ADR O-ADR
hypoxia B-ADR B-ADR
, O-ADR O-ADR
apnea B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
bradycardia B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
bronchospasm B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
lip B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
periorbital B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
face B-ADR B-ADR
edema I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
summarizes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Carbaglu O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
retrospective O-ADR O-ADR
case O-ADR O-ADR
series O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
three O-ADR O-ADR
factors O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
largest O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
volume B-ADR B-ADR
depletion I-ADR I-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
loop O-ADR O-ADR
diuretics O-ADR O-ADR
, O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
age O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Eye B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
setting O-ADR O-ADR
is O-ADR O-ADR
inappropriate O-ADR O-ADR
. O-ADR O-ADR
Impaired B-ADR B-ADR
glucose I-ADR I-ADR
tolerance I-ADR I-ADR
. O-ADR O-ADR
New O-ADR O-ADR
Malignancies O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
new O-ADR O-ADR
malignancies B-ADR B-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Serious O-ADR O-ADR
Dermatologic O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
dermatologic B-ADR B-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
SJS B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Drug O-ADR O-ADR
Reaction O-ADR O-ADR
with O-ADR O-ADR
Eosinophilia O-ADR O-ADR
and O-ADR O-ADR
Systemic O-ADR O-ADR
Symptoms O-ADR O-ADR
( O-ADR O-ADR
DRESS O-ADR O-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
Multiorgan O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Drug B-ADR B-ADR
Reaction I-ADR I-ADR
with I-ADR I-ADR
Eosinophilia I-ADR I-ADR
and I-ADR I-ADR
Systemic I-ADR I-ADR
Symptoms I-ADR I-ADR
( O-ADR O-ADR
DRESS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
also O-ADR O-ADR
known O-ADR O-ADR
as O-ADR O-ADR
Multiorgan B-ADR B-ADR
Hypersensitivity I-ADR I-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
Abnormal O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
clinically O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
and O-ADR O-ADR
disturbance B-ADR B-ADR
in I-ADR I-ADR
gait I-ADR I-ADR
were O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
Prolia O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
Xgeva O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Atypical B-ADR B-ADR
femoral I-ADR I-ADR
fractures I-ADR I-ADR
: O-ADR O-ADR
Have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
fatal B-ADR B-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurred O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
remission O-ADR O-ADR
. O-ADR O-ADR
Activated O-ADR O-ADR
prothrombin O-ADR O-ADR
complex O-ADR O-ADR
concentrates O-ADR O-ADR
( O-ADR O-ADR
aPCCs O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
FEIBA O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
recombinant O-ADR O-ADR
Factor O-ADR O-ADR
VIIa O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
concentrates O-ADR O-ADR
of O-ADR O-ADR
coagulation O-ADR O-ADR
factors O-ADR O-ADR
II O-ADR O-ADR
, O-ADR O-ADR
IX O-ADR O-ADR
or O-ADR O-ADR
X O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
but O-ADR O-ADR
their O-ADR O-ADR
use O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Promptly O-ADR O-ADR
evaluate O-ADR O-ADR
any O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
loss O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
drop O-ADR O-ADR
in O-ADR O-ADR
hemoglobin O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
hematocrit O-ADR O-ADR
or O-ADR O-ADR
hypotension O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
dose O-ADR O-ADR
for O-ADR O-ADR
moderate O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
until O-ADR O-ADR
return O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
improvement O-ADR O-ADR
to O-ADR O-ADR
mild O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
receiving O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Proteinuria B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
urine O-ADR O-ADR
protein O-ADR O-ADR
. O-ADR O-ADR
Higher O-ADR O-ADR
proportions O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
marked O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
of O-ADR O-ADR
hyperphosphatemia B-ADR B-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
for O-ADR O-ADR
age O-ADR O-ADR
17 O-ADR O-ADR
- O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
for O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
66 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
on O-ADR O-ADR
FARXIGA O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Thrombotic O-ADR O-ADR
Events O-ADR O-ADR
COMETRIQ O-ADR O-ADR
treatment O-ADR O-ADR
results O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
thrombotic B-ADR B-ADR
events I-ADR I-ADR
( O-ADR O-ADR
venous B-ADR B-ADR
thromboembolism I-ADR I-ADR
: O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolism I-ADR I-ADR
: O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
harm O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
Beleodaq O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
two O-ADR O-ADR
concurrent O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
hand O-ADR O-ADR
through O-ADR O-ADR
Day O-ADR O-ADR
60 O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR B-ADR
DISCONTINUATION O-ADR I-ADR
OF O-ADR O-ADR
PRADAXA O-ADR B-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC O-ADR B-ADR
EVENTS O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
EPIDURAL B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR O-ADR
DISCONTINUATION O-ADR O-ADR
OF O-ADR O-ADR
PRADAXA O-ADR O-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC O-ADR B-ADR
EVENTS O-ADR I-ADR
: O-ADR O-ADR
Premature O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
PRADAXA O-ADR O-ADR
, O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic O-ADR B-ADR
events O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
for O-ADR O-ADR
recurrent O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
includes O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
and O-ADR O-ADR
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
. O-ADR O-ADR
Generally O-ADR O-ADR
milder O-ADR O-ADR
withdrawal O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
dysphoria O-ADR O-ADR
, O-ADR O-ADR
anxiety O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
insomnia O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
abrupt O-ADR O-ADR
discontinuance O-ADR O-ADR
of O-ADR O-ADR
benzodiazepines O-ADR O-ADR
taken O-ADR O-ADR
continuously O-ADR O-ADR
at O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
for O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
serum O-ADR O-ADR
potassium O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
fluid O-ADR O-ADR
retention O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
monthly O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Endophthalmitis B-ADR B-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
detachments I-ADR I-ADR
* O-ADR O-ADR
Increased B-ADR B-ADR
intraocular I-ADR I-ADR
pressure I-ADR I-ADR
* O-ADR O-ADR
Thromboembolic B-ADR O-ADR
events I-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
EYLEA O-ADR O-ADR
were O-ADR O-ADR
conjunctival B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
cataract B-ADR B-ADR
, O-ADR O-ADR
vitreous B-ADR B-ADR
floaters I-ADR I-ADR
, O-ADR O-ADR
intraocular B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vitreous B-ADR B-ADR
detachment I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
underlying O-ADR O-ADR
pathology O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
ascertained O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
but O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
instances O-ADR O-ADR
included O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
hepatitis I-ADR I-ADR
. O-ADR O-ADR
Implement O-ADR O-ADR
a O-ADR O-ADR
plan O-ADR O-ADR
to O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
agranulocytosis O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
Ferriprox O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
for O-ADR O-ADR
retinal O-ADR O-ADR
vein O-ADR O-ADR
thrombosis O-ADR O-ADR
immediately O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
required O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
jaundice B-ADR B-ADR
. O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
MEDY O-ADR O-ADR
was O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
( O-ADR O-ADR
warfarin O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
1430 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
following O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Oral O-ADR O-ADR
contraceptive O-ADR O-ADR
use O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
pregnancy O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
PRADAXA O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
coverage O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
anticoagulant O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
AST I-ADR I-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
were O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Lenses O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
reinserted O-ADR O-ADR
after O-ADR O-ADR
10 O-ADR O-ADR
minutes O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
BEPREVE O-ADR O-ADR
. O-ADR O-ADR
DRESS B-ADR B-ADR
typically O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
not O-ADR O-ADR
exclusively O-ADR O-ADR
, O-ADR O-ADR
presents O-ADR O-ADR
with O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
lymphadenopathy B-ADR B-ADR
, O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
organ O-ADR O-ADR
system O-ADR O-ADR
involvement O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hepatitis B-ADR B-ADR
, O-ADR O-ADR
nephritis B-ADR B-ADR
, O-ADR O-ADR
hematological B-ADR B-ADR
abnormalities I-ADR I-ADR
, O-ADR O-ADR
myocarditis B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
myositis B-ADR B-ADR
sometimes O-ADR O-ADR
resembling O-ADR O-ADR
an O-ADR O-ADR
acute O-ADR O-ADR
viral O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
CBC O-ADR O-ADR
including O-ADR O-ADR
lymphocyte O-ADR O-ADR
count O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
obtained O-ADR O-ADR
after O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
thereafter O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Fifty O-ADR O-ADR
- O-ADR O-ADR
eight O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
58 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
73 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
eight O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
Visual B-ADR B-ADR
Loss I-ADR I-ADR
: O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
and O-ADR O-ADR
fatigue B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events I-ADR O-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
electrolytes O-ADR O-ADR
if O-ADR O-ADR
QT O-ADR O-ADR
prolongation O-ADR O-ADR
is O-ADR O-ADR
detected O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Deterioration O-ADR O-ADR
of O-ADR O-ADR
Disease O-ADR O-ADR
and O-ADR O-ADR
Acute O-ADR O-ADR
Episodes O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
acutely O-ADR O-ADR
deteriorating O-ADR O-ADR
COPD O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
condition O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
from O-ADR O-ADR
unintentional O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Prescribe O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
recommended O-ADR O-ADR
patient O-ADR O-ADR
populations O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
depression B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
458 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
accumulation B-ADR B-ADR
of I-ADR I-ADR
body I-ADR I-ADR
fat I-ADR I-ADR
: O-ADR O-ADR
Observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
acute B-ADR B-ADR
exacerbations I-ADR I-ADR
of I-ADR I-ADR
hepatitis I-ADR I-ADR
B I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
HBV O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
discontinued O-ADR O-ADR
EMTRIVA O-ADR O-ADR
or O-ADR O-ADR
VIREAD O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
components O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
variety O-ADR O-ADR
of O-ADR O-ADR
CNS B-ADR B-ADR
anticholinergic I-ADR I-ADR
effects I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
somnolence B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Lack O-ADR O-ADR
of O-ADR O-ADR
Interchangeability O-ADR O-ADR
With O-ADR O-ADR
Gabapentin O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
interchangeable O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
gabapentin O-ADR O-ADR
products O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
differing O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
profiles O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
prolactin B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
Subjects O-ADR O-ADR
: O-ADR O-ADR
Selected O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
Grades O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
worsening O-ADR O-ADR
grade O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
representing O-ADR O-ADR
the O-ADR O-ADR
worst O-ADR O-ADR
- O-ADR O-ADR
grade O-ADR O-ADR
toxicity O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
VORAXAZE O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
advice O-ADR O-ADR
if O-ADR O-ADR
signs O-ADR O-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
high O-ADR O-ADR
risk O-ADR O-ADR
exposure O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
cough O-ADR O-ADR
, O-ADR O-ADR
weight O-ADR O-ADR
loss O-ADR O-ADR
, O-ADR O-ADR
subfebrile O-ADR B-ADR
temperature O-ADR I-ADR
) O-ADR O-ADR
appear O-ADR O-ADR
during O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
ILARIS O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
changes B-ADR B-ADR
in I-ADR I-ADR
FEV1 I-ADR I-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
reversible O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
T3 B-ADR O-ADR
resin I-ADR O-ADR
uptake I-ADR O-ADR
is I-ADR O-ADR
decreased I-ADR O-ADR
, O-ADR O-ADR
reflecting O-ADR O-ADR
the O-ADR O-ADR
elevated B-ADR O-ADR
TBG I-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
basal B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
was O-ADR O-ADR
28 O-ADR O-ADR
to O-ADR O-ADR
249 O-ADR O-ADR
days O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
197 O-ADR O-ADR
days O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cleviprex O-ADR O-ADR
gives O-ADR O-ADR
no O-ADR O-ADR
protection O-ADR O-ADR
against O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
abrupt O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
withdrawal O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
of O-ADR O-ADR
PRES B-ADR B-ADR
are O-ADR O-ADR
usually O-ADR O-ADR
reversible O-ADR O-ADR
but O-ADR O-ADR
may O-ADR O-ADR
evolve O-ADR O-ADR
into O-ADR O-ADR
ischemic B-ADR B-ADR
stroke I-ADR I-ADR
or O-ADR O-ADR
cerebral B-ADR B-ADR
hemorrhage I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Hepatitis O-ADR O-ADR
B O-ADR O-ADR
Virus O-ADR O-ADR
Reactivation O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
hepatitis I-ADR I-ADR
B I-ADR I-ADR
virus I-ADR I-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
chronic O-ADR O-ADR
carriers O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
virus O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
ovarian O-ADR O-ADR
cancer O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
vasodilators O-ADR O-ADR
are O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
additive O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
anticipated O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
should O-ADR O-ADR
undergo O-ADR O-ADR
periodic O-ADR O-ADR
urinalysis O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Visual O-ADR O-ADR
Abnormalities O-ADR O-ADR
Retinal B-ADR B-ADR
vascular I-ADR I-ADR
thrombosis I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
estrogens O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
usefulness O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
prevention O-ADR O-ADR
of O-ADR O-ADR
NSF O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
General O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Site O-ADR O-ADR
Conditions O-ADR O-ADR
: O-ADR O-ADR
Asthenia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
malignancies B-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
84 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
MULTAQ O-ADR O-ADR
doubles O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
Higher O-ADR O-ADR
Incidence O-ADR O-ADR
for O-ADR O-ADR
PROMACTA O-ADR O-ADR
versus O-ADR O-ADR
Placebo O-ADR O-ADR
from O-ADR O-ADR
Two O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
6 O-ADR O-ADR
Years O-ADR O-ADR
and O-ADR O-ADR
Older O-ADR O-ADR
with O-ADR O-ADR
Chronic O-ADR O-ADR
Immune O-ADR O-ADR
( O-ADR O-ADR
Idiopathic O-ADR O-ADR
) O-ADR O-ADR
Thrombocytopenia O-ADR B-ADR
PROMACTA O-ADR O-ADR
Placebo O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
82 O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
40 O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
16 O-ADR O-ADR
5 O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
12 O-ADR O-ADR
5 O-ADR O-ADR
Rhinitis B-ADR B-ADR
11 O-ADR O-ADR
8 O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
9 O-ADR O-ADR
5 O-ADR O-ADR
Cough B-ADR B-ADR
9 O-ADR O-ADR
0 O-ADR O-ADR
Oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
9 O-ADR O-ADR
3 O-ADR O-ADR
Toothache B-ADR B-ADR
6 O-ADR O-ADR
0 O-ADR O-ADR
AST B-ADR B-ADR
increased I-ADR I-ADR
5 O-ADR O-ADR
0 O-ADR O-ADR
Diarrhea B-ADR B-ADR
5 O-ADR O-ADR
3 O-ADR O-ADR
Rash B-ADR B-ADR
5 O-ADR O-ADR
3 O-ADR O-ADR
ALT B-ADR B-ADR
increaseda O-ADR I-ADR
6 O-ADR O-ADR
0 O-ADR O-ADR
Vitamin B-ADR B-ADR
D I-ADR I-ADR
deficiency I-ADR I-ADR
4 O-ADR O-ADR
0 O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
Includes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
or O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
> O-ADR O-ADR
3 O-ADR O-ADR
x O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
jaundice B-ADR B-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
abnormal B-ADR B-ADR
liver I-ADR I-ADR
function I-ADR I-ADR
test O-ADR I-ADR
results O-ADR I-ADR
, O-ADR O-ADR
liver B-ADR B-ADR
disorder I-ADR I-ADR
. O-ADR O-ADR
No O-ADR O-ADR
reports O-ADR O-ADR
involved O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
methylene O-ADR O-ADR
blue O-ADR O-ADR
by O-ADR O-ADR
other O-ADR O-ADR
routes O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
oral O-ADR O-ADR
tablets O-ADR O-ADR
or O-ADR O-ADR
local O-ADR O-ADR
tissue O-ADR O-ADR
injection O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
Families O-ADR O-ADR
and O-ADR O-ADR
caregivers O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antidepressants O-ADR O-ADR
for O-ADR O-ADR
major O-ADR O-ADR
depressive O-ADR O-ADR
disorder O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
psychiatric O-ADR O-ADR
and O-ADR O-ADR
nonpsychiatric O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
alerted O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
agitation O-ADR O-ADR
, O-ADR O-ADR
irritability O-ADR O-ADR
, O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
symptoms O-ADR O-ADR
described O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidality O-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
such O-ADR O-ADR
symptoms O-ADR O-ADR
immediately O-ADR O-ADR
to O-ADR O-ADR
healthcare O-ADR O-ADR
providers O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
ULORIC O-ADR O-ADR
if O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
alternate O-ADR O-ADR
etiology O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
found O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Extravasation O-ADR O-ADR
and O-ADR O-ADR
Injection B-ADR O-ADR
Site I-ADR O-ADR
Reactions I-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
Bleeding O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
bleeding O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
peptic O-ADR O-ADR
ulceration O-ADR O-ADR
. O-ADR O-ADR
AST B-ADR B-ADR
greater I-ADR I-ADR
than I-ADR I-ADR
or I-ADR I-ADR
equal I-ADR I-ADR
to I-ADR I-ADR
3 I-ADR I-ADR
x I-ADR I-ADR
ULN I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
34 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
four O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
cutaneous O-ADR O-ADR
malignancies I-ADR I-ADR
were O-ADR O-ADR
identified O-ADR O-ADR
: O-ADR O-ADR
KRAS B-ADR B-ADR
mutation I-ADR I-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
pancreatic I-ADR I-ADR
adenocarcinoma I-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
recurrent B-ADR O-ADR
NRAS I-ADR B-ADR
mutation I-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
colorectal I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
head B-ADR B-ADR
and I-ADR I-ADR
neck I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
glioblastoma B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Less O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Severe O-ADR O-ADR
or O-ADR O-ADR
Essential O-ADR O-ADR
Hypertension O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
essential O-ADR O-ADR
hypertension O-ADR O-ADR
included O-ADR O-ADR
: O-ADR O-ADR
Cardiac O-ADR O-ADR
: O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
arrestNervous O-ADR I-ADR
system O-ADR O-ADR
: O-ADR O-ADR
syncopeRespiratory O-ADR B-ADR
: O-ADR O-ADR
dyspnea B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
Marketing O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Clinical O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
estimate O-ADR O-ADR
reliably O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
patients O-ADR O-ADR
carefully O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
increased O-ADR O-ADR
when O-ADR O-ADR
JARDIANCE O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
sulfonylurea O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
93 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
reported O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
antihistamines O-ADR O-ADR
, O-ADR O-ADR
steroids O-ADR O-ADR
, O-ADR O-ADR
bronchodilators O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
epinephrine O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
subjects O-ADR O-ADR
aged O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
hospitalizations O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
151 O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
130 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Takeda O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
TAKEDA O-ADR O-ADR
- O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
3327 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
six O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
everolimus O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
three O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Central O-ADR O-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Effects O-ADR O-ADR
Toviaz O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
anticholinergic B-ADR B-ADR
central I-ADR I-ADR
nervous I-ADR I-ADR
sytem I-ADR I-ADR
( I-ADR I-ADR
CNS I-ADR B-ADR
) I-ADR I-ADR
effects I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
1493 O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
equally O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
OTEZLA O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
or O-ADR O-ADR
OTEZLA O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
/ O-ADR O-ADR
1342 O-ADR O-ADR
) O-ADR O-ADR
iloperidone O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hematocrit B-ADR B-ADR
at I-ADR I-ADR
least I-ADR I-ADR
one I-ADR I-ADR
time I-ADR I-ADR
below I-ADR I-ADR
the I-ADR I-ADR
extended I-ADR I-ADR
normal I-ADR I-ADR
range I-ADR I-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
randomization O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
585 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
New O-ADR O-ADR
Onset O-ADR O-ADR
or O-ADR O-ADR
Worsening O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
Renal B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
Fanconi B-ADR B-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
renal B-ADR B-ADR
tubular I-ADR I-ADR
injury I-ADR I-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
a O-ADR O-ADR
restricted O-ADR O-ADR
program O-ADR O-ADR
for O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
called O-ADR O-ADR
the O-ADR O-ADR
ENTEREG O-ADR O-ADR
Access O-ADR O-ADR
Support O-ADR O-ADR
and O-ADR O-ADR
Education O-ADR O-ADR
( O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
new O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
AEs O-ADR O-ADR
that O-ADR O-ADR
emerged O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
later O-ADR O-ADR
treatment O-ADR O-ADR
cycles O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
Prolia O-ADR O-ADR
Postmarketing O-ADR O-ADR
Active O-ADR O-ADR
Safety O-ADR O-ADR
Surveillance O-ADR O-ADR
Program O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
to O-ADR O-ADR
collect O-ADR O-ADR
information O-ADR O-ADR
from O-ADR O-ADR
prescribers O-ADR O-ADR
on O-ADR O-ADR
specific O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
Edarbi O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
> O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
serum B-ADR B-ADR
creatinine I-ADR I-ADR
increases I-ADR I-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
previously O-ADR O-ADR
received O-ADR O-ADR
another O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
type O-ADR O-ADR
A O-ADR O-ADR
product O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
GILENYA O-ADR O-ADR
remains O-ADR O-ADR
uncertain O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
APTIOM O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Epilepsy O-ADR O-ADR
and O-ADR O-ADR
many O-ADR O-ADR
other O-ADR O-ADR
illnesses O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
AEDs O-ADR O-ADR
are O-ADR O-ADR
prescribed O-ADR O-ADR
are O-ADR O-ADR
themselves O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
morbidity O-ADR B-ADR
and O-ADR O-ADR
mortality O-ADR B-ADR
and O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR B-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behavior O-ADR B-ADR
. O-ADR O-ADR
Increased B-ADR B-ADR
plasma I-ADR I-ADR
high I-ADR I-ADR
- O-ADR O-ADR
density O-ADR O-ADR
lipoprotein I-ADR I-ADR
, O-ADR O-ADR
reduced B-ADR B-ADR
low I-ADR I-ADR
- O-ADR O-ADR
density O-ADR O-ADR
lipoprotein I-ADR I-ADR
( I-ADR I-ADR
LDL I-ADR I-ADR
) I-ADR I-ADR
cholesterol I-ADR I-ADR
concentrations I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
triglyceride I-ADR I-ADR
levels I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
difference O-ADR O-ADR
was O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
antibody O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
vaccine O-ADR O-ADR
between O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
pneumococcal O-ADR O-ADR
polysaccharide O-ADR O-ADR
vaccine O-ADR O-ADR
and O-ADR O-ADR
influenza O-ADR O-ADR
vaccine O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
important O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
postmarketing O-ADR O-ADR
experience O-ADR O-ADR
were O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
, O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myelodysplastic B-ADR B-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
support O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
when O-ADR O-ADR
Vimizim O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
discontinuing O-ADR O-ADR
Prolia O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
Muscle B-ADR B-ADR
Pain I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypotension O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Bladder B-ADR B-ADR
Cancer I-ADR I-ADR
: O-ADR O-ADR
An O-ADR O-ADR
imbalance O-ADR B-ADR
in O-ADR O-ADR
bladder B-ADR B-ADR
cancers I-ADR I-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
priapism B-ADR B-ADR
may O-ADR O-ADR
require O-ADR O-ADR
surgical O-ADR O-ADR
intervention O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
periodic O-ADR O-ADR
( O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
systematic O-ADR O-ADR
visual O-ADR O-ADR
monitoring O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
ophthalmic O-ADR O-ADR
professional O-ADR O-ADR
. O-ADR O-ADR
Twenty O-ADR O-ADR
- O-ADR O-ADR
nine O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
85 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
enterocolitis B-ADR B-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
prednisone O-ADR O-ADR
equivalent O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
ranging O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
corticosteroid O-ADR O-ADR
taper O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
71 O-ADR O-ADR
% O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
; O-ADR O-ADR
32 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
of O-ADR O-ADR
Hispanic O-ADR O-ADR
or O-ADR O-ADR
Latino O-ADR O-ADR
ethnicity O-ADR O-ADR
. O-ADR O-ADR
Idelalisib O-ADR O-ADR
is O-ADR O-ADR
teratogenic B-ADR B-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
systemic O-ADR O-ADR
exposures O-ADR O-ADR
12 O-ADR O-ADR
times O-ADR O-ADR
those O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
also O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
neutralizing O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
blinatumomab O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
7 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
had O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
; O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
resolution O-ADR O-ADR
ranged O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
AST O-ADR O-ADR
or O-ADR O-ADR
ALT O-ADR O-ADR
rise O-ADR O-ADR
above O-ADR O-ADR
five O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
bilirubin O-ADR O-ADR
rises O-ADR O-ADR
above O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
, O-ADR O-ADR
interrupt O-ADR O-ADR
ZYTIGA O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
closely O-ADR O-ADR
monitor O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Stop O-ADR O-ADR
Natazia O-ADR O-ADR
if O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
unexplained O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
, O-ADR O-ADR
proptosis O-ADR O-ADR
, O-ADR O-ADR
diplopia O-ADR O-ADR
, O-ADR O-ADR
papilledema O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
retinal O-ADR O-ADR
vascular O-ADR O-ADR
lesions O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
managed O-ADR O-ADR
without O-ADR O-ADR
surgical O-ADR O-ADR
intervention O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
consequences O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Plasma O-ADR O-ADR
Zinc O-ADR O-ADR
Concentration O-ADR O-ADR
Decreased B-ADR B-ADR
plasma I-ADR I-ADR
zinc I-ADR I-ADR
concentrations I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
on O-ADR O-ADR
Ferriprox O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
adequate O-ADR O-ADR
hyperglycemic O-ADR O-ADR
control O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
achieved O-ADR O-ADR
with O-ADR O-ADR
optimal O-ADR O-ADR
medical O-ADR O-ADR
management O-ADR O-ADR
, O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
Serum O-ADR O-ADR
Liver O-ADR O-ADR
Enzyme O-ADR O-ADR
Activities O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
642 O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Ferriprox O-ADR O-ADR
developed O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
values I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
symptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
asymptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
60 O-ADR O-ADR
bpm O-ADR O-ADR
or O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
evaluate O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
adjust O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Risk O-ADR O-ADR
for O-ADR O-ADR
Image O-ADR O-ADR
Misinterpretation O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Errors O-ADR O-ADR
Errors O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Neuraceq O-ADR O-ADR
estimation O-ADR O-ADR
of O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
amyloid O-ADR O-ADR
plaque O-ADR O-ADR
density O-ADR O-ADR
during O-ADR O-ADR
image O-ADR O-ADR
interpretation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
MajorMajor O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
were O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
symptomatic O-ADR O-ADR
episodes O-ADR O-ADR
requiring O-ADR O-ADR
external O-ADR O-ADR
( O-ADR O-ADR
third O-ADR O-ADR
party O-ADR O-ADR
) O-ADR O-ADR
assistance O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
impairment B-ADR B-ADR
in I-ADR I-ADR
consciousness I-ADR I-ADR
with O-ADR O-ADR
a O-ADR O-ADR
plasma B-ADR O-ADR
glucose I-ADR O-ADR
value I-ADR O-ADR
< I-ADR O-ADR
54 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
and O-ADR O-ADR
prompt O-ADR O-ADR
recovery O-ADR O-ADR
after O-ADR O-ADR
glucose O-ADR O-ADR
or O-ADR O-ADR
glucagon O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
in O-ADR O-ADR
949 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimens O-ADR O-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
or O-ADR O-ADR
EBV O-ADR O-ADR
serostatus O-ADR O-ADR
unknown O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
/ O-ADR O-ADR
139 O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
810 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
certolizumab O-ADR O-ADR
pegol O-ADR O-ADR
detectable O-ADR O-ADR
on O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
occasion O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
105 O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
509 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
clinical O-ADR O-ADR
context O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
liver O-ADR O-ADR
enzyme O-ADR O-ADR
elevations O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
abnormal O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
persist O-ADR O-ADR
or O-ADR O-ADR
worsen O-ADR O-ADR
, O-ADR O-ADR
NESINA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
interrupted O-ADR O-ADR
and O-ADR O-ADR
investigation O-ADR O-ADR
done O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
the O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
. O-ADR O-ADR
Keep O-ADR O-ADR
bottle O-ADR O-ADR
tightly O-ADR O-ADR
closed O-ADR O-ADR
when O-ADR O-ADR
not O-ADR O-ADR
in O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
anaphylactic O-ADR O-ADR
- O-ADR O-ADR
type O-ADR O-ADR
reaction O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
oxcarbazepine O-ADR O-ADR
or O-ADR O-ADR
APTIOM O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
titration O-ADR O-ADR
period O-ADR O-ADR
( O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
maintenance O-ADR O-ADR
period O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
also O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
younger O-ADR O-ADR
adults O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Pancreatitis O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
combined O-ADR O-ADR
eight O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
and O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
6177 O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
were O-ADR O-ADR
ILD B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
AST B-ADR B-ADR
elevation I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
when O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
SIRTURO O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
QT O-ADR O-ADR
prolonging O-ADR O-ADR
drugs O-ADR O-ADR
including O-ADR O-ADR
fluoroquinolones O-ADR O-ADR
and O-ADR O-ADR
macrolide O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
antimycobacterial O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
clofazimine O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
Torsade O-ADR O-ADR
de O-ADR O-ADR
Pointes O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
congenital O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
or O-ADR O-ADR
ongoing O-ADR O-ADR
hypothyroidism O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
or O-ADR O-ADR
ongoing O-ADR O-ADR
bradyarrhythmias O-ADR O-ADR
* O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
uncompensated O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
* O-ADR O-ADR
serum O-ADR O-ADR
calcium O-ADR O-ADR
, O-ADR O-ADR
magnesium O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
potassium O-ADR O-ADR
levels O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
lower O-ADR O-ADR
limits O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
If O-ADR O-ADR
necessary O-ADR O-ADR
, O-ADR O-ADR
bedaquiline O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
a O-ADR O-ADR
favorable O-ADR O-ADR
benefit O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
frequent O-ADR O-ADR
ECG O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
and O-ADR O-ADR
persisted O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
assessed O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
Cognitive B-ADR O-ADR
dysfunction O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
those O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
DUREZOL O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
included O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
IOP I-ADR I-ADR
, O-ADR O-ADR
iritis B-ADR B-ADR
, O-ADR O-ADR
conjunctival B-ADR B-ADR
hyperemia I-ADR I-ADR
, O-ADR O-ADR
punctate B-ADR B-ADR
keratitis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
uveitis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
30 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
34 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
than O-ADR O-ADR
half O-ADR O-ADR
( O-ADR O-ADR
55 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
male O-ADR O-ADR
; O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
when O-ADR O-ADR
POTIGA O-ADR O-ADR
is O-ADR O-ADR
prescribed O-ADR O-ADR
with O-ADR O-ADR
medicines O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
prolonged O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
ventricular O-ADR B-ADR
hypertrophy O-ADR I-ADR
, O-ADR O-ADR
hypokalemia O-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
hypertension B-ADR B-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
56 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
39 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Cardiac B-ADR B-ADR
Arrhythmia I-ADR I-ADR
and O-ADR O-ADR
Sudden B-ADR O-ADR
Cardiac I-ADR I-ADR
Death I-ADR I-ADR
during O-ADR O-ADR
General O-ADR O-ADR
Anesthesia O-ADR O-ADR
for O-ADR O-ADR
Central O-ADR O-ADR
Venous O-ADR O-ADR
Catheter O-ADR O-ADR
Placement O-ADR O-ADR
: O-ADR O-ADR
Caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
general O-ADR O-ADR
anesthesia O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
placement O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
central O-ADR O-ADR
venous O-ADR O-ADR
catheter O-ADR O-ADR
intended O-ADR O-ADR
for O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusion O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
occurring O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
monotherapy O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
serum O-ADR O-ADR
phosphorus O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
measured O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypotension O-ADR O-ADR
in O-ADR O-ADR
Volume O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
Salt O-ADR O-ADR
- O-ADR O-ADR
Depleted O-ADR O-ADR
Patients O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
activated O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
system O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
volume O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
salt O-ADR O-ADR
- O-ADR O-ADR
depleted O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
those O-ADR O-ADR
being O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
diuretics O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
symptomatic B-ADR B-ADR
hypotension I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
. O-ADR O-ADR
Dizziness B-ADR B-ADR
led O-ADR O-ADR
to O-ADR O-ADR
withdrawal O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
apparent O-ADR O-ADR
association O-ADR O-ADR
between O-ADR O-ADR
mean O-ADR O-ADR
or O-ADR O-ADR
peak O-ADR O-ADR
IgG O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
asthma O-ADR O-ADR
is O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
on O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
medium O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
inhibition O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
fully O-ADR O-ADR
understood O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
dermatitis O-ADR O-ADR
is O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
corticosteroid O-ADR O-ADR
tapering O-ADR O-ADR
should O-ADR O-ADR
occur O-ADR O-ADR
over O-ADR O-ADR
a O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
. O-ADR O-ADR
Psychiatric O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Suicidal B-ADR B-ADR
ideation I-ADR I-ADR
. O-ADR O-ADR
Program O-ADR O-ADR
include O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
hospitalized O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
484 O-ADR O-ADR
subjects O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
analyses O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
development O-ADR O-ADR
program O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
, O-ADR O-ADR
myasthenia B-ADR B-ADR
gravis I-ADR I-ADR
and O-ADR O-ADR
additional O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
many O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
many O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
operative O-ADR O-ADR
procedure O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
Cleviprex O-ADR O-ADR
and O-ADR O-ADR
relatively O-ADR O-ADR
few O-ADR O-ADR
plausibly O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
lower O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
Interactions O-ADR O-ADR
Due O-ADR O-ADR
to O-ADR O-ADR
significant O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
everolimus O-ADR O-ADR
, O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
with O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
/ O-ADR O-ADR
PgP O-ADR O-ADR
inhibitors O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Refer O-ADR O-ADR
to O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
for O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
modifications O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
discontinue O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
leucovorin O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
determination O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
leucovorin O-ADR O-ADR
treatment O-ADR O-ADR
threshold O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
types O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
excluding O-ADR O-ADR
hypoglycemia B-ADR B-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
test O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
with O-ADR O-ADR
expertise O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Venous O-ADR O-ADR
Thromboembolism O-ADR O-ADR
( O-ADR O-ADR
VTE O-ADR O-ADR
) O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
WHI O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
substudy O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
VTE B-ADR B-ADR
[ O-ADR O-ADR
DVT B-ADR B-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
PE B-ADR B-ADR
) O-ADR O-ADR
] O-ADR O-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
for O-ADR O-ADR
women O-ADR O-ADR
receiving O-ADR O-ADR
daily O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
30 O-ADR O-ADR
versus O-ADR O-ADR
22 O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
women O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
only O-ADR O-ADR
the O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
DVT B-ADR B-ADR
reached O-ADR O-ADR
statistical O-ADR O-ADR
significance O-ADR O-ADR
( O-ADR O-ADR
23 O-ADR O-ADR
versus O-ADR O-ADR
15 O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
women O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Testing O-ADR O-ADR
for O-ADR O-ADR
IgG O-ADR O-ADR
titers O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
if O-ADR O-ADR
patients O-ADR O-ADR
develop O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
lose O-ADR O-ADR
clinical O-ADR O-ADR
response O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Anemia B-ADR B-ADR
- O-ADR O-ADR
The O-ADR O-ADR
addition O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
to O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
additional O-ADR B-ADR
decrease B-ADR I-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
concentrations I-ADR I-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
highly O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
while O-ADR O-ADR
using O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
ending O-ADR O-ADR
treatment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
IgG O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
annually O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
variety O-ADR O-ADR
of O-ADR O-ADR
sources O-ADR O-ADR
including O-ADR O-ADR
registries O-ADR O-ADR
and O-ADR O-ADR
spontaneous O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
reports O-ADR O-ADR
. O-ADR O-ADR
Reduction O-ADR O-ADR
of O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Stroke O-ADR O-ADR
and O-ADR O-ADR
Systemic O-ADR O-ADR
Embolism O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Nonvalvular O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
and O-ADR O-ADR
AVERROES O-ADR O-ADR
studies O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
11 O-ADR O-ADR
, O-ADR O-ADR
284 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
ELIQUIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
602 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
ELIQUIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
TAFINLAR O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
results O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
basal B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
. O-ADR O-ADR
Rare O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
neurological B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
seizure B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
optic B-ADR B-ADR
neuritis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GRANIX O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
adequately O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
negative O-ADR O-ADR
image O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
recurrent O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
positive O-ADR O-ADR
image O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
confirm O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
recurrent O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
conditions O-ADR O-ADR
and O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
varied O-ADR O-ADR
greatly O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
multiple O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
clinical O-ADR O-ADR
pharmacology O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
healthy O-ADR O-ADR
volunteers O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
LGS O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
PML O-ADR B-ADR
is O-ADR O-ADR
usually O-ADR O-ADR
diagnosed O-ADR O-ADR
by O-ADR O-ADR
brain O-ADR O-ADR
imaging O-ADR O-ADR
, O-ADR O-ADR
cerebrospinal O-ADR O-ADR
fluid O-ADR O-ADR
( O-ADR O-ADR
CSF O-ADR O-ADR
) O-ADR O-ADR
testing O-ADR O-ADR
for O-ADR O-ADR
JC O-ADR O-ADR
viral O-ADR O-ADR
DNA O-ADR O-ADR
by O-ADR O-ADR
polymerase O-ADR O-ADR
chain O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
PCR O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
brain O-ADR O-ADR
biopsy O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
reduction O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
dose O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
when O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
moderate O-ADR O-ADR
CYP3A4 O-ADR O-ADR
/ O-ADR O-ADR
PgP O-ADR O-ADR
inhibitor O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Effects O-ADR O-ADR
Following O-ADR O-ADR
GILENYA O-ADR O-ADR
Discontinuation O-ADR O-ADR
Fingolimod O-ADR O-ADR
remains O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
blood O-ADR O-ADR
and O-ADR O-ADR
has O-ADR O-ADR
pharmacodynamic O-ADR O-ADR
effects O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
decreased B-ADR B-ADR
lymphocyte I-ADR I-ADR
counts I-ADR I-ADR
, O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
CYP3A O-ADR O-ADR
inducers O-ADR O-ADR
: O-ADR O-ADR
Concomitant O-ADR O-ADR
use O-ADR O-ADR
with O-ADR O-ADR
strong O-ADR O-ADR
CYP3A O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
wort O-ADR O-ADR
) O-ADR O-ADR
substantially O-ADR O-ADR
decreases O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
ivacaftor O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
diminish O-ADR O-ADR
effectiveness O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Application B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
to O-ADR O-ADR
emphasize O-ADR O-ADR
that O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
, O-ADR O-ADR
they O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
necessarily O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
it O-ADR O-ADR
. O-ADR O-ADR
Non O-ADR B-ADR
- O-ADR O-ADR
acute O-ADR O-ADR
hypersensitivity B-ADR I-ADR
reactions I-ADR I-ADR
including O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
facial B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
and O-ADR O-ADR
typically O-ADR O-ADR
occurred O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
week O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
recent O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
Reduction O-ADR O-ADR
in O-ADR O-ADR
Heart O-ADR O-ADR
Rate O-ADR O-ADR
After O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
heart B-ADR B-ADR
rate I-ADR I-ADR
decrease I-ADR I-ADR
starts O-ADR O-ADR
within O-ADR O-ADR
an O-ADR O-ADR
hour O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Geriatric O-ADR O-ADR
Use O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
EPS B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events I-ADR I-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
akathisia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
Commonly O-ADR O-ADR
Reported O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
Monotherapy O-ADR O-ADR
a O-ADR O-ADR
Pneumonia B-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
bronchopneumonia B-ADR B-ADR
. O-ADR O-ADR
One O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
urticaria B-ADR B-ADR
had O-ADR O-ADR
recurrence O-ADR O-ADR
when O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Endogenous O-ADR O-ADR
Anterior O-ADR O-ADR
Uveitis O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
200 O-ADR O-ADR
subjects O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
endogenous O-ADR O-ADR
anterior O-ADR O-ADR
uveitis O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
106 O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
DUREZOL O-ADR O-ADR
. O-ADR O-ADR
Cognitive B-ADR B-ADR
dysfunction I-ADR I-ADR
events O-ADR I-ADR
were O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
monotherapy O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
QT B-ADR B-ADR
- O-ADR O-ADR
prolonging O-ADR O-ADR
effect O-ADR I-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
hours O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED B-ADR O-ADR
MORTALITY I-ADR B-ADR
IN O-ADR O-ADR
ELDERLY O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DEMENTIA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
PSYCHOSIS O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED B-ADR O-ADR
MORTALITY I-ADR B-ADR
IN O-ADR O-ADR
ELDERLY O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DEMENTIA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
PSYCHOSIS O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
worsening B-ADR B-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
With O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
Incidence O-ADR O-ADR
for O-ADR O-ADR
Any O-ADR O-ADR
Grade O-ADR O-ADR
or O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Incidence O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
Higher O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
212 O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Any O-ADR O-ADR
GradeGrading O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
NCI O-ADR O-ADR
Common O-ADR O-ADR
Terminology O-ADR O-ADR
Criteria O-ADR O-ADR
for O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
( O-ADR O-ADR
CTCAE O-ADR O-ADR
) O-ADR O-ADR
version O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
Higher O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
lymphatic O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
Anemia B-ADR B-ADR
Neutropenia B-ADR B-ADR
Thrombocytopenia B-ADR B-ADR
Leukopenia B-ADR B-ADR
251816119 O-ADR O-ADR
23131588 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
Nausea B-ADR B-ADR
Constipation B-ADR B-ADR
DiarrheaDiarrhea O-ADR B-ADR
includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
colitis B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
enteritis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
neutropenic B-ADR B-ADR
colitis I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
pruritus B-ADR B-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
after O-ADR O-ADR
each O-ADR O-ADR
injection O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
injections O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
newly O-ADR O-ADR
diagnosed O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pulmonary O-ADR O-ADR
MDR O-ADR O-ADR
- O-ADR O-ADR
TB O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
increased B-ADR B-ADR
AST I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
alkaline I-ADR I-ADR
phosphatase I-ADR I-ADR
, O-ADR O-ADR
hypocalcemia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hyperbilirubinemia B-ADR B-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
for O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
bradycardia O-ADR O-ADR
if O-ADR O-ADR
no O-ADR O-ADR
contributing O-ADR O-ADR
concomitant O-ADR O-ADR
medication O-ADR O-ADR
is O-ADR O-ADR
identified O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
concomitant O-ADR O-ADR
medication O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
hypotension O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
asymptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
60 O-ADR O-ADR
bpm O-ADR O-ADR
or O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
medication O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
adjusted O-ADR O-ADR
or O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
resume O-ADR O-ADR
ZYKADIA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
upon O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
asymptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
60 O-ADR O-ADR
bpm O-ADR O-ADR
or O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
when O-ADR O-ADR
taking O-ADR O-ADR
Ferriprox O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Studies O-ADR O-ADR
have O-ADR O-ADR
shown O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
hepatocellular B-ADR B-ADR
carcinoma I-ADR I-ADR
in O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
8 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
COC O-ADR O-ADR
users O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Ferriprox O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
discontinued O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
increased B-ADR B-ADR
serum I-ADR I-ADR
ALT I-ADR I-ADR
levels O-ADR I-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
both I-ADR I-ADR
ALT I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Bleeding O-ADR O-ADR
Irregularities O-ADR O-ADR
Breakthrough B-ADR B-ADR
bleeding I-ADR I-ADR
and O-ADR O-ADR
spotting B-ADR B-ADR
sometimes O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
COCs O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
three O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Oral O-ADR B-ADR
contraceptive O-ADR I-ADR
- O-ADR O-ADR
related O-ADR O-ADR
cholestasis B-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pregnancy O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
cholestasis O-ADR O-ADR
. O-ADR O-ADR
AdreView O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
effectiveness O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
in O-ADR O-ADR
neonates O-ADR O-ADR
( O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Forty O-ADR O-ADR
- O-ADR O-ADR
four O-ADR O-ADR
( O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
dermatitis B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
complete O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
improved O-ADR O-ADR
to O-ADR O-ADR
mild O-ADR O-ADR
( O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
no O-ADR O-ADR
reported O-ADR O-ADR
improvement O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
was O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
noncomparative O-ADR O-ADR
study O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
individualized O-ADR O-ADR
pulmonary O-ADR O-ADR
MDR O-ADR O-ADR
- O-ADR O-ADR
TB O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Incidence O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Adjunctive O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Partial O-ADR O-ADR
- O-ADR O-ADR
Onset O-ADR O-ADR
Seizures O-ADR O-ADR
( O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
numerically O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
) O-ADR O-ADR
Across O-ADR O-ADR
all O-ADR O-ADR
YERVOY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
511 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
intestinal B-ADR B-ADR
perforation I-ADR I-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
died B-ADR B-ADR
as O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
complications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
26 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
hospitalized O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
enterocolitis B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Interference O-ADR O-ADR
with O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
COCs O-ADR O-ADR
may O-ADR O-ADR
change O-ADR O-ADR
the O-ADR O-ADR
results O-ADR O-ADR
of O-ADR O-ADR
some O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
coagulation O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
lipids O-ADR O-ADR
, O-ADR O-ADR
glucose O-ADR O-ADR
tolerance O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
binding O-ADR O-ADR
proteins O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Macrovascular O-ADR O-ADR
outcomes O-ADR O-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Malignancies O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
and O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Macrovascular O-ADR O-ADR
outcomes O-ADR O-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
reasons O-ADR O-ADR
for O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
pooled O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MDD O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
834 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
PRISTIQ O-ADR O-ADR
( O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Anaphylactic O-ADR O-ADR
Reactions O-ADR O-ADR
and O-ADR O-ADR
Angioedema O-ADR O-ADR
Rare O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
APTIOM O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
bradycardia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
205 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
1669 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
Measure O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
promptly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
report O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
indicate O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
anorexia O-ADR O-ADR
, O-ADR O-ADR
right O-ADR O-ADR
upper O-ADR O-ADR
abdominal O-ADR O-ADR
discomfort O-ADR O-ADR
, O-ADR O-ADR
dark O-ADR O-ADR
urine O-ADR O-ADR
or O-ADR O-ADR
jaundice O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
dermatologic B-ADR B-ADR
reactions I-ADR I-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
use O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Flushing O-ADR O-ADR
TECFIDERA O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
flushing B-ADR B-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
warmth B-ADR B-ADR
, O-ADR O-ADR
redness B-ADR B-ADR
, O-ADR O-ADR
itching B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
burning B-ADR B-ADR
sensation I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
CBC O-ADR O-ADR
including O-ADR O-ADR
lymphocyte O-ADR O-ADR
count O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
obtained O-ADR O-ADR
. O-ADR O-ADR
Reduction O-ADR O-ADR
of O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Stroke O-ADR O-ADR
and O-ADR O-ADR
Systemic O-ADR O-ADR
Embolism O-ADR O-ADR
in O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
valvular O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
The O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
LY O-ADR O-ADR
( O-ADR O-ADR
Randomized O-ADR O-ADR
Evaluation O-ADR O-ADR
of O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
Anticoagulant O-ADR O-ADR
Therapy O-ADR O-ADR
) O-ADR O-ADR
study O-ADR O-ADR
provided O-ADR O-ADR
safety O-ADR O-ADR
information O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
two O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
and O-ADR O-ADR
warfarin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
cardiovascular O-ADR O-ADR
or O-ADR O-ADR
cerebrovascular O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
antipsychotic O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
[ O-ADR O-ADR
seeBoxed O-ADR O-ADR
Warningand O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
was O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
rating O-ADR O-ADR
scale O-ADR O-ADR
scores O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
accompanying O-ADR O-ADR
reactions O-ADR O-ADR
included O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
wheezing B-ADR B-ADR
, O-ADR O-ADR
tachypnea B-ADR B-ADR
, O-ADR O-ADR
cyanosis B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
oxygen I-ADR I-ADR
saturation I-ADR I-ADR
, O-ADR O-ADR
convulsions B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
/ O-ADR O-ADR
increased O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
flushing O-ADR O-ADR
/ O-ADR O-ADR
feeling O-ADR O-ADR
hot B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
pallor B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
coldness I-ADR I-ADR
, O-ADR O-ADR
restlessness B-ADR B-ADR
, O-ADR O-ADR
nervousness B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
paresthesia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
was O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
808 O-ADR O-ADR
subjects O-ADR O-ADR
included O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
analyses O-ADR O-ADR
. O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
Class O-ADR O-ADR
/ O-ADR O-ADR
Preferred O-ADR O-ADR
Term O-ADR O-ADR
Placebo O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
166 O-ADR O-ADR
% O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
* O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
158 O-ADR O-ADR
% O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
Dyspepsia B-ADR B-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
Oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
0 O-ADR O-ADR
5 O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
Fatigue B-ADR B-ADR
2 O-ADR O-ADR
4 O-ADR O-ADR
Edema B-ADR B-ADR
peripheral I-ADR I-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Investigations O-ADR O-ADR
Increased B-ADR B-ADR
weight I-ADR I-ADR
0 O-ADR O-ADR
3 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Dizziness B-ADR B-ADR
2 O-ADR O-ADR
4 O-ADR O-ADR
Other O-ADR O-ADR
extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
akathisia B-ADR B-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
6 O-ADR O-ADR
Somnolence B-ADR B-ADR
? O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
finding O-ADR O-ADR
with O-ADR O-ADR
salmeterol O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Infusion O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
adverse B-ADR O-ADR
events I-ADR O-ADR
associated I-ADR O-ADR
with I-ADR O-ADR
the I-ADR O-ADR
infusion I-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
251 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
458 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
99 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
anticholinergic O-ADR O-ADR
CNS O-ADR O-ADR
effects O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
after O-ADR O-ADR
beginning O-ADR O-ADR
treatment O-ADR O-ADR
or O-ADR O-ADR
increasing O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
, O-ADR O-ADR
Integrase O-ADR O-ADR
Strand O-ADR O-ADR
Transfer O-ADR O-ADR
Inhibitor O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
Subjects O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
an O-ADR O-ADR
international O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
ING111762 O-ADR O-ADR
, O-ADR O-ADR
SAILING O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
719 O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
, O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
adults O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
and O-ADR O-ADR
received O-ADR O-ADR
either O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
or O-ADR O-ADR
raltegravir O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
investigator O-ADR O-ADR
- O-ADR O-ADR
selected O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
fully O-ADR O-ADR
active O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cataracts B-ADR B-ADR
: O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
congenital O-ADR O-ADR
lens I-ADR I-ADR
opacities I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALYDECO O-ADR O-ADR
. O-ADR O-ADR
Institute O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
for O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
neuropathy O-ADR O-ADR
. O-ADR O-ADR
ENTEREG O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
a O-ADR O-ADR
program O-ADR O-ADR
called O-ADR O-ADR
the O-ADR O-ADR
ENTEREG O-ADR O-ADR
Access O-ADR O-ADR
Support O-ADR O-ADR
and O-ADR O-ADR
Education O-ADR O-ADR
( O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
. O-ADR O-ADR
E O-ADR O-ADR
. O-ADR O-ADR
) O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
highly O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
. O-ADR O-ADR
Patient O-ADR O-ADR
monitoring O-ADR O-ADR
may O-ADR O-ADR
help O-ADR O-ADR
detect O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
PVAN O-ADR O-ADR
. O-ADR O-ADR
Obtain O-ADR O-ADR
frequent O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
to O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
neutropenia O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
GILENYA O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
elevation O-ADR O-ADR
exceeded O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
PML O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
levels O-ADR O-ADR
of O-ADR O-ADR
overall O-ADR O-ADR
immunosuppression O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
and O-ADR O-ADR
concomitant O-ADR O-ADR
immunosuppressives O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
MMF O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
exceeded O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
permitted O-ADR O-ADR
to O-ADR O-ADR
participate O-ADR O-ADR
sequentially O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
; O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
collected O-ADR O-ADR
during O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
was O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
KALBITOR O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
collected O-ADR O-ADR
during O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Healthcare O-ADR O-ADR
providers O-ADR O-ADR
should O-ADR O-ADR
follow O-ADR O-ADR
current O-ADR O-ADR
CDC O-ADR O-ADR
guidelines O-ADR O-ADR
both O-ADR O-ADR
to O-ADR O-ADR
evaluate O-ADR O-ADR
for O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
possible O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infections O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
from O-ADR O-ADR
study O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
genital B-ADR B-ADR
infection I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
or O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Atypical O-ADR O-ADR
Subtrochanteric O-ADR O-ADR
and O-ADR O-ADR
Diaphyseal O-ADR O-ADR
Femoral B-ADR O-ADR
Fractures I-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Prolia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Neurologic O-ADR O-ADR
Reactions O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
CIMZIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
rare O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
new O-ADR O-ADR
onset O-ADR O-ADR
or O-ADR O-ADR
exacerbation O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
radiographic O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
central B-ADR B-ADR
nervous I-ADR I-ADR
system I-ADR I-ADR
demyelinating I-ADR I-ADR
disease I-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
multiple B-ADR B-ADR
sclerosis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
peripheral B-ADR B-ADR
demyelinating I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Guillain B-ADR B-ADR
- O-ADR O-ADR
Barre O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
permanent O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
< O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cholestatic O-ADR O-ADR
jaundice O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
past O-ADR O-ADR
estrogen O-ADR O-ADR
use O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
recurrence O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
Malignancies O-ADR O-ADR
One O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
malignancy B-ADR B-ADR
other O-ADR O-ADR
than O-ADR O-ADR
lymphoma B-ADR B-ADR
and O-ADR O-ADR
NMSC B-ADR B-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
responded O-ADR O-ADR
to O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
regimen O-ADR O-ADR
overall O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
647 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
21 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
332 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
half O-ADR O-ADR
the O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
lymphomas B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
Hodgkin O-ADR O-ADR
' I-ADR I-ADR
s O-ADR O-ADR
lymphoma I-ADR I-ADR
. O-ADR O-ADR
During O-ADR O-ADR
randomized O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
( O-ADR O-ADR
AST O-ADR B-ADR
: O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ALT O-ADR B-ADR
: O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
ULORIC O-ADR O-ADR
and O-ADR O-ADR
allopurinol O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Neutrophils O-ADR O-ADR
and O-ADR O-ADR
Platelets O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
decreased B-ADR B-ADR
neutrophil I-ADR I-ADR
and I-ADR I-ADR
platelet I-ADR I-ADR
counts I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
immediately O-ADR O-ADR
symptoms O-ADR O-ADR
suggesting O-ADR O-ADR
hepatic O-ADR O-ADR
injury O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
anorexia O-ADR O-ADR
, O-ADR O-ADR
nausea O-ADR O-ADR
, O-ADR O-ADR
vomiting O-ADR O-ADR
, O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
malaise O-ADR O-ADR
, O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
right O-ADR O-ADR
upper O-ADR O-ADR
quadrant O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
jaundice O-ADR O-ADR
, O-ADR O-ADR
dark O-ADR O-ADR
urine O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
itching O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
the O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
observational O-ADR O-ADR
study O-ADR O-ADR
evaluated O-ADR O-ADR
whether O-ADR O-ADR
recent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
NAION B-ADR B-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
lesser O-ADR O-ADR
elevations O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
ALT O-ADR O-ADR
or O-ADR O-ADR
bilirubin O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
alternate O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ULORIC O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
CDAD O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
or O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
antibacterials O-ADR O-ADR
not O-ADR O-ADR
directed O-ADR O-ADR
against O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
fully O-ADR O-ADR
understood O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR I-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
( O-ADR O-ADR
CDAD B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
nearly O-ADR O-ADR
all O-ADR O-ADR
systemic O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Teflaro O-ADR O-ADR
. O-ADR O-ADR
Neoplasms O-ADR O-ADR
Benign O-ADR O-ADR
, O-ADR O-ADR
Malignant O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Unspecified O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
cysts O-ADR O-ADR
and O-ADR O-ADR
polyps O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Skin B-ADR B-ADR
papilloma I-ADR I-ADR
. O-ADR O-ADR
No O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
effect O-ADR O-ADR
relationship O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
transaminase O-ADR B-ADR
elevations O-ADR I-ADR
was O-ADR O-ADR
noted O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
portions O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
active B-ADR O-ADR
TB I-ADR B-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
31 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
06 O-ADR O-ADR
; O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
92 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
42 O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
07 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Counseling O-ADR O-ADR
patients O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
protective O-ADR O-ADR
measures O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
guard O-ADR O-ADR
against O-ADR O-ADR
sexually O-ADR O-ADR
transmitted O-ADR O-ADR
diseases O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Human O-ADR O-ADR
Immunodeficiency O-ADR O-ADR
Virus O-ADR O-ADR
( O-ADR O-ADR
HIV O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Geriatric O-ADR O-ADR
Patients O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
advanced O-ADR O-ADR
hormone O-ADR O-ADR
receptor O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
, O-ADR O-ADR
HER2 O-ADR O-ADR
- O-ADR O-ADR
negative O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
cause O-ADR O-ADR
within O-ADR O-ADR
28 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
AFINITOR O-ADR O-ADR
dose O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
< O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
Transient O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
absolute I-ADR I-ADR
neutrophil I-ADR I-ADR
count I-ADR I-ADR
) O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ILARIS O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
to1 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
was O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
when O-ADR O-ADR
TANZEUM O-ADR O-ADR
was O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALBITOR O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
consider O-ADR O-ADR
PML O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
neurological O-ADR O-ADR
, O-ADR O-ADR
cognitive O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
behavioral O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
LGS O-ADR O-ADR
Placebo O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
lists O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ONFI O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
dose O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
parallel O-ADR O-ADR
group O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
of O-ADR O-ADR
adjunctive O-ADR O-ADR
AED O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
15 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Serum O-ADR O-ADR
transaminase O-ADR O-ADR
levels O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
normal O-ADR O-ADR
within O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Sickle O-ADR O-ADR
Cell O-ADR O-ADR
Disease O-ADR O-ADR
Severe O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
sickle B-ADR B-ADR
cell I-ADR I-ADR
crises I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
sickle O-ADR O-ADR
cell O-ADR O-ADR
disease O-ADR O-ADR
receiving O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Antibody O-ADR O-ADR
titers O-ADR O-ADR
for O-ADR O-ADR
cellular O-ADR O-ADR
uptake O-ADR O-ADR
inhibition O-ADR O-ADR
were O-ADR O-ADR
present O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
of O-ADR O-ADR
59 O-ADR O-ADR
( O-ADR O-ADR
31 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
by O-ADR O-ADR
Week O-ADR O-ADR
78 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
NHL O-ADR O-ADR
( O-ADR O-ADR
frequency O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
weight B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
stomatitis B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
remaining O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
symptoms O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
each O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
infection B-ADR B-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
act O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
system O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
and O-ADR O-ADR
third O-ADR O-ADR
trimesters O-ADR O-ADR
of O-ADR O-ADR
pregnancy O-ADR O-ADR
reduces B-ADR B-ADR
fetal I-ADR I-ADR
renal I-ADR I-ADR
function I-ADR I-ADR
and O-ADR O-ADR
increases O-ADR O-ADR
neonatal B-ADR B-ADR
morbidity I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Posterior B-ADR B-ADR
reversible I-ADR I-ADR
encephalopathy I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PRES B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
If O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
DaTscan O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
IgE O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
experience O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
More O-ADR O-ADR
hepatic B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SIRTURO O-ADR O-ADR
plus O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
tuberculosis O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
tuberculosis O-ADR O-ADR
without O-ADR O-ADR
the O-ADR O-ADR
addition O-ADR O-ADR
of O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
725 O-ADR O-ADR
men O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
731 O-ADR O-ADR
men O-ADR O-ADR
were O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
Prolia O-ADR O-ADR
administered O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
60 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
SCC O-ADR B-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
both O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Vimizim O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
infections B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Temporarily O-ADR O-ADR
suspend O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
XALKORI O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
APTIOM O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Osteonecrosis O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
Jaw O-ADR O-ADR
Osteonecrosis B-ADR O-ADR
of I-ADR O-ADR
the I-ADR I-ADR
jaw I-ADR I-ADR
( O-ADR O-ADR
ONJ B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
lower I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
upper I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
tenderness I-ADR I-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
XIAFLEX O-ADR O-ADR
contains O-ADR O-ADR
foreign O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
to O-ADR O-ADR
XIAFLEX O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Depression O-ADR O-ADR
Women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
observed O-ADR O-ADR
and O-ADR O-ADR
Natazia O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
depression O-ADR O-ADR
recurs O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
degree O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
401 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
71 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
very O-ADR O-ADR
similar O-ADR O-ADR
( O-ADR O-ADR
but O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
identical O-ADR O-ADR
) O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
5 O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
: O-ADR O-ADR
3 O-ADR O-ADR
in O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
Cognitive O-ADR O-ADR
and O-ADR O-ADR
Motor O-ADR O-ADR
Impairment O-ADR O-ADR
FANAPT O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
antipsychotics O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
to O-ADR O-ADR
impair B-ADR O-ADR
judgment I-ADR O-ADR
. O-ADR O-ADR
FARXIGA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
bladder O-ADR O-ADR
cancer O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
bladder O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
formation O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
blinatumomab O-ADR O-ADR
antibodies O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
effect O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Amgen O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
77 O-ADR O-ADR
- O-ADR O-ADR
AMGEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
772 O-ADR O-ADR
- O-ADR O-ADR
6436 O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
discuss O-ADR O-ADR
antibody O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
treatment O-ADR O-ADR
arms O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
SIRTURO O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
MDR O-ADR O-ADR
- O-ADR O-ADR
TB O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
1670 O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
TRULICITY O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
TRULICITY O-ADR O-ADR
of O-ADR O-ADR
23 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Neuraceq O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
all O-ADR O-ADR
radiopharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
Elevations O-ADR O-ADR
of O-ADR O-ADR
AST O-ADR O-ADR
, O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
bilirubin O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
baseline O-ADR O-ADR
should O-ADR O-ADR
prompt O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Be O-ADR O-ADR
alert O-ADR O-ADR
to O-ADR O-ADR
hypokalemia O-ADR O-ADR
and O-ADR O-ADR
hyperglycemia O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
new O-ADR O-ADR
safety O-ADR O-ADR
signals O-ADR O-ADR
were O-ADR O-ADR
identified O-ADR O-ADR
among O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
retreated O-ADR O-ADR
with O-ADR O-ADR
XIAFLEX O-ADR O-ADR
. O-ADR O-ADR
CTCAE O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
deaths B-ADR B-ADR
clearly O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
ZYTIGA O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
events O-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Macrovascular O-ADR O-ADR
Outcomes O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
four O-ADR O-ADR
pivotal O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
PRADAXA O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
similar O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
22 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
warfarin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
any O-ADR O-ADR
specific O-ADR O-ADR
medication O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
AdreView O-ADR O-ADR
dosing O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Hyperglycemia O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZYKADIA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
frequency O-ADR O-ADR
, O-ADR O-ADR
type O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
comparable O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
except O-ADR O-ADR
for O-ADR O-ADR
rash B-ADR B-ADR
which O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR B-ADR
DISCONTINUATION O-ADR O-ADR
OF O-ADR O-ADR
PRADAXA O-ADR B-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC O-ADR B-ADR
EVENTS O-ADR I-ADR
, O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
EPIDURAL B-ADR B-ADR
HEMATOMA I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR B-ADR
DISCONTINUATION O-ADR O-ADR
OF O-ADR O-ADR
PRADAXA O-ADR O-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC O-ADR B-ADR
EVENTS O-ADR I-ADR
, O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
EPIDURAL B-ADR O-ADR
HEMATOMA I-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR O-ADR
DISCONTINUATION O-ADR O-ADR
OF O-ADR O-ADR
PRADAXA O-ADR O-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC O-ADR B-ADR
EVENTSPremature O-ADR I-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
PRADAXA O-ADR O-ADR
, O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic O-ADR B-ADR
events O-ADR I-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
into O-ADR O-ADR
corpora B-ADR B-ADR
cavernosa I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
penis I-ADR I-ADR
may I-ADR I-ADR
result I-ADR I-ADR
in I-ADR I-ADR
damage I-ADR I-ADR
to O-ADR O-ADR
those O-ADR O-ADR
structures O-ADR O-ADR
and O-ADR O-ADR
possible O-ADR O-ADR
injury O-ADR B-ADR
such O-ADR O-ADR
as O-ADR O-ADR
corporal B-ADR B-ADR
rupture I-ADR I-ADR
( O-ADR O-ADR
penile B-ADR B-ADR
fracture I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
almost O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
97 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Tissue O-ADR O-ADR
culture O-ADR O-ADR
experiments O-ADR O-ADR
indicate O-ADR O-ADR
that O-ADR O-ADR
approximately O-ADR O-ADR
one O-ADR O-ADR
- O-ADR O-ADR
third O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
breast O-ADR O-ADR
cancers O-ADR O-ADR
are O-ADR O-ADR
prolactin O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
factor O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
importance O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
prescription O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
is O-ADR O-ADR
contemplated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
previously O-ADR O-ADR
detected O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
population O-ADR O-ADR
included O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
78 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
/ O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
other O-ADR O-ADR
or O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
477 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
8 O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
: O-ADR O-ADR
2 O-ADR O-ADR
in O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
in O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
or O-ADR O-ADR
serostatus O-ADR O-ADR
unknown O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Janssen O-ADR O-ADR
Therapeutics O-ADR O-ADR
, O-ADR O-ADR
Division O-ADR O-ADR
of O-ADR O-ADR
Janssen O-ADR O-ADR
Products O-ADR O-ADR
, O-ADR O-ADR
LP O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
JANSSEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
526 O-ADR O-ADR
- O-ADR O-ADR
7736 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
neutropenia O-ADR O-ADR
( O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
< O-ADR O-ADR
1000 O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
discontinue O-ADR O-ADR
FANAPT O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
WBC O-ADR O-ADR
followed O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
TREANDA O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
120 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
intravenously O-ADR O-ADR
on O-ADR O-ADR
Days O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
eight O-ADR O-ADR
21 O-ADR O-ADR
- O-ADR O-ADR
day O-ADR O-ADR
cycles O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
. O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Depending O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
hyponatremia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
or O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
adjunctive O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
415 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
410 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
APTIOM O-ADR O-ADR
had O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
serum O-ADR B-ADR
sodium O-ADR I-ADR
value O-ADR I-ADR
less O-ADR I-ADR
than O-ADR I-ADR
125 O-ADR I-ADR
mEq O-ADR I-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
assigned O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
PlaceboN O-ADR O-ADR
= O-ADR O-ADR
646 O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mgN O-ADR O-ADR
= O-ADR O-ADR
833 O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mgN O-ADR O-ADR
= O-ADR O-ADR
834 O-ADR O-ADR
Female B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Increased B-ADR B-ADR
urination I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Male B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Vulvovaginal B-ADR B-ADR
pruritus I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
Thirst B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Constipation B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Nausea B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
was O-ADR O-ADR
also O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
visual B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
. O-ADR O-ADR
Inhalation O-ADR O-ADR
of O-ADR O-ADR
high O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
may O-ADR O-ADR
produce O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
plasma I-ADR I-ADR
glucose I-ADR I-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
to O-ADR O-ADR
rinse O-ADR O-ADR
his O-ADR O-ADR
/ O-ADR O-ADR
her O-ADR O-ADR
mouth O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
without O-ADR O-ADR
swallowing O-ADR O-ADR
after O-ADR O-ADR
inhalation O-ADR O-ADR
to O-ADR O-ADR
help O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Discontinuation O-ADR O-ADR
in O-ADR O-ADR
All O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
3 O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
199 O-ADR O-ADR
of O-ADR O-ADR
813 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
45 O-ADR O-ADR
of O-ADR O-ADR
427 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
: O-ADR O-ADR
eye B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
flu B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
symptoms I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
allergic B-ADR B-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
localized B-ADR B-ADR
allergic I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
herpes B-ADR B-ADR
zoster I-ADR I-ADR
, O-ADR O-ADR
muscular B-ADR B-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
spasm I-ADR I-ADR
, O-ADR O-ADR
dysarthria B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
and O-ADR O-ADR
hypersensitivity B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
When O-ADR O-ADR
pregnancy O-ADR O-ADR
is O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Edarbi O-ADR O-ADR
as O-ADR O-ADR
soon O-ADR O-ADR
as O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
gastrointestinal O-ADR O-ADR
perforation O-ADR O-ADR
or O-ADR O-ADR
fistula O-ADR O-ADR
periodically O-ADR O-ADR
throughout O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PHN O-ADR O-ADR
receiving O-ADR O-ADR
HORIZANT O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
to O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
withdrawal O-ADR O-ADR
seizure O-ADR O-ADR
, O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vertigo B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
or O-ADR O-ADR
dizziness B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
more O-ADR O-ADR
closely O-ADR O-ADR
during O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
constipation B-ADR B-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
taking O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
taking O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
taking O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
late O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
available O-ADR O-ADR
samples O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
59 O-ADR O-ADR
, O-ADR O-ADR
100 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
developed O-ADR O-ADR
IgG O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
substantial O-ADR O-ADR
evidence O-ADR O-ADR
from O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
maintenance O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
with O-ADR O-ADR
depression O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
antidepressants O-ADR O-ADR
can O-ADR O-ADR
delay O-ADR O-ADR
the O-ADR O-ADR
recurrence O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
obtained O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
are O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
, O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
Active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
larger O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
tooth O-ADR O-ADR
extraction O-ADR O-ADR
, O-ADR O-ADR
dental O-ADR O-ADR
implants O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
surgery O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
cancer O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
therapies O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Suicidal O-ADR O-ADR
Thoughts O-ADR O-ADR
and O-ADR O-ADR
Behaviors O-ADR O-ADR
in O-ADR O-ADR
Children O-ADR O-ADR
, O-ADR O-ADR
Adolescents O-ADR O-ADR
and O-ADR O-ADR
Young O-ADR O-ADR
Adults O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
depressive O-ADR O-ADR
disorder O-ADR O-ADR
( O-ADR O-ADR
MDD O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
adult O-ADR O-ADR
and O-ADR O-ADR
pediatric O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
their O-ADR O-ADR
depression O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
ideation O-ADR O-ADR
and O-ADR O-ADR
behavior O-ADR O-ADR
( O-ADR O-ADR
suicidality O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
whether O-ADR O-ADR
or O-ADR O-ADR
not O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
antidepressant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
may O-ADR O-ADR
persist O-ADR O-ADR
until O-ADR O-ADR
significant O-ADR O-ADR
remission O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Auxilium O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
663 O-ADR O-ADR
- O-ADR O-ADR
0412 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
preexisting O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
elevated B-ADR B-ADR
liver I-ADR I-ADR
enzymes I-ADR I-ADR
when O-ADR O-ADR
taking O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
fever B-ADR B-ADR
( O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
serious O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
71 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
39 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
feasible O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
4 O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
weeks O-ADR O-ADR
before O-ADR O-ADR
surgery O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
type O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thromboembolism O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
during O-ADR O-ADR
periods O-ADR O-ADR
of O-ADR O-ADR
prolonged O-ADR O-ADR
immobilization O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
19 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Stepwise O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
dose O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
further O-ADR O-ADR
lowering O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
when O-ADR O-ADR
taking O-ADR O-ADR
a O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitor O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
and O-ADR O-ADR
Past O-ADR O-ADR
History O-ADR O-ADR
of O-ADR O-ADR
Cholestatic O-ADR O-ADR
Jaundice O-ADR O-ADR
DUAVEE O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
or O-ADR O-ADR
past O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
cholestatic O-ADR O-ADR
jaundice O-ADR O-ADR
. O-ADR O-ADR
Infusion O-ADR O-ADR
reactions O-ADR O-ADR
Two O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
finding O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Eight O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
cytogenetic B-ADR B-ADR
abnormality I-ADR I-ADR
reported O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
complex O-ADR O-ADR
changes B-ADR B-ADR
in I-ADR I-ADR
chromosome I-ADR I-ADR
7 I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
hemorrhage I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
immobilization O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
venous O-ADR O-ADR
thromboembolic O-ADR O-ADR
events O-ADR O-ADR
independent O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
prolonged O-ADR O-ADR
immobilization O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
surgical O-ADR O-ADR
recovery O-ADR O-ADR
, O-ADR O-ADR
prolonged O-ADR O-ADR
bed O-ADR O-ADR
rest O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
DUAVEE O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
only O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
fully O-ADR O-ADR
ambulatory O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
alters O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
flora O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
colon O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
permit O-ADR O-ADR
overgrowth O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
RA O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
highly O-ADR O-ADR
active O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
lymphoma O-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
- O-ADR O-ADR
Serious O-ADR O-ADR
acute B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
during O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
, O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
adults O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
asthenia B-ADR B-ADR
. O-ADR O-ADR
Inhibitors O-ADR O-ADR
of O-ADR O-ADR
CYP3A4 O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
STENDRA O-ADR O-ADR
clearance O-ADR O-ADR
and O-ADR O-ADR
increase O-ADR O-ADR
plasma O-ADR O-ADR
concentrations O-ADR O-ADR
of O-ADR O-ADR
avanafil O-ADR O-ADR
. O-ADR O-ADR
ESCAPE O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
ESCAPE O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
CLVN O-ADR O-ADR
= O-ADR O-ADR
53 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
PBON O-ADR O-ADR
= O-ADR O-ADR
51 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
CLVN O-ADR O-ADR
= O-ADR O-ADR
61 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
PBON O-ADR O-ADR
= O-ADR O-ADR
49 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Any O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
27 O-ADR O-ADR
( O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
21 O-ADR O-ADR
( O-ADR O-ADR
41 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
32 O-ADR O-ADR
( O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
24 O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
Atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
- O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
- O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
- O-ADR O-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
21 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Three O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
parallel O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
studies O-ADR O-ADR
called O-ADR O-ADR
ECLIPSE O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
longer O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
cardiac O-ADR O-ADR
surgery O-ADR O-ADR
patients O-ADR O-ADR
define O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
perioperative O-ADR O-ADR
hypertension O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
51 O-ADR O-ADR
- O-ADR O-ADR
80 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
AMPYRA O-ADR O-ADR
plasma O-ADR O-ADR
levels O-ADR O-ADR
may O-ADR O-ADR
approach O-ADR O-ADR
those O-ADR O-ADR
seen O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
15 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Urinary O-ADR O-ADR
Tract O-ADR O-ADR
Infections O-ADR O-ADR
Urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
UTIs B-ADR B-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
as O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AMPYRA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
CAPS O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
employed O-ADR O-ADR
the O-ADR O-ADR
biosensor O-ADR O-ADR
binding O-ADR O-ADR
assay O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
most O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
SJIA O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
employed O-ADR O-ADR
the O-ADR O-ADR
bridging O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
drive O-ADR O-ADR
a O-ADR O-ADR
car O-ADR O-ADR
or O-ADR O-ADR
operate O-ADR O-ADR
other O-ADR O-ADR
complex O-ADR O-ADR
machinery O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
gained O-ADR O-ADR
sufficient O-ADR O-ADR
experience O-ADR O-ADR
on O-ADR O-ADR
HORIZANT O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
whether O-ADR O-ADR
HORIZANT O-ADR O-ADR
impairs O-ADR O-ADR
their O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
perform O-ADR O-ADR
these O-ADR O-ADR
tasks O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
STRIBILD O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
HBV O-ADR O-ADR
) O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
coinfected O-ADR O-ADR
with O-ADR O-ADR
HBV O-ADR O-ADR
and O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
48 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
malignancies B-ADR B-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
non O-ADR B-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin O-ADR I-ADR
cancers O-ADR I-ADR
, O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
458 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
ILD B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Occurs O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
64 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
32 O-ADR O-ADR
- O-ADR O-ADR
87 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
FETAL B-ADR B-ADR
TOXICITY I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Anakinra O-ADR O-ADR
Concurrent O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
anakinra O-ADR O-ADR
( O-ADR O-ADR
an O-ADR O-ADR
interleukin O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
antagonist O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
another O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
portion O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections O-ADR B-ADR
and O-ADR O-ADR
neutropenia O-ADR B-ADR
and O-ADR O-ADR
no O-ADR O-ADR
additional O-ADR O-ADR
benefits O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
may O-ADR O-ADR
depend O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
renin O-ADR O-ADR
- O-ADR O-ADR
angiotensin O-ADR O-ADR
system O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
renal O-ADR O-ADR
artery O-ADR O-ADR
stenosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
volume O-ADR O-ADR
depletion O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
angiotensin O-ADR O-ADR
- O-ADR O-ADR
converting O-ADR O-ADR
enzyme O-ADR O-ADR
inhibitors O-ADR O-ADR
and O-ADR O-ADR
angiotensin O-ADR O-ADR
receptor O-ADR O-ADR
blockers O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
oliguria B-ADR B-ADR
or O-ADR O-ADR
progressive B-ADR B-ADR
azotemia I-ADR I-ADR
and O-ADR O-ADR
rarely O-ADR O-ADR
with O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
44 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XTANDI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
shows O-ADR O-ADR
absolute O-ADR O-ADR
and O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
by O-ADR O-ADR
indication O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
evaluated O-ADR O-ADR
AEDs O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
in O-ADR O-ADR
Prolia O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
men O-ADR O-ADR
with O-ADR O-ADR
nonmetastatic O-ADR O-ADR
prostate O-ADR O-ADR
cancer O-ADR O-ADR
receiving O-ADR O-ADR
ADT O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cataracts B-ADR B-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Prolia O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
death B-ADR B-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
Lysis I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
TLS B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
TLS O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
super O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
use O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
alternative O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
197 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
212 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
196 O-ADR O-ADR
Major O-ADR O-ADR
[ O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
Minor O-ADR O-ADR
[ O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
67 O-ADR O-ADR
( O-ADR O-ADR
34 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
92 O-ADR O-ADR
( O-ADR O-ADR
43 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
79 O-ADR O-ADR
( O-ADR O-ADR
40 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
Genital O-ADR O-ADR
Mycotic O-ADR O-ADR
Infections O-ADR O-ADR
Genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Hyperprolactinemia O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
antagonize O-ADR O-ADR
dopamine O-ADR O-ADR
D2 O-ADR O-ADR
receptors O-ADR O-ADR
, O-ADR O-ADR
FANAPT O-ADR O-ADR
elevates B-ADR B-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
. O-ADR O-ADR
Upon O-ADR O-ADR
improvement O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
, O-ADR O-ADR
initiate O-ADR O-ADR
corticosteroid O-ADR O-ADR
taper O-ADR O-ADR
and O-ADR O-ADR
continue O-ADR O-ADR
to O-ADR O-ADR
taper O-ADR O-ADR
over O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
and O-ADR O-ADR
regularly O-ADR O-ADR
during O-ADR O-ADR
COMETRIQ O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
estimated O-ADR O-ADR
incidence O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
behavior I-ADR I-ADR
among O-ADR O-ADR
27 O-ADR O-ADR
, O-ADR O-ADR
863 O-ADR O-ADR
AED O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
among O-ADR O-ADR
16 O-ADR O-ADR
, O-ADR O-ADR
029 O-ADR O-ADR
placebo O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
for O-ADR O-ADR
every O-ADR O-ADR
530 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
Rash B-ADR B-ADR
was O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
limiting O-ADR O-ADR
and O-ADR O-ADR
generally O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
on O-ADR O-ADR
continued O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
hyperammonemia O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
dialysis O-ADR O-ADR
, O-ADR O-ADR
preferably O-ADR O-ADR
hemodialysis O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
remove O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
burden O-ADR O-ADR
of O-ADR O-ADR
ammonia O-ADR O-ADR
. O-ADR O-ADR
ONFI O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
tapered O-ADR O-ADR
by O-ADR O-ADR
decreasing O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
every O-ADR O-ADR
week O-ADR O-ADR
by O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
until O-ADR O-ADR
discontinuation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
CTCAE O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
elevations B-ADR B-ADR
of I-ADR I-ADR
lipase I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
animal O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
deferiprone O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
organogenesis O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
embryofetal B-ADR B-ADR
death I-ADR I-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
equivalent O-ADR O-ADR
human O-ADR O-ADR
clinical O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
concurrent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
cause O-ADR O-ADR
diarrhea O-ADR O-ADR
. O-ADR O-ADR
Errors O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
brain O-ADR O-ADR
atrophy O-ADR O-ADR
that O-ADR O-ADR
limits O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
distinguish O-ADR O-ADR
gray O-ADR O-ADR
and O-ADR O-ADR
white O-ADR O-ADR
matter O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
Neuraceq O-ADR O-ADR
scan O-ADR O-ADR
. O-ADR O-ADR
Neuraceq O-ADR O-ADR
scan O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
amyloid O-ADR O-ADR
plaques O-ADR O-ADR
only O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
image O-ADR O-ADR
acquisition O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
scan O-ADR O-ADR
result O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
preclude O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
amyloid O-ADR O-ADR
plaques O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
future O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
Emergent O-ADR O-ADR
Adverse O-ADR O-ADR
ReactionsIncludes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
possibly O-ADR O-ADR
, O-ADR O-ADR
probably O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
very O-ADR O-ADR
likely O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
AST B-ADR B-ADR
increases I-ADR I-ADR
( O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ZYTIGA O-ADR O-ADR
, O-ADR O-ADR
typically O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
resolution O-ADR O-ADR
ranged O-ADR O-ADR
between O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
across O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
following O-ADR O-ADR
interruption O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
instances O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
profile O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
each O-ADR O-ADR
injection O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
injections O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
Besivance O-ADR O-ADR
is O-ADR O-ADR
for O-ADR O-ADR
topical O-ADR O-ADR
ophthalmic O-ADR O-ADR
use O-ADR O-ADR
only O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
injected O-ADR O-ADR
subconjunctivally O-ADR O-ADR
, O-ADR O-ADR
nor O-ADR O-ADR
should O-ADR O-ADR
it O-ADR O-ADR
be O-ADR O-ADR
introduced O-ADR O-ADR
directly O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
anterior O-ADR O-ADR
chamber O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
eye O-ADR O-ADR
. O-ADR O-ADR
Lenses O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
reinserted O-ADR O-ADR
after O-ADR O-ADR
10 O-ADR O-ADR
minutes O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
DUREZOL O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Increased B-ADR B-ADR
mortality I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
Prolongation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hemoptysis B-ADR B-ADR
and O-ADR O-ADR
chest B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
symptomatic O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
infectious O-ADR O-ADR
etiologies O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
endoscopic O-ADR O-ADR
evaluation O-ADR O-ADR
for O-ADR O-ADR
persistent O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Six O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
lymphocyte B-ADR B-ADR
counts I-ADR I-ADR
< I-ADR I-ADR
0 I-ADR I-ADR
. O-ADR O-ADR
5x10 O-ADR O-ADR
9 I-ADR I-ADR
/ I-ADR I-ADR
L O-ADR O-ADR
( O-ADR O-ADR
lower O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR I-ADR
normal O-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
91x10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Flushing B-ADR B-ADR
symptoms O-ADR O-ADR
generally O-ADR O-ADR
began O-ADR O-ADR
soon O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
usually O-ADR O-ADR
improved O-ADR O-ADR
or O-ADR O-ADR
resolved O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
obtaining O-ADR O-ADR
a O-ADR O-ADR
liver O-ADR O-ADR
test O-ADR O-ADR
panel O-ADR O-ADR
and O-ADR O-ADR
assessing O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
NESINA O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
half O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Ocular O-ADR O-ADR
Surgery O-ADR O-ADR
Ocular B-ADR O-ADR
adverse I-ADR O-ADR
reactions I-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
DUREZOL O-ADR O-ADR
included O-ADR O-ADR
corneal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
conjunctival B-ADR B-ADR
hyperemia I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
photophobia B-ADR B-ADR
, O-ADR O-ADR
posterior B-ADR B-ADR
capsule I-ADR I-ADR
opacification I-ADR I-ADR
, O-ADR O-ADR
anterior B-ADR B-ADR
chamber I-ADR I-ADR
cells I-ADR I-ADR
, O-ADR O-ADR
anterior B-ADR B-ADR
chamber I-ADR I-ADR
flare I-ADR I-ADR
, O-ADR O-ADR
conjunctival B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
blepharitis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
potassium I-ADR I-ADR
is O-ADR O-ADR
usually O-ADR O-ADR
transient O-ADR O-ADR
, O-ADR O-ADR
not O-ADR O-ADR
requiring O-ADR O-ADR
supplementation O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
gastritis O-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
symptoms O-ADR I-ADR
and O-ADR O-ADR
bleeding B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Boehringer O-ADR O-ADR
Ingelheim O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
( O-ADR O-ADR
800 O-ADR O-ADR
) O-ADR O-ADR
542 O-ADR O-ADR
- O-ADR O-ADR
6257 O-ADR O-ADR
or O-ADR O-ADR
( O-ADR O-ADR
800 O-ADR O-ADR
) O-ADR O-ADR
459 O-ADR O-ADR
- O-ADR O-ADR
9906 O-ADR O-ADR
TTY O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Heart B-ADR B-ADR
rates I-ADR I-ADR
below I-ADR I-ADR
40 I-ADR I-ADR
beats I-ADR I-ADR
per I-ADR I-ADR
minute I-ADR I-ADR
were O-ADR O-ADR
rarely O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
801 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
585 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
or O-ADR O-ADR
longer O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
311 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
DaTscan O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
INLYTA O-ADR O-ADR
is O-ADR O-ADR
interrupted O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
antihypertensive O-ADR O-ADR
medications O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
hypotension O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administering O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
following O-ADR O-ADR
an O-ADR O-ADR
anaphylactic O-ADR O-ADR
or O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
estimated O-ADR O-ADR
incidence O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
behavior I-ADR I-ADR
among O-ADR O-ADR
27 O-ADR O-ADR
, O-ADR O-ADR
863 O-ADR O-ADR
AED O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
among O-ADR O-ADR
16 O-ADR O-ADR
, O-ADR O-ADR
029 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
for O-ADR O-ADR
every O-ADR O-ADR
530 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
decreased B-ADR B-ADR
hemoglobin I-ADR I-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
alkaline B-ADR B-ADR
phosphatase I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
bicarbonate B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
aspartate I-ADR I-ADR
transaminase I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
cytochrome O-ADR O-ADR
P450 O-ADR O-ADR
enzyme O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
phenobarbital O-ADR O-ADR
, O-ADR O-ADR
carbamazepine O-ADR O-ADR
, O-ADR O-ADR
phenytoin O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
reactions O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Tables O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
or O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
for O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
included O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
extrasystoles B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
abdominal I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
allergic B-ADR B-ADR
rhinitis I-ADR I-ADR
, O-ADR O-ADR
pharyngitis B-ADR B-ADR
, O-ADR O-ADR
rhinitis B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
supraventricular B-ADR B-ADR
extrasystoles I-ADR I-ADR
, O-ADR O-ADR
ventricular B-ADR B-ADR
extrasystoles I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
sinusitis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumonia B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
considered O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
if O-ADR O-ADR
it O-ADR O-ADR
occurred O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
time O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
therapy O-ADR O-ADR
following O-ADR O-ADR
baseline O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Toviaz O-ADR O-ADR
4 O-ADR O-ADR
or O-ADR O-ADR
8 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
specific O-ADR O-ADR
IgE O-ADR O-ADR
antibodies O-ADR O-ADR
and O-ADR O-ADR
experienced O-ADR O-ADR
hypersensitivity B-ADR O-ADR
reactions I-ADR O-ADR
were O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
rechallenged O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
slower O-ADR O-ADR
infusion O-ADR O-ADR
rate O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
starting O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
continued O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
treatment O-ADR O-ADR
under O-ADR O-ADR
close O-ADR O-ADR
clinical O-ADR O-ADR
supervision O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Includes O-ADR O-ADR
5 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
before O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
apixaban O-ADR O-ADR
( O-ADR O-ADR
administered O-ADR O-ADR
12 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
post O-ADR O-ADR
surgery O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
canakinumab O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
CAPS O-ADR O-ADR
and O-ADR O-ADR
SJIA O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
it O-ADR O-ADR
takes O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
to O-ADR O-ADR
eliminate O-ADR O-ADR
GILENYA O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
body O-ADR O-ADR
, O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
use O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
stopping O-ADR O-ADR
GILENYA O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Astellas O-ADR O-ADR
Pharma O-ADR O-ADR
US O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
727 O-ADR O-ADR
- O-ADR O-ADR
7003 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
serotonergic O-ADR O-ADR
drugs O-ADR O-ADR
is O-ADR O-ADR
clinically O-ADR O-ADR
warranted O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
aware O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
serotonin O-ADR O-ADR
syndrome O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
and O-ADR O-ADR
dose O-ADR O-ADR
increases O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Malignant O-ADR O-ADR
Neoplasms O-ADR O-ADR
Endometrial O-ADR O-ADR
Cancer O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
endometrial B-ADR B-ADR
cancer I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
unopposed O-ADR O-ADR
estrogen O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
uterus O-ADR O-ADR
. O-ADR O-ADR
Standard O-ADR O-ADR
international O-ADR O-ADR
guidelines O-ADR O-ADR
were O-ADR O-ADR
followed O-ADR O-ADR
for O-ADR O-ADR
infection O-ADR O-ADR
prophylaxis O-ADR O-ADR
for O-ADR O-ADR
herpes O-ADR O-ADR
simplex O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
HSV O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
varicella O-ADR O-ADR
- O-ADR O-ADR
zoster O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
VZV O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Pneumocystis O-ADR B-ADR
jiroveci O-ADR I-ADR
pneumonia O-ADR I-ADR
( O-ADR O-ADR
PCP O-ADR B-ADR
) O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
auto O-ADR O-ADR
- O-ADR O-ADR
HSCT O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
Dysphagia O-ADR O-ADR
Esophageal B-ADR B-ADR
dysmotility I-ADR I-ADR
and O-ADR O-ADR
aspiration B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
concomitant O-ADR O-ADR
moderate O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
erythromycin O-ADR O-ADR
, O-ADR O-ADR
amprenavir O-ADR O-ADR
, O-ADR O-ADR
aprepitant O-ADR O-ADR
, O-ADR O-ADR
diltiazem O-ADR O-ADR
, O-ADR O-ADR
fluconazole O-ADR O-ADR
, O-ADR O-ADR
fosamprenavir O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
verapamil O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
is O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
not O-ADR O-ADR
to O-ADR O-ADR
exceed O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
[ O-ADR O-ADR
seeDrug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
( O-ADR O-ADR
MI O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
stroke O-ADR O-ADR
. O-ADR O-ADR
Contact O-ADR O-ADR
your O-ADR O-ADR
local O-ADR O-ADR
Genzyme O-ADR O-ADR
representative O-ADR O-ADR
or O-ADR O-ADR
Genzyme O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
745 O-ADR O-ADR
- O-ADR O-ADR
4447 O-ADR O-ADR
for O-ADR O-ADR
information O-ADR O-ADR
on O-ADR O-ADR
testing O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
obtain O-ADR O-ADR
a O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
box O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Prolonged O-ADR O-ADR
Erection O-ADR O-ADR
Prolonged B-ADR O-ADR
erection I-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
hours O-ADR O-ADR
and O-ADR O-ADR
priapism B-ADR B-ADR
( O-ADR O-ADR
painful B-ADR B-ADR
erections I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
6 O-ADR O-ADR
hours O-ADR O-ADR
in O-ADR O-ADR
duration O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Embryofetal O-ADR O-ADR
Toxicity O-ADR O-ADR
( O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Ribavirin O-ADR O-ADR
and O-ADR O-ADR
Peginterferon O-ADR O-ADR
Alfa O-ADR O-ADR
) O-ADR O-ADR
Ribavirin O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
birth B-ADR B-ADR
defects I-ADR I-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
exposed I-ADR O-ADR
fetus I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hepatic O-ADR O-ADR
Effects O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
fatal B-ADR B-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
ULORIC O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
reports O-ADR O-ADR
contain O-ADR O-ADR
insufficient O-ADR O-ADR
information O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
the O-ADR O-ADR
probable O-ADR O-ADR
cause O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Values O-ADR O-ADR
Changes O-ADR O-ADR
in O-ADR O-ADR
selected O-ADR O-ADR
hematological O-ADR O-ADR
parameters O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
and O-ADR O-ADR
REBETOL O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Sudden O-ADR O-ADR
Hearing O-ADR O-ADR
Loss O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
loss B-ADR B-ADR
of I-ADR I-ADR
hearing I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
tinnitus B-ADR B-ADR
or O-ADR O-ADR
dizziness B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
reports O-ADR O-ADR
note O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
receiving O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
glucocorticoids O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
AMPYRA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Hypocalcemia O-ADR O-ADR
Estrogen O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
hypoparathyroidism O-ADR O-ADR
as O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
hypocalcemia O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
JEVTANA O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
asthenia B-ADR B-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
nature O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
seen O-ADR O-ADR
with O-ADR O-ADR
this O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
toxicities O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
result O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
combination O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
prescribers O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
aware O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
' O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
their O-ADR O-ADR
own O-ADR O-ADR
driving O-ADR O-ADR
competence O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
their O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
the O-ADR O-ADR
degree O-ADR O-ADR
of O-ADR O-ADR
somnolence O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
HORIZANT O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
imperfect O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
somnolence B-ADR B-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
somnolence B-ADR B-ADR
persisted O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
about O-ADR O-ADR
27 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
hemoglobin I-ADR I-ADR
, O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
alkaline I-ADR I-ADR
phosphatase I-ADR I-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
aspartate I-ADR I-ADR
transaminase I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
potassium B-ADR B-ADR
decreased I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
. O-ADR O-ADR
Exacerbation O-ADR O-ADR
Trial O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
76 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
subjects O-ADR O-ADR
received O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
009 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
010 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
pancreatic O-ADR O-ADR
or O-ADR O-ADR
gastric O-ADR O-ADR
anastomosis O-ADR O-ADR
. O-ADR O-ADR
Pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
199 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
monotherapy O-ADR O-ADR
and O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
different O-ADR O-ADR
AEDs O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
AEDs O-ADR O-ADR
had O-ADR O-ADR
approximately O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
[ O-ADR O-ADR
adjusted O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
( O-ADR O-ADR
CI O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
] O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Creatine O-ADR O-ADR
Kinase O-ADR O-ADR
( O-ADR O-ADR
CK O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CK B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
were O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR B-ADR
mania O-ADR I-ADR
. O-ADR O-ADR
Extrapyramidal O-ADR O-ADR
Symptoms O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
data O-ADR O-ADR
was O-ADR O-ADR
objectively O-ADR O-ADR
collected O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
Simpson O-ADR O-ADR
Angus O-ADR O-ADR
Rating O-ADR O-ADR
Scale O-ADR O-ADR
for O-ADR O-ADR
extrapyramidal B-ADR O-ADR
symptoms I-ADR O-ADR
( O-ADR O-ADR
EPS B-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
Barnes O-ADR O-ADR
Akathisia O-ADR O-ADR
Scale O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
akathisia B-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
Assessments O-ADR O-ADR
of O-ADR O-ADR
Involuntary O-ADR O-ADR
Movement O-ADR O-ADR
Scales O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
dyskinesias B-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Arterial O-ADR O-ADR
Thromboembolic O-ADR O-ADR
Events O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
deaths B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
prior O-ADR O-ADR
regimens O-ADR O-ADR
. O-ADR O-ADR
What O-ADR O-ADR
should O-ADR O-ADR
I O-ADR O-ADR
tell O-ADR O-ADR
my O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
before O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
significance O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
finding O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
includes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
higher O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XTANDI O-ADR O-ADR
arm O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Avoid O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Other O-ADR O-ADR
Antiretroviral O-ADR O-ADR
Products O-ADR O-ADR
STRIBILD O-ADR O-ADR
is O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
complete O-ADR O-ADR
regimen O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
coadministration O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antiretroviral O-ADR O-ADR
products O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Hematologic O-ADR O-ADR
Cytopenias O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
aplastic B-ADR B-ADR
anemia I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
Medical O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
hypertension O-ADR O-ADR
was O-ADR O-ADR
balanced O-ADR O-ADR
between O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Effects O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
, O-ADR O-ADR
like O-ADR O-ADR
other O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
produce O-ADR O-ADR
a O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular B-ADR O-ADR
effect I-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
as O-ADR O-ADR
measured O-ADR O-ADR
by O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
pulse I-ADR I-ADR
rate I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Excessive O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Other O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
Acting O-ADR O-ADR
Beta2 O-ADR O-ADR
- O-ADR O-ADR
Agonists O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
inhaled O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
more O-ADR O-ADR
often O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
doses O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
containing O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
overdose O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
contains O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
attribution O-ADR O-ADR
, O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
CLL O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Acute O-ADR O-ADR
Respiratory O-ADR O-ADR
Complications O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
febrile O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
illness O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
infusion O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
complications O-ADR O-ADR
from O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
enterocolitis O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
204 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Should O-ADR O-ADR
the O-ADR O-ADR
physician O-ADR O-ADR
decide O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
anticoagulation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
context O-ADR O-ADR
of O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
anesthesia O-ADR O-ADR
/ O-ADR O-ADR
analgesia O-ADR O-ADR
or O-ADR O-ADR
lumbar O-ADR O-ADR
puncture O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
frequently O-ADR O-ADR
to O-ADR O-ADR
detect O-ADR O-ADR
any O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neurological O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
midline O-ADR O-ADR
back O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
sensory O-ADR O-ADR
and O-ADR O-ADR
motor O-ADR O-ADR
deficits O-ADR O-ADR
( O-ADR O-ADR
numbness O-ADR O-ADR
, O-ADR O-ADR
tingling O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
weakness O-ADR O-ADR
in O-ADR O-ADR
lower O-ADR O-ADR
limbs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
bowel O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
bladder O-ADR O-ADR
dysfunction O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
underlying O-ADR O-ADR
medical O-ADR O-ADR
conditions O-ADR O-ADR
might O-ADR O-ADR
be O-ADR O-ADR
compromised O-ADR O-ADR
by O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
hypokalemia O-ADR O-ADR
or O-ADR O-ADR
fluid O-ADR O-ADR
retention O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
recent O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
or O-ADR O-ADR
ventricular O-ADR O-ADR
arrhythmia O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
81 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
local O-ADR B-ADR
reactions O-ADR I-ADR
resolved O-ADR O-ADR
without O-ADR O-ADR
intervention O-ADR O-ADR
within O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
peripheral O-ADR O-ADR
motor O-ADR O-ADR
and O-ADR O-ADR
sensory O-ADR O-ADR
neuropathy O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
Ferriprox O-ADR O-ADR
therapy O-ADR O-ADR
if O-ADR O-ADR
neutropenia O-ADR O-ADR
develops O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
include O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
and O-ADR O-ADR
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
. O-ADR O-ADR
Subject O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
is O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
cumulative O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
days O-ADR O-ADR
from O-ADR O-ADR
first O-ADR O-ADR
drug O-ADR O-ADR
intake O-ADR O-ADR
to O-ADR O-ADR
event O-ADR O-ADR
date O-ADR O-ADR
, O-ADR O-ADR
date O-ADR O-ADR
of O-ADR O-ADR
last O-ADR O-ADR
drug O-ADR O-ADR
intake O-ADR O-ADR
+ O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
death O-ADR B-ADR
date O-ADR O-ADR
( O-ADR O-ADR
whatever O-ADR O-ADR
occurred O-ADR O-ADR
first O-ADR O-ADR
) O-ADR O-ADR
across O-ADR O-ADR
all O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
divided O-ADR O-ADR
by O-ADR O-ADR
365 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
Anyone O-ADR O-ADR
considering O-ADR O-ADR
prescribing O-ADR O-ADR
ONFI O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
AED O-ADR O-ADR
must O-ADR O-ADR
balance O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
untreated O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
were O-ADR O-ADR
commonly O-ADR O-ADR
dyspepsia B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
upper I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
epigastric B-ADR B-ADR
discomfort I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
gastritis O-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
GERD B-ADR B-ADR
, O-ADR O-ADR
esophagitis B-ADR B-ADR
, O-ADR O-ADR
erosive B-ADR B-ADR
gastritis I-ADR I-ADR
, O-ADR O-ADR
gastric B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
hemorrhagic B-ADR B-ADR
gastritis I-ADR I-ADR
, O-ADR O-ADR
hemorrhagic B-ADR B-ADR
erosive I-ADR I-ADR
gastritis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
gastrointestinal B-ADR B-ADR
ulcer I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
ZYKADIA O-ADR O-ADR
with O-ADR O-ADR
resumption O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
alanine O-ADR O-ADR
aminotransferase O-ADR O-ADR
or O-ADR O-ADR
aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
> O-ADR O-ADR
3 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
( O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
than O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
aminotransferase O-ADR O-ADR
levels O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
no O-ADR O-ADR
prior O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
XIAFLEX O-ADR O-ADR
, O-ADR O-ADR
97 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
after O-ADR O-ADR
two O-ADR O-ADR
concurrent O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
total O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
hand O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
abiraterone O-ADR O-ADR
acetate O-ADR O-ADR
arm O-ADR O-ADR
were O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
alkaline I-ADR I-ADR
phosphatase I-ADR I-ADR
, O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
AST I-ADR I-ADR
, O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
ALT I-ADR I-ADR
and O-ADR O-ADR
hypokalemia B-ADR B-ADR
. O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
with O-ADR O-ADR
Rheumatoid O-ADR O-ADR
Arthritis O-ADR O-ADR
CIMZIA O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
primarily O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Fasting O-ADR O-ADR
Glucose O-ADR O-ADR
FANAPT O-ADR O-ADR
Placebo O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
Mean O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
114 O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
228 O-ADR O-ADR
Serum O-ADR O-ADR
Glucose O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Proportion O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Shifts O-ADR O-ADR
Serum O-ADR O-ADR
Glucose O-ADR O-ADR
Normal O-ADR O-ADR
to O-ADR O-ADR
High O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
to O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
126 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
80 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
/ O-ADR O-ADR
169 O-ADR O-ADR
) O-ADR O-ADR
Pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
glucose O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
including O-ADR O-ADR
longer O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Palmar B-ADR B-ADR
- O-ADR O-ADR
plantar O-ADR O-ADR
Erythrodysesthesia I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PPES B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Interrupt O-ADR O-ADR
COMETRIQ O-ADR O-ADR
, O-ADR O-ADR
decrease O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Abrupt O-ADR O-ADR
discontinuation O-ADR O-ADR
or O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
appearance O-ADR O-ADR
of O-ADR O-ADR
new O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
include O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
irritability B-ADR B-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
anxiety B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
abnormal B-ADR B-ADR
dreams I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
item O-ADR O-ADR
{ O-ADR O-ADR
Viral O-ADR O-ADR
infections O-ADR O-ADR
- O-ADR O-ADR
Employment O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
corticosteroid O-ADR O-ADR
medication O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
herpes O-ADR O-ADR
simplex O-ADR O-ADR
requires O-ADR O-ADR
great O-ADR O-ADR
caution O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
in O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
cardiovascular O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
cerebrovascular O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
might O-ADR O-ADR
be O-ADR O-ADR
compromised O-ADR O-ADR
by O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
Glaucoma O-ADR O-ADR
and O-ADR O-ADR
Cataracts O-ADR O-ADR
Glaucoma B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
intraocular I-ADR I-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cataracts B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
or O-ADR O-ADR
asthma O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
myelosuppression O-ADR O-ADR
following O-ADR O-ADR
TREANDA O-ADR O-ADR
treatment O-ADR O-ADR
to O-ADR O-ADR
contact O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
are O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
night B-ADR B-ADR
sweats I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
myalgia B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
were O-ADR O-ADR
monitored O-ADR O-ADR
every O-ADR O-ADR
week O-ADR O-ADR
initially O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Valeant O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
North O-ADR O-ADR
America O-ADR O-ADR
LLC O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
321 O-ADR O-ADR
- O-ADR O-ADR
4576 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
three O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
: O-ADR O-ADR
Vimizim O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
week O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
58 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Vimizim O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
once O-ADR O-ADR
every O-ADR O-ADR
other O-ADR O-ADR
week O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
59 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
59 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
ethnic O-ADR O-ADR
distribution O-ADR O-ADR
was O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Hispanic O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Black O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
ethnic O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
finding O-ADR O-ADR
with O-ADR O-ADR
salmeterol O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
LABA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
indacaterol O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredient O-ADR O-ADR
in O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
Toxicity I-ADR I-ADR
and O-ADR O-ADR
Hepatic B-ADR B-ADR
Failure I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
proteinuria O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
throughout O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
seizure O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
engaging O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
activity O-ADR O-ADR
where O-ADR O-ADR
sudden O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
consciousness O-ADR O-ADR
could O-ADR O-ADR
cause O-ADR O-ADR
serious O-ADR O-ADR
harm O-ADR O-ADR
to O-ADR O-ADR
themselves O-ADR O-ADR
or O-ADR O-ADR
others O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
symptoms O-ADR O-ADR
are O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
of O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
include O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
generalized B-ADR B-ADR
muscle I-ADR I-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
ptosis B-ADR B-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
dysarthria B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
incontinence I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
or O-ADR O-ADR
diabetes O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
) O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Nephrogenic B-ADR B-ADR
Systemic I-ADR I-ADR
Fibrosis I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
14 O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
2 B-ADR B-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
AV I-ADR I-ADR
block I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
hours O-ADR O-ADR
postdose O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
6 O-ADR O-ADR
hours O-ADR O-ADR
postdose O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
871 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
chemotherapy O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
844 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
seizure B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Congestive O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
worsening B-ADR B-ADR
congestive I-ADR I-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
new B-ADR B-ADR
onset I-ADR I-ADR
CHF I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
were O-ADR O-ADR
serum B-ADR B-ADR
transaminase I-ADR I-ADR
elevations I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
basal B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
included O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
flushing O-ADR O-ADR
/ O-ADR O-ADR
feeling O-ADR O-ADR
hot B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
, O-ADR O-ADR
paresthesia B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
local B-ADR B-ADR
swelling I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
dyspnea O-ADR O-ADR
to O-ADR O-ADR
exclude O-ADR O-ADR
cardiopulmonary O-ADR O-ADR
conditions O-ADR O-ADR
including O-ADR O-ADR
cardiac O-ADR O-ADR
failure O-ADR O-ADR
and O-ADR O-ADR
pulmonary O-ADR O-ADR
syndromes O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
anaphylactic B-ADR O-ADR
reactions I-ADR O-ADR
, O-ADR O-ADR
epinephrine O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Includes O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
enteritis B-ADR B-ADR
, O-ADR O-ADR
enterocolitis B-ADR B-ADR
, O-ADR O-ADR
colitis B-ADR B-ADR
, O-ADR O-ADR
defecation B-ADR B-ADR
urgency I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
steatorrhea B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Keratitis O-ADR O-ADR
Keratitis B-ADR B-ADR
, O-ADR O-ADR
characterized O-ADR O-ADR
as O-ADR O-ADR
worsening B-ADR B-ADR
eye I-ADR I-ADR
inflammation I-ADR I-ADR
, O-ADR O-ADR
lacrimation B-ADR B-ADR
, O-ADR O-ADR
light B-ADR B-ADR
sensitivity I-ADR I-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
red B-ADR B-ADR
eye I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
among O-ADR O-ADR
3865 O-ADR O-ADR
patients O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
viral O-ADR B-ADR
diseases O-ADR I-ADR
or O-ADR O-ADR
CJD O-ADR B-ADR
have O-ADR O-ADR
ever O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
albumin O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Immunizations O-ADR O-ADR
: O-ADR O-ADR
avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
modify O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
and O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
gp O-ADR O-ADR
inhibitors O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
15 O-ADR O-ADR
- O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Symptomatic O-ADR O-ADR
treatment O-ADR O-ADR
employed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
included O-ADR O-ADR
steroid O-ADR O-ADR
and O-ADR O-ADR
mydriatic O-ADR O-ADR
ophthalmic O-ADR O-ADR
drops O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
VORAXAZE O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
collected O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
flow O-ADR O-ADR
sheet O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
daily O-ADR O-ADR
log O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
characterized O-ADR O-ADR
as O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
glucarpidase O-ADR B-ADR
toxicity O-ADR I-ADR
. O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Post B-ADR B-ADR
- O-ADR O-ADR
Transplant O-ADR O-ADR
Lymphoproliferative I-ADR I-ADR
Disorder I-ADR I-ADR
( O-ADR O-ADR
PTLD B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
, O-ADR O-ADR
predominantly O-ADR O-ADR
involving O-ADR O-ADR
the O-ADR O-ADR
CNS O-ADR O-ADR
; O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
neurological O-ADR O-ADR
, O-ADR O-ADR
cognitive O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
behavioral O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
of O-ADR O-ADR
Vizamyl O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
761 O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
N O-ADR O-ADR
( O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
Flushing B-ADR B-ADR
16 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Increased B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
13 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
10 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Dizziness B-ADR B-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
Ask O-ADR O-ADR
patients O-ADR O-ADR
about O-ADR O-ADR
prior O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
Vizamyl O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
two O-ADR O-ADR
trials O-ADR O-ADR
also O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
403 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hepatic O-ADR O-ADR
Decompensation O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Chronic O-ADR O-ADR
Hepatitis O-ADR O-ADR
C O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
, O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
interferon O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR O-ADR
decompensation I-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
low O-ADR O-ADR
WBC O-ADR O-ADR
/ O-ADR O-ADR
ANC O-ADR O-ADR
or O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
, O-ADR O-ADR
perform O-ADR O-ADR
a O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
CBC O-ADR O-ADR
) O-ADR O-ADR
frequently O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
few O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
SPRINT O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
previously O-ADR O-ADR
untreated O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
RESPOND O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
failed O-ADR O-ADR
previous O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
evaluated O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
four O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
lead O-ADR O-ADR
- O-ADR O-ADR
in O-ADR O-ADR
period O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Acute O-ADR O-ADR
Pancreatitis O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
pancreatitis I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
134 O-ADR O-ADR
) O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
757 O-ADR O-ADR
) O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1279 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1277 O-ADR O-ADR
) O-ADR O-ADR
Liver B-ADR O-ADR
Function I-ADR O-ADR
Abnormalities I-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
Nausea B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
Arthralgia B-ADR B-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Rash B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
from O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
liver B-ADR B-ADR
function I-ADR I-ADR
abnormalities I-ADR I-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
allopurinol O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
You O-ADR O-ADR
can O-ADR O-ADR
ask O-ADR O-ADR
your O-ADR O-ADR
pharmacist O-ADR O-ADR
or O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
for O-ADR O-ADR
information O-ADR O-ADR
about O-ADR O-ADR
DUAVEE O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
written O-ADR O-ADR
for O-ADR O-ADR
health O-ADR O-ADR
professionals O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
if O-ADR O-ADR
confirmed O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anemia O-ADR O-ADR
develops O-ADR O-ADR
during O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Teflaro O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
hemolytic O-ADR O-ADR
anemia O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
treatment O-ADR O-ADR
included O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
cardiorespiratory I-ADR I-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
Urinary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Interstitial B-ADR B-ADR
nephritis I-ADR I-ADR
. O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
may O-ADR O-ADR
reoccur O-ADR O-ADR
if O-ADR O-ADR
PROMACTA O-ADR O-ADR
is O-ADR O-ADR
reinitiated O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
arterial O-ADR O-ADR
vascular O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
, O-ADR O-ADR
tobacco O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
hypercholesterolemia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
obesity O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
VTE O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
personal O-ADR O-ADR
history O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
VTE O-ADR O-ADR
, O-ADR O-ADR
obesity O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
systemic O-ADR O-ADR
lupus O-ADR O-ADR
erythematosus O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
managed O-ADR O-ADR
appropriately O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
benefit O-ADR O-ADR
for O-ADR O-ADR
reinitiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
to O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
consider O-ADR O-ADR
cautiously O-ADR O-ADR
reintroducing O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
measure O-ADR O-ADR
serum O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
weekly O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
phase O-ADR O-ADR
. O-ADR O-ADR
BRAF O-ADR O-ADR
V600E O-ADR O-ADR
or O-ADR O-ADR
V600K O-ADR O-ADR
Unresectable O-ADR O-ADR
or O-ADR O-ADR
Metastatic O-ADR O-ADR
Melanoma O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
trials O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
202 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
BRAF O-ADR O-ADR
V600 O-ADR O-ADR
mutation O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
unresectable O-ADR O-ADR
or O-ADR O-ADR
metastatic O-ADR O-ADR
melanoma O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
TAFINLAR O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
or O-ADR O-ADR
unacceptable O-ADR O-ADR
toxicity O-ADR O-ADR
. O-ADR O-ADR
Diagnostic O-ADR O-ADR
studies O-ADR O-ADR
including O-ADR O-ADR
a O-ADR O-ADR
direct O-ADR O-ADR
Coombs O-ADR O-ADR
' O-ADR O-ADR
test O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
may O-ADR O-ADR
worsen O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
initiating O-ADR O-ADR
or O-ADR O-ADR
escalating O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
STENDRA O-ADR O-ADR
is O-ADR O-ADR
uncertain O-ADR O-ADR
. O-ADR O-ADR
Ask O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
for O-ADR O-ADR
ways O-ADR O-ADR
to O-ADR O-ADR
lower O-ADR O-ADR
your O-ADR O-ADR
chances O-ADR O-ADR
of O-ADR O-ADR
getting O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR O-ADR
included O-ADR O-ADR
: O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
swollen B-ADR B-ADR
tongue I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
wheezing B-ADR B-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
medical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
- O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
systemic O-ADR O-ADR
illness O-ADR O-ADR
on O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
empiric O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
reside O-ADR O-ADR
in O-ADR O-ADR
or O-ADR O-ADR
travel O-ADR O-ADR
to O-ADR O-ADR
regions O-ADR O-ADR
where O-ADR O-ADR
mycoses O-ADR B-ADR
are O-ADR O-ADR
endemic O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
tuberculosis O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
previously O-ADR O-ADR
or O-ADR O-ADR
recently O-ADR O-ADR
traveled O-ADR O-ADR
to O-ADR O-ADR
countries O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
prevalence O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
close O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
person O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
tuberculosis O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
albiglutide O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
. O-ADR O-ADR
Doses O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
189 O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
50 O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
and O-ADR O-ADR
Reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Recurrence O-ADR O-ADR
of O-ADR O-ADR
Deep O-ADR O-ADR
Venous O-ADR O-ADR
Thrombosis O-ADR O-ADR
and O-ADR O-ADR
Pulmonary O-ADR O-ADR
Embolism O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
and O-ADR O-ADR
concomitant O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
gp O-ADR O-ADR
inhibitors O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CrCl O-ADR O-ADR
< O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
ophthalmological O-ADR O-ADR
evaluation O-ADR O-ADR
at O-ADR O-ADR
any O-ADR O-ADR
time O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
reports O-ADR O-ADR
visual O-ADR O-ADR
disturbances O-ADR O-ADR
and O-ADR O-ADR
compare O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
theoretical O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
Creutzfeldt B-ADR B-ADR
- O-ADR O-ADR
Jakob O-ADR O-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
CJD B-ADR B-ADR
) O-ADR O-ADR
is O-ADR O-ADR
also O-ADR O-ADR
considered O-ADR O-ADR
extremely O-ADR O-ADR
remote O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
medical O-ADR O-ADR
interventions O-ADR O-ADR
required O-ADR O-ADR
during O-ADR O-ADR
AFINITOR O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
for O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
stomatitis B-ADR B-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
is O-ADR O-ADR
warranted O-ADR O-ADR
when O-ADR O-ADR
prescribing O-ADR O-ADR
FANAPT O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
inhibit O-ADR O-ADR
FANAPT O-ADR O-ADR
metabolism O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interaction O-ADR O-ADR
s O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
reduced O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
CYP2D6 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Priapism B-ADR B-ADR
: O-ADR O-ADR
Cases O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
GILOTRIF O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
fibrosis I-ADR I-ADR
and O-ADR O-ADR
restrictive B-ADR B-ADR
pulmonary I-ADR I-ADR
disease I-ADR I-ADR
. O-ADR O-ADR
Posterior O-ADR B-ADR
reversible O-ADR I-ADR
encephalopathy O-ADR I-ADR
syndrome O-ADR I-ADR
( O-ADR O-ADR
PRES O-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
formerly O-ADR O-ADR
termed O-ADR O-ADR
Reversible O-ADR B-ADR
Posterior O-ADR I-ADR
Leukoencephalopathy O-ADR I-ADR
Syndrome O-ADR I-ADR
( O-ADR O-ADR
RPLS O-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
neurological O-ADR O-ADR
disorder O-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
seizure O-ADR B-ADR
, O-ADR O-ADR
headache O-ADR B-ADR
, O-ADR O-ADR
lethargy O-ADR B-ADR
, O-ADR O-ADR
confusion O-ADR B-ADR
, O-ADR O-ADR
blindness O-ADR B-ADR
, O-ADR O-ADR
altered O-ADR B-ADR
consciousness O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
visual O-ADR B-ADR
and O-ADR I-ADR
neurological O-ADR I-ADR
disturbances O-ADR I-ADR
, O-ADR O-ADR
along O-ADR O-ADR
with O-ADR O-ADR
hypertension O-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
by O-ADR O-ADR
neuro O-ADR O-ADR
- O-ADR O-ADR
radiological O-ADR O-ADR
imaging O-ADR O-ADR
( O-ADR O-ADR
MRI O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
association O-ADR O-ADR
between O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
icatibant O-ADR O-ADR
antibodies O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
B O-ADR O-ADR
oxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
W O-ADR O-ADR
arning O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
confirmatory O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
ZERBAXA O-ADR O-ADR
, O-ADR O-ADR
make O-ADR O-ADR
careful O-ADR O-ADR
inquiry O-ADR O-ADR
about O-ADR O-ADR
previous O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
cephalosporins O-ADR O-ADR
, O-ADR O-ADR
penicillins O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactams O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
experiencing O-ADR O-ADR
seizure B-ADR B-ADR
were O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
from O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
seizure O-ADR B-ADR
events O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
Class O-ADR O-ADR
/ O-ADR O-ADR
Preferred O-ADR O-ADR
Term O-ADR O-ADR
Placebo O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
203 O-ADR O-ADR
% O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
* O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
379 O-ADR O-ADR
% O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
Dry B-ADR B-ADR
mouth I-ADR I-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Dyspepsia B-ADR B-ADR
2 O-ADR O-ADR
4 O-ADR O-ADR
Oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
Toothache B-ADR B-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
Fatigue B-ADR B-ADR
2 O-ADR O-ADR
4 O-ADR O-ADR
Investigations O-ADR O-ADR
Increased B-ADR B-ADR
weight I-ADR I-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
5 O-ADR O-ADR
Metabolism O-ADR O-ADR
disorders O-ADR O-ADR
Increased B-ADR B-ADR
appetite I-ADR I-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
connective O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
Arthralgia B-ADR B-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Akathisia B-ADR B-ADR
2 O-ADR O-ADR
4 O-ADR O-ADR
Dizziness B-ADR B-ADR
3 O-ADR O-ADR
11 O-ADR O-ADR
Dysgeusia B-ADR B-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
Headache B-ADR B-ADR
11 O-ADR O-ADR
12 O-ADR O-ADR
Other O-ADR O-ADR
extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
akathisia B-ADR B-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
7 O-ADR O-ADR
Somnolence B-ADR B-ADR
? O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
were O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
liver B-ADR B-ADR
transaminase I-ADR I-ADR
elevation I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
TLS O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
uric O-ADR O-ADR
acid O-ADR O-ADR
levels O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
regimen O-ADR O-ADR
of O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
979 O-ADR O-ADR
patients O-ADR O-ADR
including O-ADR O-ADR
647 O-ADR O-ADR
adults O-ADR O-ADR
( O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
16 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
332 O-ADR O-ADR
children O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
younger O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Toxicity O-ADR O-ADR
Diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
large O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
US O-ADR O-ADR
study O-ADR O-ADR
that O-ADR O-ADR
compared O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonist O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
usual O-ADR O-ADR
asthma O-ADR O-ADR
therapy O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
salmeterol O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
identifies O-ADR O-ADR
the O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
test O-ADR O-ADR
abnormalities O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
2 O-ADR O-ADR
CML O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antihistamines O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
each O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
hypovolemia O-ADR B-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
changes O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
INLYTA O-ADR O-ADR
in O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
RCC O-ADR O-ADR
who O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
study O-ADR O-ADR
versus O-ADR O-ADR
sorafenib O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
myelosuppression O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
leukocytes O-ADR O-ADR
, O-ADR O-ADR
platelets O-ADR O-ADR
, O-ADR O-ADR
hemoglobin O-ADR O-ADR
( O-ADR O-ADR
Hgb O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
neutrophils O-ADR O-ADR
frequently O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
B O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
malignancies O-ADR O-ADR
( O-ADR O-ADR
MCL O-ADR O-ADR
, O-ADR O-ADR
CLL O-ADR O-ADR
, O-ADR O-ADR
WM O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
bruising B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Dulaglutide O-ADR O-ADR
causes O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Discontinuation O-ADR O-ADR
Syndrome O-ADR O-ADR
Discontinuation O-ADR O-ADR
symptoms O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
systematically O-ADR O-ADR
and O-ADR O-ADR
prospectively O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
Major O-ADR O-ADR
Depressive O-ADR O-ADR
Disorder O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Thrombophlebitis B-ADR B-ADR
, O-ADR O-ADR
vasculitis B-ADR B-ADR
. O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
included O-ADR O-ADR
197 O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
463 O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
which O-ADR O-ADR
includes O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
switched O-ADR O-ADR
to O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
Following O-ADR O-ADR
Chemotherapy O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
enrolled O-ADR O-ADR
1195 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
metastatic O-ADR O-ADR
CRPC O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
received O-ADR O-ADR
prior O-ADR O-ADR
docetaxel O-ADR O-ADR
chemotherapy O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
bilirubin O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
also O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
patients O-ADR O-ADR
using O-ADR O-ADR
standards O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheals O-ADR O-ADR
, O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
emetics O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fluid O-ADR O-ADR
replacement O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
2338 O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
FARXIGA O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
21 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AMPYRA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
bAnnual O-ADR O-ADR
event O-ADR O-ADR
rate O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
pt O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
= O-ADR O-ADR
100 O-ADR O-ADR
* O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
event O-ADR O-ADR
/ O-ADR O-ADR
subject O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hematologic O-ADR O-ADR
Toxicities O-ADR O-ADR
Prolonged O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
) O-ADR O-ADR
severe O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
or O-ADR O-ADR
anemia B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
lymphatic O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
thrombocytosis B-ADR B-ADR
, O-ADR O-ADR
pancytopenia B-ADR B-ADR
. O-ADR O-ADR
Complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
neutropenia O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Radiation O-ADR O-ADR
Risks O-ADR O-ADR
Choline O-ADR O-ADR
C O-ADR O-ADR
11 O-ADR O-ADR
Injection O-ADR O-ADR
contributes O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
overall O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reduction O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
neutropenia B-ADR B-ADR
was O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
62 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
ApoPharma O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
: O-ADR O-ADR
Telephone O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
949 O-ADR O-ADR
- O-ADR O-ADR
0995 O-ADR O-ADR
Email O-ADR O-ADR
: O-ADR O-ADR
medicalsafety O-ADR O-ADR
@ O-ADR O-ADR
apopharma O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
} O-ADR O-ADR
} O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
also O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
Agranulocytosis O-ADR O-ADR
/ O-ADR O-ADR
Neutropenia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congenital O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Neutropenia O-ADR O-ADR
Severe O-ADR O-ADR
neutropenia B-ADR B-ADR
( O-ADR O-ADR
ANC O-ADR B-ADR
< O-ADR O-ADR
500 O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
lasting O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
week O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
62 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
rapid O-ADR O-ADR
titration O-ADR O-ADR
would O-ADR O-ADR
be O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
orthostatic O-ADR B-ADR
hypotension O-ADR I-ADR
and O-ADR O-ADR
syncope O-ADR B-ADR
. O-ADR O-ADR
Median O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
days O-ADR O-ADR
for O-ADR O-ADR
pooled O-ADR O-ADR
studies O-ADR O-ADR
: O-ADR O-ADR
1203 O-ADR O-ADR
for O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
1163 O-ADR O-ADR
for O-ADR O-ADR
cyclosporine O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
? O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
endocrinopathies I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Gilead O-ADR O-ADR
Sciences O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
GILEAD O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
protocol O-ADR O-ADR
included O-ADR O-ADR
provisions O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
placebo O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
16 O-ADR O-ADR
or O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
either O-ADR O-ADR
by O-ADR O-ADR
patient O-ADR O-ADR
response O-ADR O-ADR
( O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
uncontrolled O-ADR O-ADR
disease O-ADR O-ADR
activity O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
by O-ADR O-ADR
design O-ADR O-ADR
, O-ADR O-ADR
so O-ADR O-ADR
that O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
be O-ADR O-ADR
unambiguously O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
given O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
patients O-ADR O-ADR
continued O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
void O-ADR O-ADR
spontaneously O-ADR O-ADR
after O-ADR O-ADR
catheter O-ADR O-ADR
removal O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Glucose O-ADR O-ADR
Mean O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
( O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
> O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
FANAPT O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
773 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
723 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
425 O-ADR O-ADR
) O-ADR O-ADR
FANAPT O-ADR O-ADR
20 O-ADR O-ADR
- O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
34 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
31 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
18 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
Dyslipidemia O-ADR B-ADR
Undesirable B-ADR B-ADR
alterations I-ADR I-ADR
in I-ADR I-ADR
lipids I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotics O-ADR O-ADR
. O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
RLS O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
primarily O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
642 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
TRULICITY O-ADR O-ADR
will O-ADR O-ADR
cause O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
medullary B-ADR B-ADR
thyroid I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
MTC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
the O-ADR O-ADR
human O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
dulaglutide O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
rodent O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
include O-ADR O-ADR
anaphylactic B-ADR B-ADR
shock I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
myelosuppression B-ADR B-ADR
, O-ADR O-ADR
gastrointestinal B-ADR B-ADR
toxicity I-ADR I-ADR
( O-ADR O-ADR
diarrhea B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
fluid B-ADR B-ADR
retention I-ADR I-ADR
, O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
measures O-ADR O-ADR
to O-ADR O-ADR
prevent O-ADR O-ADR
severe O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
antihistamines O-ADR O-ADR
, O-ADR O-ADR
antipyretics O-ADR O-ADR
and O-ADR O-ADR
corticosteroids O-ADR O-ADR
in O-ADR O-ADR
subsequent O-ADR O-ADR
cycles O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
experienced O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
ingrown B-ADR B-ADR
toenails I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
vesicles I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
baseline O-ADR O-ADR
hemoglobin O-ADR O-ADR
value O-ADR O-ADR
was O-ADR O-ADR
approximately O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
across O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
19 O-ADR O-ADR
to O-ADR O-ADR
97 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
, O-ADR O-ADR
64 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
; O-ADR O-ADR
64 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
undergoing O-ADR O-ADR
a O-ADR O-ADR
surgery O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
bowel O-ADR O-ADR
resection O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
average O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
from1 O-ADR O-ADR
week O-ADR O-ADR
to O-ADR O-ADR
93 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
64 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
37 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
and O-ADR O-ADR
40 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
23 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
chemotherapy O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Growth O-ADR B-ADR
of O-ADR I-ADR
Resistant O-ADR I-ADR
Organisms O-ADR I-ADR
with O-ADR O-ADR
Prolonged O-ADR O-ADR
Use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Spread O-ADR O-ADR
of O-ADR O-ADR
Toxin O-ADR O-ADR
Effect O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
approved O-ADR O-ADR
botulinum O-ADR O-ADR
toxins O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
botulinum O-ADR O-ADR
toxin B-ADR B-ADR
effects I-ADR I-ADR
may I-ADR I-ADR
, I-ADR I-ADR
in I-ADR I-ADR
some I-ADR I-ADR
cases I-ADR I-ADR
, I-ADR I-ADR
be I-ADR I-ADR
observed I-ADR I-ADR
beyond I-ADR I-ADR
the I-ADR I-ADR
site I-ADR I-ADR
of I-ADR I-ADR
local I-ADR I-ADR
injection I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
forms O-ADR O-ADR
specifically O-ADR O-ADR
requested O-ADR O-ADR
information O-ADR O-ADR
on O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
allergic B-ADR O-ADR
reactions I-ADR O-ADR
, O-ADR O-ADR
thrombotic B-ADR O-ADR
events I-ADR O-ADR
, O-ADR O-ADR
hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
, O-ADR O-ADR
hepatobiliary B-ADR O-ADR
disorders I-ADR O-ADR
, O-ADR O-ADR
pancreatic B-ADR O-ADR
disorders I-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hyperglycemia B-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
AST O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
throughout O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Macrovascular O-ADR O-ADR
Outcomes O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
switching O-ADR O-ADR
to O-ADR O-ADR
STRIBILD O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
flatulence B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
034 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
087 O-ADR O-ADR
subjects O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
strength O-ADR O-ADR
of O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
/ O-ADR O-ADR
vilanterol O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
alters O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
flora O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
colon O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
permit O-ADR O-ADR
overgrowth O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
dexamethasone O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
Kyprolis O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
reactions O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
on O-ADR O-ADR
OTEZLA O-ADR O-ADR
and O-ADR O-ADR
With O-ADR O-ADR
Greater O-ADR O-ADR
Frequency O-ADR O-ADR
Than O-ADR O-ADR
in O-ADR O-ADR
Subjects O-ADR O-ADR
on O-ADR O-ADR
Placebo O-ADR O-ADR
; O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
Day O-ADR O-ADR
112 O-ADR O-ADR
( O-ADR O-ADR
Week O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Two O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
experienced O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Zylera O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
LLC O-ADR O-ADR
. O-ADR O-ADR
Exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
antibacterial O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
ELIQUIS O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
serious O-ADR O-ADR
, O-ADR O-ADR
potentially O-ADR O-ADR
fatal B-ADR B-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
known O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
of O-ADR O-ADR
having O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
DaTscan O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
DaTscan O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
based O-ADR O-ADR
upon O-ADR O-ADR
an O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
expected O-ADR O-ADR
benefits O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hypersensitivity O-ADR O-ADR
risks O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
causes O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
medullary B-ADR B-ADR
thyroid I-ADR I-ADR
carcinoma I-ADR I-ADR
( O-ADR O-ADR
MTC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Nonclinical O-ADR O-ADR
Toxicology O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anticoagulation O-ADR O-ADR
with O-ADR O-ADR
ELIQUIS O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
coverage O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
anticoagulant O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
studies O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
show O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
with O-ADR O-ADR
antidepressant O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
over O-ADR O-ADR
age O-ADR O-ADR
24 O-ADR O-ADR
; O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
risk O-ADR O-ADR
with O-ADR O-ADR
antidepressant O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
aged O-ADR O-ADR
65 O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
such O-ADR O-ADR
, O-ADR O-ADR
reliability O-ADR O-ADR
in O-ADR O-ADR
estimating O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
establishing O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
safety O-ADR O-ADR
information O-ADR O-ADR
was O-ADR O-ADR
collected O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
records O-ADR O-ADR
submitted O-ADR O-ADR
by O-ADR O-ADR
treating O-ADR O-ADR
physicians O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
continue O-ADR O-ADR
TAFINLAR O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
dose O-ADR O-ADR
if O-ADR O-ADR
absolute O-ADR O-ADR
LVEF O-ADR O-ADR
value O-ADR O-ADR
decreases O-ADR O-ADR
by O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
from O-ADR O-ADR
pretreatment O-ADR O-ADR
values O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
lower O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
infection O-ADR O-ADR
develops O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
carefully O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
stop O-ADR O-ADR
CIMZIA O-ADR O-ADR
if O-ADR O-ADR
infection O-ADR O-ADR
becomes O-ADR O-ADR
serious O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Invasive B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
- O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
systemic O-ADR O-ADR
illness O-ADR O-ADR
on O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
empiric O-ADR O-ADR
antifungal O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
reside O-ADR O-ADR
or O-ADR O-ADR
travel O-ADR O-ADR
to O-ADR O-ADR
regions O-ADR O-ADR
where O-ADR O-ADR
mycoses O-ADR O-ADR
are O-ADR O-ADR
endemic O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
and O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Heart B-ADR B-ADR
failure I-ADR I-ADR
, I-ADR O-ADR
worsening I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
allergic B-ADR B-ADR
reactions I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatitis B-ADR B-ADR
B I-ADR I-ADR
virus I-ADR I-ADR
reactivation I-ADR I-ADR
- O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
HBV O-ADR O-ADR
infection O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
also O-ADR O-ADR
received O-ADR O-ADR
basiliximab O-ADR O-ADR
induction O-ADR O-ADR
, O-ADR O-ADR
mycophenolate O-ADR O-ADR
mofetil O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
produces O-ADR O-ADR
toxins O-ADR O-ADR
A O-ADR O-ADR
and O-ADR O-ADR
B O-ADR O-ADR
which O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
CDAD O-ADR B-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
assay O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
, O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Stroke O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
WHI O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
substudy O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
statistically O-ADR O-ADR
significant O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
stroke B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
50 O-ADR O-ADR
to O-ADR O-ADR
79 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
receiving O-ADR O-ADR
daily O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
( O-ADR O-ADR
CE O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
women O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
age O-ADR O-ADR
group O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
45 O-ADR O-ADR
versus O-ADR O-ADR
33 O-ADR O-ADR
per O-ADR O-ADR
10 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
women O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
extension O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
cataracts B-ADR B-ADR
developed O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
underwent O-ADR O-ADR
ocular O-ADR O-ADR
examination O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Hyperprolactinemia O-ADR O-ADR
Like O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
antagonize O-ADR O-ADR
dopamine O-ADR O-ADR
D2receptors O-ADR O-ADR
, O-ADR O-ADR
SAPHRIS O-ADR O-ADR
can O-ADR O-ADR
elevate B-ADR B-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
elevation O-ADR O-ADR
can O-ADR O-ADR
persist O-ADR O-ADR
during O-ADR O-ADR
chronic O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
, O-ADR O-ADR
cataracts B-ADR B-ADR
developed O-ADR O-ADR
or O-ADR O-ADR
worsened O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hemoglobin O-ADR O-ADR
is O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
g O-ADR O-ADR
per O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
in O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
ribavirin O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
hemoglobin O-ADR O-ADR
is O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
g O-ADR O-ADR
per O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ribavirin O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Less O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
subject O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
to O-ADR O-ADR
240 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
is O-ADR O-ADR
measured O-ADR O-ADR
and O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
elevated O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
further O-ADR O-ADR
evaluated O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
glycopeptide O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
DALVANCE O-ADR O-ADR
; O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
glycopeptides O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
without O-ADR O-ADR
known O-ADR O-ADR
underlying O-ADR O-ADR
renal O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Arthralgias B-ADR B-ADR
and O-ADR O-ADR
muscle B-ADR B-ADR
pain I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
proximal B-ADR B-ADR
renal I-ADR I-ADR
tubulopathy I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
brentuximab O-ADR O-ADR
vedotin O-ADR O-ADR
antibodies O-ADR O-ADR
on O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Thrombotic O-ADR O-ADR
/ O-ADR O-ADR
Thromboembolic O-ADR O-ADR
Complications O-ADR O-ADR
In O-ADR O-ADR
two O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
hepatitis O-ADR O-ADR
C O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
31 O-ADR O-ADR
/ O-ADR O-ADR
955 O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
thrombotic B-ADR B-ADR
event I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PROMACTA O-ADR O-ADR
versus O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
induced O-ADR O-ADR
hemolytic O-ADR O-ADR
anemia O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Teflaro O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
and O-ADR O-ADR
supportive O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
Ophthalmologic O-ADR O-ADR
: O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
arteritic O-ADR O-ADR
anterior I-ADR I-ADR
ischemic I-ADR I-ADR
optic I-ADR I-ADR
neuropathy I-ADR I-ADR
( O-ADR O-ADR
NAION B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
decreased B-ADR B-ADR
vision I-ADR I-ADR
including O-ADR O-ADR
permanent B-ADR B-ADR
loss I-ADR I-ADR
of I-ADR I-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
rarely O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
in O-ADR O-ADR
temporal O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
phosphodiesterase O-ADR O-ADR
type O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
PDE5 O-ADR O-ADR
) O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
immune O-ADR O-ADR
response O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assays O-ADR O-ADR
used O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
cycles O-ADR O-ADR
initiated O-ADR O-ADR
was O-ADR O-ADR
22 O-ADR O-ADR
cycles O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
14 O-ADR O-ADR
cycles O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
Rd O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
or O-ADR O-ADR
chronic O-ADR O-ADR
hypertension O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
GFR O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Plasmodium O-ADR O-ADR
vivax O-ADR O-ADR
Infection O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
limited O-ADR O-ADR
data O-ADR O-ADR
( O-ADR O-ADR
43 O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
effective O-ADR O-ADR
in O-ADR O-ADR
treating O-ADR O-ADR
the O-ADR O-ADR
erythrocytic O-ADR O-ADR
stage O-ADR O-ADR
of O-ADR O-ADR
P O-ADR O-ADR
. O-ADR O-ADR
vivax O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
clinically O-ADR O-ADR
important O-ADR O-ADR
localized O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Avoid O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
periocular O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
the O-ADR O-ADR
purposes O-ADR O-ADR
of O-ADR O-ADR
assessing O-ADR O-ADR
Response O-ADR O-ADR
- O-ADR O-ADR
Guided O-ADR O-ADR
Therapy O-ADR O-ADR
milestones O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
confirmed O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
detectable O-ADR O-ADR
but O-ADR O-ADR
below O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
quantification O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
result O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
equivalent O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
undetectable O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
result O-ADR O-ADR
( O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
Target O-ADR O-ADR
Not O-ADR O-ADR
Detected O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
or O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
Not O-ADR O-ADR
Detected O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
additional O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
death B-ADR B-ADR
was O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
neutropenia B-ADR B-ADR
without O-ADR O-ADR
a O-ADR O-ADR
documented O-ADR O-ADR
infection B-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
listed O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
MedDRA O-ADR O-ADR
version O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Effect O-ADR O-ADR
of O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
gp O-ADR O-ADR
Inducers O-ADR O-ADR
and O-ADR O-ADR
Inhibitors O-ADR O-ADR
on O-ADR O-ADR
Dabigatran O-ADR O-ADR
Exposure O-ADR O-ADR
The O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
with O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
gp O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
) O-ADR O-ADR
reduces O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
dabigatran O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
generally O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
? O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
416 O-ADR O-ADR
- O-ADR O-ADR
9637 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1308 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
depression B-ADR B-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
506 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
039 O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
88 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
46 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
occurred O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
remained O-ADR O-ADR
stable O-ADR O-ADR
through O-ADR O-ADR
48 O-ADR O-ADR
to O-ADR O-ADR
96 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
reactions O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
immediately O-ADR O-ADR
following O-ADR O-ADR
or O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
included O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
which O-ADR O-ADR
presented O-ADR O-ADR
as O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
and O-ADR O-ADR
chest B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
summarizes O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
described O-ADR O-ADR
above O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
for O-ADR O-ADR
pulmonary O-ADR O-ADR
hypertension O-ADR O-ADR
until O-ADR O-ADR
resolved O-ADR O-ADR
or O-ADR O-ADR
returned O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
whether O-ADR O-ADR
to O-ADR O-ADR
restart O-ADR O-ADR
Kyprolis O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
benefit O-ADR O-ADR
/ O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
combined O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
Studies O-ADR O-ADR
115 O-ADR O-ADR
and O-ADR O-ADR
121 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
all O-ADR O-ADR
grades O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
switching O-ADR O-ADR
to O-ADR O-ADR
STRIBILD O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
group O-ADR O-ADR
who O-ADR O-ADR
stayed O-ADR O-ADR
on O-ADR O-ADR
their O-ADR O-ADR
baseline O-ADR O-ADR
antiretroviral O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
RTV O-ADR O-ADR
- O-ADR O-ADR
boosted O-ADR O-ADR
PI O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
or O-ADR O-ADR
NNRTI O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
is O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
four O-ADR O-ADR
26 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Laryngeal O-ADR B-ADR
attacks O-ADR I-ADR
: O-ADR O-ADR
Following O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
laryngeal O-ADR O-ADR
attacks O-ADR O-ADR
with O-ADR O-ADR
FIRAZYR O-ADR O-ADR
, O-ADR O-ADR
advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
. O-ADR O-ADR
Vascular O-ADR O-ADR
Disorders O-ADR O-ADR
superficial B-ADR B-ADR
phlebitis I-ADR I-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
NEPHROGENIC B-ADR B-ADR
SYSTEMIC I-ADR I-ADR
FIBROSIS I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF B-ADR B-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
CHF O-ADR O-ADR
and O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
CHF O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ENDOMETRIAL B-ADR B-ADR
CANCER I-ADR I-ADR
, O-ADR O-ADR
CARDIOVASCULAR B-ADR B-ADR
DISORDERS I-ADR I-ADR
, O-ADR O-ADR
AND O-ADR O-ADR
PROBABLE O-ADR O-ADR
DEMENTIA B-ADR B-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ENDOMETRIAL B-ADR B-ADR
CANCER I-ADR I-ADR
, O-ADR O-ADR
CARDIOVASCULAR B-ADR B-ADR
DISORDERS I-ADR I-ADR
, O-ADR O-ADR
AND O-ADR O-ADR
PROBABLE O-ADR O-ADR
DEMENTIA B-ADR B-ADR
* O-ADR O-ADR
Women O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
additional O-ADR O-ADR
estrogens O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
endometrial B-ADR B-ADR
cancer I-ADR I-ADR
in O-ADR O-ADR
a O-ADR O-ADR
woman O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
uterus O-ADR O-ADR
who O-ADR O-ADR
uses O-ADR O-ADR
unopposed O-ADR B-ADR
estrogens O-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
most O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
this O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
consequence O-ADR O-ADR
of O-ADR O-ADR
weakening O-ADR B-ADR
of O-ADR I-ADR
muscles O-ADR I-ADR
in O-ADR I-ADR
the O-ADR I-ADR
area O-ADR I-ADR
of O-ADR I-ADR
injection O-ADR I-ADR
that O-ADR O-ADR
are O-ADR O-ADR
involved O-ADR O-ADR
in O-ADR O-ADR
breathing O-ADR O-ADR
or O-ADR O-ADR
swallowing O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
( O-ADR O-ADR
all O-ADR O-ADR
Grades O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
EMTP O-ADR O-ADR
trial O-ADR O-ADR
is O-ADR O-ADR
provided O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Bausch O-ADR O-ADR
& O-ADR O-ADR
Lomb O-ADR O-ADR
Incorporated O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
323 O-ADR O-ADR
- O-ADR O-ADR
0000 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Topical O-ADR O-ADR
Ophthalmic O-ADR O-ADR
Use O-ADR O-ADR
Only O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ILD B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
diarrhea O-ADR B-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
diarrhea O-ADR B-ADR
per O-ADR O-ADR
patient O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BOSULIF O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
221 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Lymphopenia B-ADR B-ADR
: O-ADR O-ADR
Obtain O-ADR O-ADR
a O-ADR O-ADR
CBC O-ADR O-ADR
including O-ADR O-ADR
lymphocyte O-ADR O-ADR
count O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
TECFIDERA O-ADR O-ADR
, O-ADR O-ADR
after O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
occurring O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
include O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
Most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
muscular B-ADR B-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
neck B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
eye B-ADR B-ADR
disorders I-ADR I-ADR
. O-ADR O-ADR
Glucagon O-ADR O-ADR
- O-ADR O-ADR
like O-ADR O-ADR
peptide O-ADR O-ADR
( O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
receptor O-ADR O-ADR
agonists O-ADR O-ADR
have O-ADR O-ADR
induced O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
adenomas I-ADR I-ADR
in O-ADR O-ADR
mice O-ADR O-ADR
and O-ADR O-ADR
rats O-ADR O-ADR
at O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
exposures O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
occurring O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
were O-ADR O-ADR
described O-ADR O-ADR
above O-ADR O-ADR
. O-ADR O-ADR
BK B-ADR B-ADR
virus I-ADR I-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
nephropathy I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
NULOJIX O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
graft O-ADR B-ADR
loss O-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
cyclosporine O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
none O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
graft O-ADR B-ADR
loss O-ADR I-ADR
) O-ADR O-ADR
by O-ADR O-ADR
Year O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Cytokine O-ADR O-ADR
Release O-ADR O-ADR
Syndrome O-ADR O-ADR
Cytokine B-ADR B-ADR
Release I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
CRS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
in O-ADR O-ADR
Chronic O-ADR O-ADR
Lymphocytic O-ADR O-ADR
Leukemia O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
reflect O-ADR O-ADR
subject O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Zydelig O-ADR O-ADR
from O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
218 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
CLL O-ADR O-ADR
received O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
8 O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
rituximab O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
Zydelig O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
measles O-ADR O-ADR
, O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
pooled O-ADR O-ADR
intramuscular O-ADR O-ADR
immunoglobulin O-ADR O-ADR
( O-ADR O-ADR
IG O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EOVIST O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
immune O-ADR O-ADR
system O-ADR O-ADR
responds O-ADR O-ADR
may O-ADR O-ADR
develop O-ADR O-ADR
an O-ADR O-ADR
inflammatory B-ADR O-ADR
response I-ADR O-ADR
to O-ADR O-ADR
indolent O-ADR O-ADR
or O-ADR O-ADR
residual O-ADR B-ADR
opportunistic B-ADR I-ADR
infections I-ADR I-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Mycobacterium B-ADR B-ADR
avium I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
cytomegalovirus B-ADR B-ADR
, O-ADR O-ADR
Pneumocystis B-ADR B-ADR
jiroveci I-ADR I-ADR
pneumonia I-ADR I-ADR
( O-ADR O-ADR
PCP B-ADR B-ADR
) O-ADR O-ADR
or O-ADR O-ADR
tuberculosis B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
necessitate O-ADR O-ADR
further O-ADR O-ADR
evaluation O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
collagenase O-ADR O-ADR
clostridium O-ADR O-ADR
histolyticum O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
carry O-ADR O-ADR
a O-ADR O-ADR
warning O-ADR O-ADR
card O-ADR O-ADR
indicating O-ADR O-ADR
that O-ADR O-ADR
they O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
supplementary O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
during O-ADR O-ADR
periods O-ADR O-ADR
of O-ADR O-ADR
stress O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
COPD O-ADR O-ADR
exacerbation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
asthma O-ADR O-ADR
attack O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
possible O-ADR O-ADR
that O-ADR O-ADR
systemic O-ADR B-ADR
corticosteroid O-ADR I-ADR
effects O-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hypercorticism B-ADR B-ADR
and O-ADR O-ADR
adrenal B-ADR B-ADR
suppression I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
adrenal B-ADR B-ADR
crisis I-ADR I-ADR
) O-ADR O-ADR
may O-ADR O-ADR
appear O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
small O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
sensitive O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
effects O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
withdrawal O-ADR O-ADR
from O-ADR O-ADR
oral O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
experience O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
systemically O-ADR O-ADR
active O-ADR O-ADR
corticosteroid O-ADR O-ADR
withdrawal O-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
joint O-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
muscular O-ADR B-ADR
pain O-ADR I-ADR
, O-ADR O-ADR
lassitude O-ADR B-ADR
, O-ADR O-ADR
depression O-ADR B-ADR
) O-ADR O-ADR
despite O-ADR O-ADR
maintenance O-ADR O-ADR
or O-ADR O-ADR
even O-ADR O-ADR
improvement O-ADR O-ADR
of O-ADR O-ADR
respiratory O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
per O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
until O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
reflects O-ADR O-ADR
its O-ADR O-ADR
alpha1 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
antagonist O-ADR O-ADR
properties O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
volume B-ADR B-ADR
depletion I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
hypovolemia B-ADR B-ADR
, O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
hypotension B-ADR B-ADR
) O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
study O-ADR O-ADR
and O-ADR O-ADR
13 O-ADR O-ADR
- O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
pools O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
within O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
JUBLIA O-ADR O-ADR
and O-ADR O-ADR
those O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
vehicle O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
357 O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Infections O-ADR O-ADR
Infection B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
septic B-ADR B-ADR
shock I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
death B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
and O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
skin O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
severe O-ADR O-ADR
or O-ADR O-ADR
progressive O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
TREANDA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
Besivance O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
patients O-ADR O-ADR
between O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
98 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
with O-ADR O-ADR
clinical O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bacterial O-ADR O-ADR
conjunctivitis O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
directly O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
separately O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
drop O-ADR B-ADR
in O-ADR I-ADR
body O-ADR I-ADR
estrogen O-ADR I-ADR
levels O-ADR I-ADR
causes O-ADR O-ADR
the O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
change O-ADR O-ADR
of O-ADR O-ADR
life O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
or O-ADR O-ADR
menopause O-ADR O-ADR
( O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
monthly O-ADR O-ADR
menstrual O-ADR O-ADR
periods O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Acute B-ADR B-ADR
Renal I-ADR I-ADR
Failure I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
regularly O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
Lysis I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
TLS B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Administer O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
hydration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Kyprolis O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
failure O-ADR O-ADR
throughout O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
or O-ADR O-ADR
symptom O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
GILENYA O-ADR O-ADR
and O-ADR O-ADR
perform O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
diagnostic O-ADR O-ADR
evaluation O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
unexplained O-ADR O-ADR
or O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
weight O-ADR O-ADR
loss O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
evaluate O-ADR O-ADR
weight O-ADR O-ADR
loss O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
OTEZLA O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
strong O-ADR O-ADR
cytochrome O-ADR O-ADR
P450 O-ADR O-ADR
enzyme O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
phenobarbital O-ADR O-ADR
, O-ADR O-ADR
carbamazepine O-ADR O-ADR
, O-ADR O-ADR
phenytoin O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
because O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
efficacy O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Depression O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
depression B-ADR B-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
they O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
gastrointestinal O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
RTV O-ADR O-ADR
- O-ADR O-ADR
boosted O-ADR O-ADR
PI O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
NNRTI O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Reduce O-ADR O-ADR
or O-ADR O-ADR
withhold O-ADR O-ADR
dose O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
CDAD O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
antibacterials O-ADR O-ADR
not O-ADR O-ADR
directed O-ADR O-ADR
against O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Venous O-ADR O-ADR
Thrombosis O-ADR O-ADR
Venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
deep B-ADR B-ADR
venous I-ADR I-ADR
thrombosis I-ADR I-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
: O-ADR O-ADR
Bleeding B-ADR B-ADR
Results O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
- O-ADR O-ADR
EXT O-ADR O-ADR
Study O-ADR O-ADR
ELIQUIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
bidN O-ADR O-ADR
= O-ADR O-ADR
840n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
ELIQUIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
bidN O-ADR O-ADR
= O-ADR O-ADR
811n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
PlaceboN O-ADR O-ADR
= O-ADR O-ADR
826n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
CRNM B-ADR B-ADR
= O-ADR O-ADR
clinically B-ADR B-ADR
relevant I-ADR I-ADR
nonmajor I-ADR I-ADR
bleeding O-ADR O-ADR
. O-ADR O-ADR
Events O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
each O-ADR O-ADR
endpoint O-ADR O-ADR
were O-ADR O-ADR
counted O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
subject O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
subjects O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
contributed O-ADR O-ADR
events O-ADR O-ADR
to O-ADR O-ADR
multiple O-ADR O-ADR
endpoints O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
observed O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
, O-ADR O-ADR
taking O-ADR O-ADR
into O-ADR O-ADR
account O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
8 O-ADR O-ADR
Phase O-ADR O-ADR
III O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
MTC B-ADR B-ADR
was O-ADR O-ADR
diagnosed O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
receiving O-ADR O-ADR
TANZEUM O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
JC B-ADR B-ADR
virus I-ADR I-ADR
infection I-ADR I-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
PML B-ADR B-ADR
and O-ADR O-ADR
death B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ADCETRIS O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
Seizures O-ADR O-ADR
Seizures B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
572 O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
379 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
503 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
203 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
HBV O-ADR O-ADR
carriers O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
several O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Routine O-ADR O-ADR
monthly O-ADR O-ADR
pregnancy O-ADR O-ADR
tests O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
during O-ADR O-ADR
this O-ADR O-ADR
time O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
Impairment I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
reporting O-ADR O-ADR
severe O-ADR O-ADR
adverse O-ADR O-ADR
gastrointestinal O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
milk O-ADR O-ADR
proteins O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Malignancies B-ADR B-ADR
- O-ADR O-ADR
More O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Intensive O-ADR O-ADR
measures O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
diarrhea O-ADR O-ADR
and O-ADR O-ADR
electrolyte O-ADR O-ADR
imbalance O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
the O-ADR O-ADR
similar O-ADR O-ADR
structural O-ADR O-ADR
formula O-ADR O-ADR
of O-ADR O-ADR
atropine O-ADR O-ADR
to O-ADR O-ADR
aclidinium O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
atropine O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
similar O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
. O-ADR O-ADR
NSF B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
fatal B-ADR B-ADR
or O-ADR O-ADR
debilitating O-ADR O-ADR
fibrosis B-ADR B-ADR
affecting O-ADR O-ADR
the O-ADR O-ADR
skin O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
and O-ADR O-ADR
internal O-ADR O-ADR
organs O-ADR O-ADR
. O-ADR O-ADR
Oral O-ADR O-ADR
contraceptives O-ADR O-ADR
containing O-ADR O-ADR
lower O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
norethindrone O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
hormonal O-ADR O-ADR
contraception O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
or O-ADR O-ADR
are O-ADR O-ADR
contraindicated O-ADR O-ADR
. O-ADR O-ADR
Eye O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
vision B-ADR B-ADR
blurred I-ADR I-ADR
. O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
Safety O-ADR O-ADR
Trials O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
three O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
double O-ADR O-ADR
blind O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
40 O-ADR O-ADR
to O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
COPD O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thromboembolism O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
PROMACTA O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
thromboembolism O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Factor O-ADR O-ADR
V O-ADR O-ADR
Leiden O-ADR O-ADR
, O-ADR O-ADR
ATIII O-ADR O-ADR
deficiency O-ADR O-ADR
, O-ADR O-ADR
antiphospholipid O-ADR O-ADR
syndrome O-ADR I-ADR
, O-ADR O-ADR
chronic O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Both O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
markedly O-ADR O-ADR
elevated O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
levels O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
reactivation O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
stop O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
begin O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
viral O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Demyelinating B-ADR B-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
exacerbation O-ADR B-ADR
or O-ADR O-ADR
new O-ADR O-ADR
onset O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cytopenias B-ADR B-ADR
, O-ADR O-ADR
pancytopenia B-ADR B-ADR
- O-ADR O-ADR
advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
if O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
stopping O-ADR O-ADR
CIMZIA O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Lupus B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndrome I-ADR I-ADR
- O-ADR O-ADR
stop O-ADR O-ADR
CIMZIA O-ADR O-ADR
if O-ADR O-ADR
syndrome O-ADR O-ADR
develops O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
developing O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
involving O-ADR O-ADR
various O-ADR O-ADR
organ O-ADR O-ADR
systems O-ADR O-ADR
and O-ADR O-ADR
sites O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
hospitalization O-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Across O-ADR O-ADR
8 O-ADR O-ADR
Phase O-ADR O-ADR
III O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
with O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
Transplant O-ADR O-ADR
recipients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seronegative O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
unknown O-ADR O-ADR
serostatus O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
NULOJIX O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Fetal B-ADR B-ADR
harm I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
SPINAL O-ADR O-ADR
/ O-ADR O-ADR
EPIDURAL O-ADR O-ADR
HEMATOMA O-ADR O-ADR
: O-ADR O-ADR
spinal B-ADR B-ADR
hematomas I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ELIQUIS O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
receiving O-ADR O-ADR
neuraxial O-ADR O-ADR
anesthesia O-ADR O-ADR
or O-ADR O-ADR
undergoing O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
visual O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
uveitis O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
change O-ADR O-ADR
in O-ADR O-ADR
vision O-ADR O-ADR
, O-ADR O-ADR
photophobia O-ADR O-ADR
, O-ADR O-ADR
eye O-ADR O-ADR
pain O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
CRNM O-ADR O-ADR
* O-ADR O-ADR
25 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
34 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
19 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
Major O-ADR O-ADR
+ O-ADR O-ADR
CRNM B-ADR B-ADR
27 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
35 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
22 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
Minor O-ADR O-ADR
75 O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
98 O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
58 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
94 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
121 O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
74 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
- O-ADR O-ADR
EXT O-ADR O-ADR
study O-ADR O-ADR
are O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
included O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
pruritus B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Pneumonia O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TANZEUM O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
comparators O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Biogen O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
456 O-ADR O-ADR
- O-ADR O-ADR
2255 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
DIFICID O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
PE O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
youngest O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
16 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
youngest O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
12 O-ADR O-ADR
cycles O-ADR O-ADR
was O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Kyprolis O-ADR O-ADR
combination O-ADR O-ADR
arm O-ADR O-ADR
versus O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
254 O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
84 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Novartis O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
669 O-ADR O-ADR
- O-ADR O-ADR
6682 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
KALYDECO O-ADR O-ADR
with O-ADR O-ADR
strong O-ADR O-ADR
CYP3A O-ADR O-ADR
inducers O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
rifampin O-ADR O-ADR
, O-ADR O-ADR
St O-ADR O-ADR
. O-ADR O-ADR
John O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
wort O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
receiving O-ADR O-ADR
study O-ADR O-ADR
drug O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
144 O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
additional O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
started O-ADR O-ADR
on O-ADR O-ADR
lipid O-ADR O-ADR
lowering O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ATRIPLA O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
not O-ADR O-ADR
taking O-ADR O-ADR
any O-ADR O-ADR
immunosuppressive O-ADR O-ADR
or O-ADR O-ADR
immunomodulatory O-ADR O-ADR
medications O-ADR O-ADR
concomitantly O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Forest O-ADR O-ADR
Laboratories O-ADR O-ADR
, O-ADR O-ADR
LLC O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
perforation I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
safety O-ADR O-ADR
information O-ADR O-ADR
was O-ADR O-ADR
prospectively O-ADR O-ADR
and O-ADR O-ADR
systematically O-ADR O-ADR
collected O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
chemotherapy O-ADR O-ADR
arm O-ADR O-ADR
received O-ADR O-ADR
pemetrexed O-ADR O-ADR
unless O-ADR O-ADR
they O-ADR O-ADR
had O-ADR O-ADR
received O-ADR O-ADR
pemetrexed O-ADR O-ADR
as O-ADR O-ADR
part O-ADR O-ADR
of O-ADR O-ADR
first O-ADR O-ADR
- O-ADR O-ADR
line O-ADR O-ADR
or O-ADR O-ADR
maintenance O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Aerosolization O-ADR O-ADR
of O-ADR O-ADR
Capsaicin O-ADR O-ADR
Aerosolization O-ADR O-ADR
of O-ADR O-ADR
capsaicin O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
upon O-ADR O-ADR
rapid O-ADR O-ADR
removal O-ADR O-ADR
of O-ADR O-ADR
Qutenza O-ADR O-ADR
patches O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Merck O-ADR O-ADR
Sharp O-ADR O-ADR
& O-ADR O-ADR
Dohme O-ADR O-ADR
Corp O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
subsidiary O-ADR O-ADR
of O-ADR O-ADR
Merck O-ADR O-ADR
& O-ADR O-ADR
Co O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
4231 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Novartis O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
669 O-ADR O-ADR
- O-ADR O-ADR
6682 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
otherwise O-ADR O-ADR
important O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Other O-ADR O-ADR
Malignancies O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
malignant B-ADR B-ADR
diseases I-ADR I-ADR
that O-ADR O-ADR
have O-ADR O-ADR
developed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
myelodysplastic B-ADR B-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
myeloproliferative B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
myeloid I-ADR I-ADR
leukemia I-ADR I-ADR
and O-ADR O-ADR
bronchial B-ADR B-ADR
carcinoma I-ADR I-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
No O-ADR O-ADR
clinically O-ADR O-ADR
meaningful O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
hematology O-ADR O-ADR
, O-ADR O-ADR
serum O-ADR O-ADR
chemistry O-ADR O-ADR
or O-ADR O-ADR
urinalysis O-ADR B-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patient O-ADR O-ADR
had O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
identified O-ADR O-ADR
systemic O-ADR O-ADR
medical O-ADR O-ADR
conditions O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
compromised O-ADR B-ADR
immune O-ADR I-ADR
system O-ADR I-ADR
function O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
previously O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
natalizumab O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
has O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
PML O-ADR B-ADR
. O-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
CRS B-ADR B-ADR
was O-ADR O-ADR
infrequently O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
IOP O-ADR O-ADR
Increase O-ADR O-ADR
Prolonged O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
glaucoma B-ADR B-ADR
with O-ADR O-ADR
damage B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
optic I-ADR I-ADR
nerve I-ADR I-ADR
, O-ADR O-ADR
defects B-ADR B-ADR
in I-ADR I-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
. O-ADR O-ADR
Fungal O-ADR O-ADR
culture O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
when O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
TLS O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
COMETRIQ O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
Adjudicated O-ADR O-ADR
Major O-ADR O-ADR
Bleeding B-ADR B-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
Treated O-ADR O-ADR
Patientsa O-ADR O-ADR
aPatients O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
or O-ADR O-ADR
within O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
stopping O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
third O-ADR O-ADR
year O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
cumulative O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
NODAT B-ADR B-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
/ O-ADR O-ADR
304 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
29 O-ADR O-ADR
/ O-ADR O-ADR
280 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
The O-ADR O-ADR
Medicines O-ADR O-ADR
Company O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
977 O-ADR O-ADR
- O-ADR O-ADR
MDCO O-ADR O-ADR
( O-ADR O-ADR
6326 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Teflaro O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
four O-ADR O-ADR
controlled O-ADR O-ADR
comparative O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
two O-ADR O-ADR
in O-ADR O-ADR
ABSSSI O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
in O-ADR O-ADR
CABP O-ADR O-ADR
) O-ADR O-ADR
which O-ADR O-ADR
included O-ADR O-ADR
1300 O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Teflaro O-ADR O-ADR
( O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
administered O-ADR O-ADR
by O-ADR O-ADR
IV O-ADR O-ADR
over O-ADR O-ADR
1 O-ADR O-ADR
hour O-ADR O-ADR
every O-ADR O-ADR
12h O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
1297 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
( O-ADR O-ADR
vancomycin O-ADR O-ADR
plus O-ADR O-ADR
aztreonam O-ADR O-ADR
or O-ADR O-ADR
ceftriaxone O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
period O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
21 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
each O-ADR O-ADR
subject O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
a O-ADR O-ADR
Week O-ADR O-ADR
12 O-ADR O-ADR
sample O-ADR O-ADR
was O-ADR O-ADR
selected O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
corresponding O-ADR O-ADR
Week O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
, O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
52 O-ADR O-ADR
samples O-ADR O-ADR
were O-ADR O-ADR
assayed O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
were O-ADR O-ADR
also O-ADR O-ADR
binding O-ADR O-ADR
antibody O-ADR O-ADR
positive O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Peripheral O-ADR O-ADR
Neuropathy O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
enrolled O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
liver O-ADR O-ADR
metastases O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
if O-ADR O-ADR
AST O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
ALT O-ADR O-ADR
> O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anaphylaxis O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
immediately O-ADR O-ADR
and O-ADR O-ADR
permanently O-ADR O-ADR
discontinue O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
and O-ADR O-ADR
administer O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
N O-ADR O-ADR
( O-ADR O-ADR
Percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
10 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Blood B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
a O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Nausea B-ADR B-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Fatigue B-ADR B-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
b O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Anxiety B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Back B-ADR B-ADR
pain I-ADR I-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Claustrophobia B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Dizziness B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Feeling B-ADR B-ADR
cold I-ADR I-ADR
c O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Insomnia B-ADR B-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Neck B-ADR B-ADR
pain I-ADR I-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
frequencies O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
infusion B-ADR B-ADR
site I-ADR I-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
pruritis B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
flushing B-ADR B-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antipsychotics O-ADR O-ADR
, O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
potentially O-ADR O-ADR
lower O-ADR O-ADR
the O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Alzheimer O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
dementia O-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Fungal O-ADR O-ADR
Infections O-ADR O-ADR
Fungal B-ADR B-ADR
infections I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
cornea I-ADR I-ADR
are O-ADR O-ADR
particularly O-ADR O-ADR
prone O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
coincidentally O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
local O-ADR O-ADR
steroid O-ADR O-ADR
application O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Perforations B-ADR B-ADR
and O-ADR O-ADR
Fistulas B-ADR O-ADR
: O-ADR O-ADR
Gastrointestinal B-ADR B-ADR
perforations I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
fistula B-ADR B-ADR
formation I-ADR I-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
genital O-ADR O-ADR
mycotic O-ADR O-ADR
infections O-ADR O-ADR
and O-ADR O-ADR
uncircumcised O-ADR O-ADR
males O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
medicate O-ADR O-ADR
in O-ADR O-ADR
subsequent O-ADR O-ADR
cycles O-ADR O-ADR
for O-ADR O-ADR
milder O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Hematologic O-ADR B-ADR
nadirs O-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
predominantly O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
third O-ADR O-ADR
week O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
ECGs O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
SIRTURO O-ADR O-ADR
if O-ADR O-ADR
significant O-ADR O-ADR
ventricular O-ADR O-ADR
arrhythmia O-ADR O-ADR
or O-ADR O-ADR
QTcF O-ADR O-ADR
interval O-ADR O-ADR
> O-ADR O-ADR
500 O-ADR O-ADR
ms O-ADR O-ADR
develops O-ADR O-ADR
. O-ADR O-ADR
Atypical O-ADR O-ADR
Subtrochanteric O-ADR O-ADR
and O-ADR O-ADR
Diaphyseal O-ADR O-ADR
Fractures O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
osteoporosis O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
program O-ADR O-ADR
, O-ADR O-ADR
atypical B-ADR B-ADR
femoral I-ADR I-ADR
fractures I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
* O-ADR O-ADR
= O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
at O-ADR O-ADR
Baseline O-ADR O-ADR
with O-ADR O-ADR
assessments O-ADR O-ADR
at O-ADR O-ADR
both O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
Endpoint O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
changes O-ADR O-ADR
averaged O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
mm O-ADR O-ADR
Hg O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
greater O-ADR O-ADR
increases O-ADR O-ADR
and O-ADR O-ADR
these O-ADR O-ADR
changes O-ADR O-ADR
lasted O-ADR O-ADR
for O-ADR O-ADR
approximately O-ADR O-ADR
two O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
patch O-ADR O-ADR
removal O-ADR O-ADR
. O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
Class O-ADR O-ADR
/ O-ADR O-ADR
Preferred O-ADR O-ADR
Term O-ADR O-ADR
Placebo O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
378 O-ADR O-ADR
% O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
274 O-ADR O-ADR
% O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
208 O-ADR O-ADR
% O-ADR O-ADR
All O-ADR O-ADR
SAPHRIS O-ADR O-ADR
S O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
572 O-ADR O-ADR
% O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
disorders O-ADR O-ADR
Constipation B-ADR B-ADR
6 O-ADR O-ADR
7 O-ADR O-ADR
4 O-ADR O-ADR
5 O-ADR O-ADR
Dry B-ADR B-ADR
mouth I-ADR I-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
Oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
1 O-ADR O-ADR
6 O-ADR O-ADR
7 O-ADR O-ADR
5 O-ADR O-ADR
Salivary B-ADR B-ADR
hypersecretion I-ADR I-ADR
0 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
2 O-ADR O-ADR
Stomach B-ADR B-ADR
discomfort I-ADR I-ADR
1 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
Vomiting B-ADR B-ADR
5 O-ADR O-ADR
4 O-ADR O-ADR
7 O-ADR O-ADR
5 O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
Fatigue B-ADR B-ADR
3 O-ADR O-ADR
4 O-ADR O-ADR
3 O-ADR O-ADR
3 O-ADR O-ADR
Irritability B-ADR B-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
Investigations O-ADR O-ADR
Increased B-ADR B-ADR
weight I-ADR I-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
Metabolism O-ADR O-ADR
disorders O-ADR O-ADR
Increased B-ADR B-ADR
appetite I-ADR I-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
3 O-ADR O-ADR
0 O-ADR O-ADR
2 O-ADR O-ADR
Nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
Akathisia O-ADR B-ADR
* O-ADR O-ADR
3 O-ADR O-ADR
4 O-ADR O-ADR
11 O-ADR O-ADR
6 O-ADR O-ADR
Dizziness B-ADR B-ADR
4 O-ADR O-ADR
7 O-ADR O-ADR
3 O-ADR O-ADR
5 O-ADR O-ADR
Extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
( O-ADR O-ADR
excluding O-ADR O-ADR
akathisia B-ADR B-ADR
) O-ADR O-ADR
7 O-ADR O-ADR
9 O-ADR O-ADR
12 O-ADR O-ADR
10 O-ADR O-ADR
Somnolence B-ADR B-ADR
? O-ADR O-ADR
Discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
ADRs O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
XTANDI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Antipsychotic O-ADR O-ADR
treatment O-ADR O-ADR
itself O-ADR O-ADR
, O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
suppress O-ADR O-ADR
( O-ADR O-ADR
or O-ADR O-ADR
partially O-ADR O-ADR
suppress O-ADR O-ADR
) O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
and O-ADR O-ADR
thereby O-ADR O-ADR
may O-ADR O-ADR
possibly O-ADR O-ADR
mask O-ADR O-ADR
the O-ADR O-ADR
underlying O-ADR O-ADR
process O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
: O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
thrombotic B-ADR I-ADR
thrombocytopenic I-ADR I-ADR
purpura O-ADR O-ADR
/ O-ADR O-ADR
hemolytic O-ADR O-ADR
uremic B-ADR B-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
TTP O-ADR O-ADR
/ O-ADR O-ADR
HUS O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
posterior B-ADR B-ADR
reversible I-ADR I-ADR
encephalopathy I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
PRES B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
protective O-ADR O-ADR
drops O-ADR O-ADR
, O-ADR O-ADR
ointment O-ADR O-ADR
, O-ADR O-ADR
therapeutic O-ADR O-ADR
soft O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
closure O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
eye O-ADR O-ADR
by O-ADR O-ADR
patching O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
means O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
acute B-ADR B-ADR
kidney I-ADR I-ADR
injury I-ADR I-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dosage O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Keratitis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Subjects O-ADR O-ADR
ranged O-ADR O-ADR
in O-ADR O-ADR
age O-ADR O-ADR
from O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
83 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
overall O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
46 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
stop O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
prescribing O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
carriers O-ADR O-ADR
of O-ADR O-ADR
HBV O-ADR O-ADR
. O-ADR O-ADR
Primary O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
clinical O-ADR O-ADR
features O-ADR O-ADR
( O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
poor O-ADR O-ADR
performance O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
previous O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
febrile O-ADR O-ADR
neutropenia O-ADR O-ADR
, O-ADR O-ADR
extensive O-ADR O-ADR
prior O-ADR O-ADR
radiation O-ADR O-ADR
ports O-ADR O-ADR
, O-ADR O-ADR
poor O-ADR O-ADR
nutritional O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
comorbidities O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
increased O-ADR O-ADR
complications O-ADR O-ADR
from O-ADR O-ADR
prolonged O-ADR O-ADR
neutropenia O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Novartis O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
669 O-ADR O-ADR
- O-ADR O-ADR
6682 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
symptoms O-ADR O-ADR
are O-ADR O-ADR
moderate O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
interrupting O-ADR O-ADR
therapy O-ADR O-ADR
until O-ADR O-ADR
symptoms O-ADR O-ADR
improve O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
121 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
one O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
21 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
three O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
were O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
glucarpidase O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
spinal O-ADR O-ADR
hematoma O-ADR O-ADR
are O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
initiate O-ADR O-ADR
urgent O-ADR O-ADR
diagnosis O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
including O-ADR O-ADR
consideration O-ADR O-ADR
for O-ADR O-ADR
spinal O-ADR O-ADR
cord O-ADR O-ADR
decompression O-ADR O-ADR
even O-ADR O-ADR
though O-ADR O-ADR
such O-ADR O-ADR
treatment O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
prevent O-ADR O-ADR
or O-ADR O-ADR
reverse O-ADR O-ADR
neurological O-ADR B-ADR
sequelae O-ADR I-ADR
. O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
patients O-ADR O-ADR
are O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
having O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
acquired O-ADR O-ADR
immunity O-ADR O-ADR
shown O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
IgG O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
viral O-ADR O-ADR
capsid O-ADR O-ADR
antigen O-ADR O-ADR
( O-ADR O-ADR
VCA O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
EBV O-ADR O-ADR
nuclear O-ADR O-ADR
antigen O-ADR O-ADR
( O-ADR O-ADR
EBNA O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
891 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
400 O-ADR O-ADR
mcg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Cardiac O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
angina B-ADR B-ADR
pectoris I-ADR I-ADR
, O-ADR O-ADR
atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
murmur I-ADR I-ADR
, O-ADR O-ADR
ECG B-ADR B-ADR
abnormal I-ADR I-ADR
, O-ADR O-ADR
palpitations B-ADR B-ADR
, O-ADR O-ADR
sinus B-ADR B-ADR
bradycardia I-ADR I-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Renal O-ADR O-ADR
Impairment O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
receptor O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
worsening B-ADR B-ADR
of I-ADR I-ADR
chronic I-ADR I-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
sometimes O-ADR O-ADR
require O-ADR O-ADR
hemodialysis O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
have O-ADR O-ADR
frequently O-ADR O-ADR
presented O-ADR I-ADR
with O-ADR O-ADR
disseminated O-ADR O-ADR
rather O-ADR O-ADR
than O-ADR O-ADR
localized O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Reproductive O-ADR O-ADR
System O-ADR O-ADR
and O-ADR O-ADR
Breast O-ADR O-ADR
Changes O-ADR O-ADR
: O-ADR O-ADR
breast B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
erectile B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
gynecomastia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
trial O-ADR O-ADR
excluded O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
abnormal O-ADR O-ADR
left O-ADR O-ADR
ventricular O-ADR O-ADR
ejection O-ADR O-ADR
fraction O-ADR O-ADR
or O-ADR O-ADR
cardiac O-ADR O-ADR
valve O-ADR O-ADR
morphology O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
corrected O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
480 O-ADR O-ADR
milliseconds O-ADR O-ADR
on O-ADR O-ADR
electrocardiogram O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
glucose O-ADR O-ADR
- O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
phosphate O-ADR O-ADR
dehydrogenase O-ADR O-ADR
deficiency O-ADR O-ADR
. O-ADR O-ADR
Monitoring O-ADR O-ADR
of O-ADR O-ADR
orthostatic O-ADR O-ADR
vital O-ADR O-ADR
signs O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
if O-ADR O-ADR
hypotension O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
progestins O-ADR O-ADR
, O-ADR O-ADR
additional O-ADR O-ADR
estrogens O-ADR O-ADR
or O-ADR O-ADR
additional O-ADR O-ADR
estrogen O-ADR O-ADR
agonist O-ADR O-ADR
/ O-ADR O-ADR
antagonists O-ADR O-ADR
. O-ADR O-ADR
Excluded O-ADR O-ADR
from O-ADR O-ADR
this O-ADR O-ADR
list O-ADR O-ADR
are O-ADR O-ADR
those O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
minor O-ADR O-ADR
, O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
plausible O-ADR O-ADR
relation O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
use O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
reports O-ADR O-ADR
too O-ADR O-ADR
imprecise O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
meaningful O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
demographic O-ADR O-ADR
and O-ADR O-ADR
baseline O-ADR O-ADR
characteristics O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
are O-ADR O-ADR
a O-ADR O-ADR
mixture O-ADR O-ADR
of O-ADR O-ADR
sodium O-ADR O-ADR
estrone O-ADR O-ADR
sulfate O-ADR O-ADR
and O-ADR O-ADR
sodium O-ADR O-ADR
equilin O-ADR O-ADR
sulfate O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
components O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
sodium O-ADR O-ADR
sulfate O-ADR O-ADR
conjugates O-ADR O-ADR
, O-ADR O-ADR
17alpha O-ADR O-ADR
- O-ADR O-ADR
dihydroequilin O-ADR O-ADR
, O-ADR O-ADR
17alpha O-ADR O-ADR
- O-ADR O-ADR
estradiol O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
17beta O-ADR O-ADR
- O-ADR O-ADR
dihydroequilin O-ADR O-ADR
. O-ADR O-ADR
Pyrexia B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
were O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reasons O-ADR O-ADR
cited O-ADR O-ADR
for O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
and O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
ejection I-ADR I-ADR
fraction I-ADR I-ADR
were O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reasons O-ADR O-ADR
cited O-ADR O-ADR
for O-ADR O-ADR
dose O-ADR O-ADR
interruptions O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
Lymphatic O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
idiopathic B-ADR B-ADR
thrombocytopenic I-ADR I-ADR
purpura I-ADR I-ADR
, O-ADR O-ADR
leukocytosis O-ADR O-ADR
/ O-ADR O-ADR
leukopenia O-ADR O-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
pancytopenia B-ADR B-ADR
, O-ADR O-ADR
splenomegaly B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
increased O-ADR O-ADR
by O-ADR O-ADR
traumatic O-ADR O-ADR
or O-ADR O-ADR
repeated O-ADR O-ADR
epidural O-ADR O-ADR
or O-ADR O-ADR
spinal O-ADR O-ADR
puncture O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
hematomas B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
permanent B-ADR B-ADR
paralysis I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
Pain O-ADR O-ADR
In O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
occasionally O-ADR O-ADR
incapacitating O-ADR B-ADR
muscle B-ADR B-ADR
pain I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
Prolia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
FULYZAQ O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
are O-ADR O-ADR
provided O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
minority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
albiglutide O-ADR O-ADR
antibodies O-ADR O-ADR
also O-ADR O-ADR
transiently O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
human O-ADR O-ADR
albumin O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
test O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
surface O-ADR O-ADR
antigen O-ADR O-ADR
, O-ADR O-ADR
consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
with O-ADR O-ADR
expertise O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
neutropenia O-ADR O-ADR
complications O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
JEVTANA O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
They O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
62 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
smoking O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
44 O-ADR O-ADR
pack O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
54 O-ADR O-ADR
% O-ADR O-ADR
identified O-ADR O-ADR
as O-ADR O-ADR
current O-ADR O-ADR
smokers O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
similar O-ADR O-ADR
trend O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
cUTI O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
during O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
suspected O-ADR O-ADR
keratitis O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
ulcerative O-ADR O-ADR
keratitis O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
interrupted O-ADR O-ADR
or O-ADR O-ADR
discontinued O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
hypersensitivity B-ADR B-ADR
or O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
FIRAZYR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
prolonged O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
cutaneous O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
lasting O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
intolerable O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
cutaneous O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
resolves O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
resume O-ADR O-ADR
GILOTRIF O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Changes O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
in O-ADR O-ADR
total O-ADR O-ADR
cholesterol O-ADR O-ADR
, O-ADR O-ADR
HDL O-ADR O-ADR
- O-ADR O-ADR
cholesterol O-ADR O-ADR
, O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
cholesterol O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
triglycerides O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
Liver B-ADR B-ADR
chemistry I-ADR I-ADR
elevations I-ADR I-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
TIVICAY O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
where O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hepatitis O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
withdrawn O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
swallowing O-ADR O-ADR
or O-ADR O-ADR
breathing O-ADR O-ADR
difficulties O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
complications O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
venous B-ADR B-ADR
thromboembolism I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Pancreatitis O-ADR O-ADR
Pancreatitis B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
DISTANT B-ADR B-ADR
SPREAD I-ADR I-ADR
OF I-ADR I-ADR
TOXIN I-ADR I-ADR
EFFECT I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
The O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
spread B-ADR B-ADR
from I-ADR I-ADR
the I-ADR I-ADR
area I-ADR I-ADR
of I-ADR I-ADR
injection I-ADR I-ADR
to I-ADR O-ADR
produce I-ADR O-ADR
symptoms I-ADR O-ADR
consistent I-ADR O-ADR
with I-ADR O-ADR
botulinum I-ADR O-ADR
toxin I-ADR B-ADR
effects I-ADR I-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
insufficiency I-ADR I-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
renal B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Mean O-ADR O-ADR
changes B-ADR B-ADR
( I-ADR I-ADR
percent I-ADR I-ADR
changes I-ADR I-ADR
) I-ADR I-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
non I-ADR I-ADR
- O-ADR O-ADR
HDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
relative O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
were O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
* O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Nephrogenic B-ADR B-ADR
Systemic I-ADR I-ADR
Fibrosis I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
are O-ADR O-ADR
no O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
using O-ADR O-ADR
JEVTANA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
APTIOM O-ADR O-ADR
) O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
hyponatremia B-ADR B-ADR
. O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Upper O-ADR O-ADR
Limb O-ADR O-ADR
Spasticity O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
muscular B-ADR B-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
fall B-ADR B-ADR
and O-ADR O-ADR
depression B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Pfizer O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
438 O-ADR O-ADR
- O-ADR O-ADR
1985 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
and O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
TECFIDERA O-ADR O-ADR
if O-ADR O-ADR
these O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
baseline O-ADR O-ADR
ophthalmologic O-ADR O-ADR
testing O-ADR O-ADR
by O-ADR O-ADR
an O-ADR O-ADR
ophthalmic O-ADR O-ADR
professional O-ADR O-ADR
and O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
testing O-ADR O-ADR
every O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contactJanssen O-ADR O-ADR
Biotech O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
JANSSEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
526 O-ADR O-ADR
- O-ADR O-ADR
7736 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
